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ABSTRACT 
 
ANNE CHRISTINE BEAUBRUN: Intravenous Vitamin D Treatment in Hemodialysis 
Patients: Patterns of Use and Association with Fracture Risk 
(Under the direction of Dr. M. Alan Brookhart and Dr. Betsy L. Sleath) 
 
The administration of intravenous vitamin D therapy is central to the treatment of 
secondary hyperparathyroidism.  Yet, there is little data documenting the variations in the use 
of these agents in large, representative samples and vitamin D’s clinical benefits are not 
clear.  The objectives of this dissertation were to describe patterns in the use of vitamin D 
and to examine the association between vitamin D exposure and fracture risk among 
hemodialysis patients. 
We described vitamin D-related trends among patients within the United States Renal 
Data System between 01/01/2000-12/31/2008.  Annual percentages of patients treated with 
each formulation were tabulated by relevant subgroups.  A retrospective cohort study was 
conducted to examine the association between vitamin D exposure and fracture risk.  Incident 
hemodialysis patients between 01/01/2000-05/31/2004 entered a 180-day baseline period 
where vitamin D exposure was assessed.  Time to the first fracture hospitalization was 
assessed over one year using multivariable Cox proportional hazard regression.  The key 
measures of vitamin exposure were measured at the facility-level: 1) the proportion of 
vitamin D users/facility (derived using mixed-effects logistic regression); and 2) the average 
vitamin D dose per patient (derived using mixed-effects linear regression).  Fractures were 
grouped into four categories
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 Vitamin D use has increased sharply from 58.6% of patients treated in 1999 to 83.9% 
of patients treated in 2008.  Paricalcitol was the preferred formulation during the study years.  
In 2008, the average dose among black patients was 84% greater than among white patients.  
No significant relation was observed between the proportion of vitamin D users or the 
average vitamin D dose per patient at the facility-level and fracture rates for all fracture 
types.  Specifically, for any fracture, the hazard ratio (HR) in adjusted models for a facility’s 
proportion of vitamin D users was 1.10 (95% CI 0.86-1.42) while the HR for a facility’s 
average vitamin D dose per patient was 0.99 (95% CI 0.90-1.09).  
In summary, vitamin D use has increased and parallels the rise in use of paricalcitol 
and doxercalciferol.  Increasing vitamin D use and average vitamin D dose administered per 
patient within dialysis facilities did not have an observed beneficial association with 
fractures. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1  Overview 
Disordered bone mineral metabolism is rampant in end-stage renal disease (ESRD) 
patients and a considerable amount of time and resources are dedicated to its evaluation and 
treatment.
1
  Intravenous (IV) vitamin D has become a mainstay in bone-mineral disorder 
management and is used to treat secondary hyperparathyroidism (SHPT), a common 
complication among patients with ESRD.
2
  SHPT, characterized by increased parathyroid 
hormone (PTH) levels, has been associated with abnormalities in bone metabolism, soft 
tissue and vascular calcification and a range of other disorders.
2, 3
  Despite IV vitamin D’s 
widespread use and its proven effectiveness in decreasing PTH levels, there is a lack of 
evidence demonstrating that pharmacologically reducing PTH levels can actually result in 
improved fracture outcomes.  There are a myriad of examples from various therapeutic areas 
documenting instances where medications were approved for their efficacy in manipulating a 
surrogate biomarker but were eventually found to confer no clinical benefit or even harm.
1
 
It is important to evaluate whether vitamin D’s benefit extends beyond treating 
SHPT.  Patients with renal failure commonly experience fractures, associated with significant 
morbidity and mortality in this patient population.
4
  The age- and sex-adjusted risk of 
fracture is reported to be several times greater among ESRD patients when compared to the 
general population.
4
  SHPT and changes in PTH levels are associated with a range of bone
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 morphologies that may be linked to an increased risk of fracture.
5
  Although it would be 
tempting for nephrologists to use vitamin D to ameliorate the high clinical burden of 
fractures observed among dialysis patients, it would be ill-advised given the general lack of 
valid, population-based studies or clinical trials documenting any benefits or harms of IV 
vitamin D use for this indication.  
Also, studies exploring racial, gender, geographic secular variations, and patterns of 
vitamin D use are needed to document any secular trends in overuse of the drug, provide 
evidence in support of dialysis quality improvement initiatives, and alleviate any health 
disparities among patients with ESRD.  There have been no large-scale population-based 
observational studies, thus far, examining the association between vitamin D exposure and 
fracture risk among dialysis patients.  Vitamin D exposure refers to vitamin D-related 
treatment decisions regarding dialysis patients.  To address these salient deficits in the 
nephrology literature, the aims and hypotheses that comprise this dissertation are described 
below. 
 
1.2  Aims and Hypotheses  
Data were derived from the United States Renal Data System (USRDS), a national 
registry of all renal disease patients. The aims of this study were: 
Aim 1: To describe patient-level, facility-level, and state-level trends in the use and 
dosage of three vitamin D analogs among prevalent hemodialysis patients. 
Mean vitamin D dose per patient per year for each formulation was estimated at the 
patient, facility, and state level.  The monthly percentages of patients treated with each type 
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of vitamin D formulation were presented in longitudinal graphs comparing secular trends in 
vitamin D use in each calendar year between 1999 and 2008. 
 
Aim 2: To investigate the association between vitamin D exposure and fracture risk by 
fracture type and among relevant subgroups among incident hemodialysis patients.  
Null Hypotheses 
H10: There is no association between the non-case-mix proportion of vitamin D users within 
a dialysis facility and fracture risk. 
H20: There is no association between the case-mix adjusted proportion of vitamin D users 
within a dialysis facility and fracture risk. 
H30: There is no association between the non-case-mix average vitamin D dose per patient 
within a dialysis facility and fracture risk. 
H40: There is no association between the case-mix adjusted average vitamin D dose per 
patient within a dialysis facility and fracture risk. 
H50: There is no association between high case-mix adjusted average vitamin D doses per 
patient at the facility-level (the 75th percentile) and fracture risk. 
Alternative Hypotheses 
H1a: The non-case-mix adjusted proportion of vitamin D users within a dialysis facility is 
negatively associated with fracture risk. 
H2a: The case-mix adjusted proportion of vitamin D users within a dialysis facility is 
negatively associated with fracture risk. 
H3a: The non-case-mix adjusted average vitamin D dose within a dialysis facility is 
negatively associated with fracture risk. 
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H4a: The case-mix adjusted average vitamin D dose within a dialysis facility is negatively 
associated with fracture risk. 
H5a: High case-mix adjusted average vitamin D doses per patient at the facility-level (the 
75
th
 percentile) are negatively associated with fracture risk. 
 
We conducted a retrospective cohort, intention-to-treat analysis using data from 
2000-2004 where vitamin D exposure variables were measured as ecological variables at the 
facility-level while covariates and fracture outcomes were measured at the individual-level.  
The measures of vitamin D exposure for Aim 2 were ecological variables measured at the 
facility-level during the 180-day baseline period: 1) the non-case-mix adjusted proportion of 
vitamin D users in each facility; 2) the case-mix adjusted proportion of vitamin D users in 
each facility; 3) the non-case-mix adjusted average vitamin D dose per patient in each 
facility; 4) the case-mix adjusted average vitamin D dose per patient in each facility; and 5) 
whether a facility was in the highest quartile of case-mix adjusted average vitamin D dose 
per patient in each facility.  We focused the presentation of results on the case-mix adjusted 
measures of vitamin D exposure because they account for variations in patient characteristics 
at a dialysis facility that may have influenced how vitamin D was delivered. 
The outcome measure for Aim 2 was fracture risk.  The dependent variable in Cox 
proportional hazard models was the time to first fracture and the parameter estimates (hazard 
ratios) reflected the fracture risk.  Hereafter, fracture risk will be described using hazard 
ratios, defined in this study as the hazard for patients in the exposure group relative to those 
who were not exposed to vitamin D.  The dependent variable was the time to first fracture, 
the time in days from the end of the baseline period to the first fracture hospitalization.  
Fracture risk was assessed during the one-year follow-up period immediately following the 
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end of the baseline period.  In sum, fracture risk was used to describe our outcome and time 
to first fracture was used to describe the dependent variable in Cox proportional hazards 
models. 
A number of statistical techniques were employed to address the high likelihood of 
confounding by indication in this analysis given that we did not have access to clinical 
variables that likely mediate the association between vitamin D use and fracture risk.  We 
adopted a facility-practice-based, grouped-treatment approach whereby vitamin D exposure 
was measured ecologically while covariates and outcomes were measured at the individual-
level.  The main measures of vitamin D exposure (the case-mix adjusted proportion of 
vitamin D users and case-mix adjusted average vitamin D dose per patient) reflected the 
facility’s likelihood to prescribe vitamin D at certain doses based on the distribution of 
demographic and clinical characteristics of patients within the facility.  There is empirical 
evidence in the nephrology literature suggesting that facility-level characteristics have a great 
influence on patient-level health outcomes.  For instance, in a study of chronic hemodialysis 
patients within a non-profit dialysis provider, Chan and colleagues found evidence 
suggesting that the most important determinant of achieving optimal anemia management 
may be at the dialysis facility-level.
6
  Even after adjusting for the use of facility treatment 
protocols, a patient’s dialysis center was strongly associated with a patient’s achievement of 
target hemoglobin values.
6
 
Fractures in any diagnoses field in any one of four broad fracture categories were 
identified: 1) vertebral; 2) pelvis/hip; 3) other [femur, lower leg (tibia, fibula, patella & 
ankle), ribs/sternum, humerus, scapula & clavicle (shoulder/upper arm), or forearm/wrist]; 
and 4) any of the above fracture types.  Each fracture type was an end-point in multivariable 
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analyses.  Crude and covariate adjusted fracture rates were estimated.  Cox proportional 
hazard models examined fracture risk in models with time to fracture as the dependent 
variable.  Analyses adjusted for baseline patient demographic and clinical characteristics.  All 
analyses were conducted in the overall patient population within age, sex, and racial 
subgroups, respectively. 
The choice of covariates and the hypothesized relationship between important 
determinants of fracture risk was guided by Andersen’s Behavioral Model of Health Services 
Use.
7
  According to the model, predisposing, enabling and need factors comprise of 
population characteristics that determine health behavior, health service use, and health 
outcomes.  In all the Cox proportional hazard regression models performed, adjustments 
were made for predisposing characteristics such as age, sex, and race, attributes inherent to 
the individual prior to the onset of disease.  We also controlled for enabling characteristics 
such as eligibility for Medicaid and organizational level factors like a dialysis facility’s 
profit-status to reflect the healthcare resources available to the patient.  Comorbidities and 
functional status markers were included in our analysis to reflect need characteristics that 
compel individuals to seek health care services. These population characteristics 
(predisposing, enabling, and need) lead to a patient’s exposure to vitamin D as they get 
treated for renal failure and SHPT within a hemodialysis facility.  Exposure to vitamin D 
within a hemodialysis facility is hypothesized to be associated with the outcome of interest, 
fracture risk.  
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1.3  Significance of the Study  
Surrogate endpoints are defined as symptoms, laboratory values (e.g., serum calcium 
levels), symptoms (e.g., inflammation), clinical markers (e.g., body mass index) , and other 
measures of treatment efficacy that are used as a proxy for clinical outcomes like morbidity 
and mortality.
8
  There are grave potential safety consequences, cost-inefficiencies, and 
potential for mismanagement of patient care when a surrogate endpoint is assumed to be an 
appropriate substitute for clinical endpoints.  For instance, sodium fluoride was shown to 
effectively increase bone mineral density but it was proven to have no effect on fracture rates 
among postmenopausal women in clinical trials.
9
  In the nephrology community, there is a 
massive dearth in the literature regarding whether the metabolic changes in PTH levels 
induced by vitamin D administration actually correct the bone abnormalities and increased 
fracture risk observed among patients with ESRD.  The prognostic value of altered PTH 
levels as a surrogate endpoint for changes in fracture risk must be validated with biochemical 
and epidemiological evidence from both randomized clinical trials and observational studies 
like that conducted herein. 
9
  
Additionally, data generated from this analysis will most likely be relevant for 
Medicare given the case-mix–adjusted ESRD prospective payment system phased-in in 2011 
that changed the way in which dialysis facilities get paid for vitamin D administration.
10
  
During our study period, IV vitamin D and other injectable drugs were billed separately from 
dialysis services with reimbursement based on the total units of the drug administered.
11
  
This payment structure prompted large increases in vitamin D dose and expenditure.
11
  
Starting in 2011, IV vitamin D is billed alongside dialysis services under a single, bundled 
rated.  With the new system, providers may be incentivized to increase cost-efficiencies by 
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reducing the administration of vitamin D and injectable medications.
1
  Once contemporary 
data of the effect of the new bundled system becomes available, understanding the potential 
clinical benefit of vitamin D under the dosage practices of the old system can be used as 
evidence for task forces charged with evaluating the effect of reimbursement changes on 
dialysis patient care.
12
 
Moreover, clinicians do have good reason to suspect an association between vitamin 
D and fracture even though the relation has yet to be proven.  Due to its high prevalence and 
observable effects on bone structure, SHPT is believed to contribute meaningfully to the 
elevation in fracture risk observed in the dialysis population as a whole.  SHPT, common 
among dialysis patients, has direct pathological effects on bone.  Among dialysis patients, 
bone mineral disorders known as renal osteodystrophy has been associated with bone pain, 
muscle tendon ruptures and increased fracture risk.
13
  The action of PTH on bone is directly 
mediated through promoting osteoclast activity and bone resorption that can result in high-
turnover bone disease as documented by bone histology.
14, 15
  These consequences are 
believed to increase the risk of fracture, which has been estimated to be 4.4 to 14 times 
higher among dialysis patients than in the general population.
16
  
 There is a tremendous lack of studies examining the predictors of fracture risk within 
the ESRD population and the few published studies have investigated factors associated with 
hip fractures, neglecting other fracture types.  The current body of literature describes the 
association between clinical parameters and fracture risk among dialysis patients, with PTH 
levels as the defining surrogate marker.
17
  There are, however, a number of other risk factors 
for fracture that likely contribute to the elevated fracture rate in dialysis patients relative to 
their age, race, and gender-matched peers. Despite the expectation of severe clinical 
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consequences for dialysis patients who fracture, the literature currently describes the effect of 
surrogate serum markers on fractures and no studies to date have examined the association 
between vitamin D dose and the risk of fracture among dialysis patients.  
This was the first large, population-based study to examine the association between 
vitamin D exposure and bone outcomes by four fracture types and by age, sex and race.  The 
burden of SHPT, bone diseases and fractures among a costly, and morbid ESRD population 
warrants the research conducted herein.  
 
1.4  Summary 
Vitamin D therapy helps to maintain appropriate mineral metabolism, prevents bone 
disease, and minimizes loss of bone strength by decreasing PTH levels.
18
  However, the 
increasing and perhaps excessive doses of vitamin D administered to dialysis patients may 
confer minimal clinical benefit with respect to fractures.  The association between IV vitamin 
D exposure and fracture outcomes, to date, has not been investigated.  In order to fill this 
gap, we first provide descriptive data of secular trends in IV vitamin D use among 
hemodialysis patients in the United States to validate studies suggesting that the use of the 
drug has been increasing. Then, we examined the association between vitamin D exposure 
and various fracture outcomes by different subgroups and fracture type. 
The paucity of research regarding the clinical efficacy of IV vitamin D and the economic 
pressures likely influencing medical decision-making among nephrologists buttresses the 
significance of this study.  Results from this research can also be used to generate quality 
improvement initiatives aimed at addressing the high fracture risk observed in dialysis 
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patients.  Identifying disparities in vitamin D use may assist in providing evidence for 
adjusting payment for vitamin D among dialysis facilities with distinct patient characteristics.  
The results generated from the two study aims are presented in two distinct, stand-
alone manuscripts.  The following chapters describe the important published literature 
guiding this dissertation, the methods employed to examine the research questions, the two 
manuscripts produced from our investigations, and concludes with a discussion of important 
findings. 
 
 
  
 
CHAPTER II 
LITERATURE REVIEW 
 
This section presents the epidemiology of secondary hyperparathyroidism (SHPT) 
and the adverse skeletal and extraskeletal health outcomes associated with the disease. 
Mechanisms of treating SHPT are explored with an emphasis on the three most commonly 
administered commercially available vitamin D formulations. The gaps in the evidence 
regarding the association between vitamin D, intermediate clinical markers, bone disease and 
fracture risk are presented to support the need for studies investigating the independent 
association between vitamin D and fracture risk among hemodialysis patients. 
PubMed and Google Scholar were used to extract relevant articles published in 
English anytime before the 2013 calendar year.  Google and Google Scholar were used to 
identify conference proceedings, academic presentations, websites and other sources with 
pertinent information.  A free-text search strategy using a combination of Boolean operators 
was employed using search strings such as “vitamin D”, “fractures”, “paricalcitol”, 
“doxercalciferol”, “calcitriol”, “bone”, “skeletal”, “risk”, “secondary hyperparythyroidism”, 
“parathyroid hormone”, “race”, and “African American”.  To confirm the sensitivity of the 
search strategy, the bibliographies of all retrieved articles were reviewed for relevant articles.
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2.1  Secondary hyperparathyroidism in end-stage renal disease 
2.1.1  Pathogenesis, epidemiology, and consequences 
  SHPT is an extremely common complication associated with chronic kidney disease 
(CKD) and ESRD.  Approximately 78% of hemodialysis patients suffer from SHPT,
19
 a 
disease characterized by increased parathyroid hormone (PTH) levels.
20
  PTH is a 
polypeptide of 84 amino acids that plays a direct role in maintaining bone metabolism 
homeostasis and regulating calcium levels including the release of calcium into the blood and 
intestinal absorption of calcium.
21, 22
  The primary role of PTH is to reduce the excretion of 
calcium from the kidneys, control the release of calcium and phosphorus from bone, increase 
urinary excretion of phosphorous, and direct the synthesis of active vitamin D in the 
kidneys.
23
  
 To assess bone metabolism and disease, clinicians traditionally use the intact 
parathyroid hormone assay system which measures the full length PTH (1-84) but also has 
been found to react with large truncated fragments of non-1–84 PTH.24  Although there are 
newer generation assays that measure the full length 1-84 PTH
24
, current dialysis care 
guidelines are based on iPTH levels, advising nephrologist to maintain the dialyzed patient at 
a range of 150 and 300 pg/mL.
25
  A full discussion of the differences between PTH assays 
and the implications of using one versus another is beyond the scope of this work.  The 
central point is that different assays, even those from the same generation can produce highly 
different PTH levels thus affecting a patient’s SHPT and bone disorder classification.25  
Hereafter, “PTH” levels will reference concentrations in articles where the exact assay used 
was not referenced; differentiating from instances where the exact assay used was identified. 
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 Calcium is the most important parameter dictating SHPT progression.  PTH secretion 
is primarily regulated by calcium-sensing receptors located on the surface of parathyroid 
cells.
23
  In order to maintain homeostasis, calcium concentrations must be rigorously 
controlled and typically must not fluctuate above or below 2% of the normal level.
23
 
Figure 1 describes the pathogenesis and consequences associated with SHPT.  
 
Figure 1.  Pathogenesis and consequences of secondary hyperparathyroidism  
 
 
Source: Brown Alex J., Slatopolsky Eduardo: Vitamin d analogs: Therapeutic applications and mechanisms for 
selectivity. Molecular Aspects of Medicine 29: 433-452, 2008 
 
 In an individual with CKD, declines in kidney function engender phosphorous 
retention.
26, 27
   Decreased renal phosphorous excretion causes the retention of phosphorous 
in the body.
27
 Traditionally, control of phosphorous levels between 4.0 to 6.0 mg/dL ideally 
manages metabolic changes.
27
  Hyperphosphatemia, elevated phosphorous levels, has a direct 
impact on parathyroid cells and plays a role in increased PTH synthesis and secretion.  PTH 
synthesis is additionally increased due to vitamin D deficiency.
26
  
  
28 
Progressive kidney decline is also associated with declines in vitamin D synthesis by 
the kidney.
28
  Reduced activation of parathyroid vitamin D receptors (VDRs) are a 
consequence of vitamin D deficiency, fostering PTH mRNA transcription and inducing PTH 
synthesis.
26
  The mRNA transcription of PTH by the parathyroid gland is further increased 
because of the decreased ionized calcium available for binding to calcium sensing-receptors 
on the surface of the parathyroid glands.
27
  
Increased PTH levels, a uremic toxin, are linked to a myriad of serious, adverse 
clinical skeletal and non-skeletal effects.
29
  Skeletal-related clinical consequences of elevated 
PTH levels include a series of bone abnormalities termed renal osteodystrophy while non-
skeletal effects include hypertension, left ventricular hypertrophy, atherosclerosis, immune 
dysfunction and renal anemia.
29
  Renal function and PTH levels are inversely correlated as 
PTH levels continually increase with decreased renal function.
30
  SHPT-induced variations in 
bone histology and increased serum phosphorous and calcium, have all been implicated as 
factors in part responsible for the increased morbidity and mortality observed in hemodialysis 
patients.
30
   
The hypocalcemia induced by the decrease in serum vitamin D levels and increased 
phosphorous retention leads to pathyroid gland hyperplasia, the effects of which are 
clinically manifested with bone disease and system toxicity.
28
  The skeletal consequences of 
SHPT such as demineralization, bone pain and fractures are described in detail in later 
sections of this chapter.  
2.1.2  Disparities 
Racial disparities in the incidence of ESRD are well documented and persist.
3
  The 
incidence of ESRD is greater among minority populations than in white populations. 
  
29 
Compared to whites, the incidence of new black and Native American ESRD patients in 
2009 was 3.5 and 1.9 times greater, respectively. The ESRD incidence rate among Hispanics 
was 1.5 times that found in non-Hispanic populations.
3
  Given the current racial disparities in 
ESRD incidence, it was important to consider possible racial variations in the manifestation 
of SHPT and other disorders clinically present in the dialysis population. 
Race is a major determinant of SHPT.
31
  Black dialysis patients generally have higher 
iPTH levels in comparison to other races.
19
  Gupta and colleagues reported an average PTH 
level of 641.7 pg/mL in black dialysis patients and 346.0 pg/mL in white dialysis patients.
31
  
In comparison with white patients, black patients were reported to have a higher mean PTH 
level in a cohort of 218 patients within an ambulatory nephrology. 
32
   Wolf and colleagues 
also reported that black patients are given the most vitamin D therapy when compared to 
other ethnicities
33
, presumably because black patients have these reportedly higher PTH 
levels. 
In the general population, parathyroid gland mass is greater among blacks and there 
may be an increased risk of SHPT among black individuals when diagnosed with chronic 
kidney disease.
29
  Nearly all non-Hispanic blacks (97%) currently suffer from vitamin D 
deficiency in the general population.
34
  Additionally, some scholars have posited that because 
of their darker skin tones, black individuals synthesize less active vitamin D, 25(OH)D3, 
causing SHPT and greater parathyroid gland mass.
29
  
 Thus, compared to white patients, black dialysis patients are more likely to be vitamin 
D deficient and have more severe SHPT.
35
  However, black patients in the general 
population, also observed to have lower levels of circulating vitamin D compared to whites, 
do not have an increased risk of musculoskeletal disease.
36
  In fact, blacks have a lower rate 
  
30 
of fractures compared to other ethnicities.  There is some evidence that the clinical 
consequences of SHPT and renal osteodystrophy may vary by race, but the studies are scant 
and traditionally have focused on white subjects.  Elevated PTH levels and SHPT of greater 
severity may actually be protective in blacks, serving as a physiologically adaptive 
mechanism to maintain bone turnover.
31
  For instance, studies of predominantly white 
patients have concluded that a PTH level of 120 to 240 pg/mL is optimal for dialysis.
31
  
However, treating black ESRD patients using these guidelines may led to over-suppression 
of parathyroid gland and a greater risk of adynamic bone disease.
31
 
There is considerable debate regarding whether current therapeutic guidelines are 
applicable to black hemodialysis patients given documented differences in calcium balance 
and bone histomorphometry between blacks and non-blacks in the general population.
13
 
Differences in iPTH level between blacks and non-blacks have been discussed in the 
literature but there is currently no consensus on the optimal level of iPTH and subsequent 
ideal vitamin D dosing for hemodialysis patients by patient ethnicity.
13
  Moore and 
colleagues concluded that the published K/DOQI guideline iPTH threshold of less than 150 
pg/mL may not accurately identify black hemodialysis patients with adynamic bonde disease 
because the authors identified many black patients with adynamic bone disease above this 
cutoff after performing transiliac bone biopsies.
13
 
Adynamic bone disease, low born-turnover, affects approximately 30% of 
hemodialysis and 50% of peritoneal dialysis patients.
31, 37
  Patients with relative 
hypoparathyrodism (1-84 PTH, 150 pg/mL) are susceptible to adynamic bone disease while 
patients with severe hyperparathyroidism (1-84 PTH, 150 pg/mL) are susceptible to osteitis 
fibrosa cystica.
31
  The applicability of current research in this area for black patients is 
  
31 
unknown given that the relationship between PTH levels and bone turnover has been 
investigated predominantly among whites.
31
 
 Higher serum iPTH thresholds may be necessary among black hemodialysis patients 
to prevent adynamic bone disease, a disorder associated with fractures and increased 
mortality.
13
  Black dialysis patients are therefore at risk for over-therapy with the PTH 
overestimation resulting in adynamic bone disease and subsequent fracture and death.
38
  This 
analysis was warranted because trends over time in vitamin D dosing among different 
subgroups, including race, has not been documented to date.  More importantly, the relation 
between vitamin D therapy and bone outcomes by race may contribute to our understanding 
of the association between facility-level vitamin D dosing practices and fractures among 
black dialysis patients.  
 
2.2  Vitamin D therapy 
SHPT therapy attempts to maintain mineral metabolism, prevent bone disease and 
minimize the skeletal complications that eventually induce loss of bone strength and 
fractures.
18
  Additionally, treatments for SHPT aim to prevent the numerous extraskeletal 
complications such as vascular calcification that are associated with the high cardiovascular 
morbidity observed in ESRD patients. SHPT is currently managed with the concurrent use of 
phosphate binders, phosphate diet restrictions, and vitamin D therapy.
39
  These therapeutic 
modalities aim to address the range of mineral metabolism disturbances found in SHPT.  
These therapies are also instrumental in the prevention of hyperphosphatemia, 
phosphate retention, and the control of serum calcium levels.  The consequences of 
hyperphosphatemia and elevated calcium phosphorous product levels include hemodynamic 
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effects such as increased cardiac stroke index, vessel calcification and cardiac calcification.
40
 
A 1mg/dL increase in phosphorous levels is associated with a 6% incremental increase in the 
relative mortality risk among hemodialysis patients.
40, 41
  The mortality rate among 
hemodialysis patients has been shown to increase by 11% for every 10mg
2
/dL
2
 increase in 
calcium phosphorous product. 
40, 41
 
The pathogenesis of SHPT and the confluence of factors that foster it illustrate the 
tremendous complexities associated with treating the disease.  Vitamin D, phosphorous, 
calcium, and PTH levels must be simultaneously controlled, especially since the 
manipulation of one parameter directly or indirectly elicits a profound influence on another.  
Treatment regimens must be evaluated often and tailored to the disparate needs of a growing 
ESRD population. 
2.2.1  Role of vitamin D therapy  
Vitamin D therapy suppresses PTH levels in both direct and indirect ways.  Treatment 
with vitamin D directly reduces PTH levels by either inhibiting the enlargement of 
parathyroid glands or decreasing PTH synthesis.
42
  When active vitamin D is administered, 
messenger RNA synthesis to induce PTH production by parathyroid glands is decreased.
30
  In 
addition to reducing PTH synthesis and secretion by the parathyroid glands, active vitamin D 
plays a role in the absorption of dietary calcium by the intestines and in skeletal bone 
formation/resorption. 
30
  Indirectly, activation of the VDR increases calcium levels that 
subsequently activate the calcium sensing receptor.
42
  The advent of newer vitamin D agents 
is driven by the need to weigh the target effectiveness endpoint of reaching the goal serum 
iPTH of 150-300 pg/mL while simultaneously maintaining appropriate calcium and 
phosphorous levels.
30
 
 
  
33 
Figure 2.  Structure of IV vitamin D formulations 
 
 
Source: Martin KJ, González EA: Vitamin D analogues for the management of secondary hyperparathyroidism. 
Am J Kidney Dis 38: S34-S40, 2001 
 
Figure 2 depicts the structures of IV calcitriol (1α,25-dihydroxyvitamin D3; Calcijex, 
Abbott Laboratories, North Chicago, IL, USA), paricalcitol (19-nor-1α,25-dihydroxyvitamin 
D2; Zemplar, Abbott Laboratories) and doxercalciferol (1α-hydroxyvitamin D2; Hectorol, 
Genzyme).  Calcitriol, paricalcitol and doxercalciferol are the three most commonly 
prescribed IV vitamin D therapies used to manage SHPT among dialysis patients.  Calcitriol 
is the native, endogenous form of vitamin D while paricalcitol and doxercalciferol are 
considered vitamin D analogs, compounds of similar structure and properties.
43
   All vitamin 
D formulations can be categorized as D2 (e.g, paricalcitol) or D3 (e.g, calcitriol) contingent 
on the presence of a single or double bond between carbons 22 or 23 of the vitamin D side 
chain.
44
  Paricalcitol has the vitamin D2 side chain but the double-bond structure at the 19-
carbon position is lacking.
45
  Like paricalcitol, doxercalciferol also contains the vitamin D2 
side chain but the structure further incorporates an α-hydroxyl group at the 1-carbon 
position.
45
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Moreover, it is important to differentiate nutritional (inactive or native) from active 
(vitamin D3 or calcitriol) vitamin D medications.  The generic term “vitamin D” refers to 
numerous substances and variants of vitamin D with very different effects and physical 
consequences.  Nutritional vitamin D refers to compounds such as cholecalciferol and 
ergocalciferol found in foods high in vitamin D content.
44
  Active vitamin D compounds 
refer to agents with the ability to activate VDRs.
44
  In contrast to active vitamin D 
compounds, nutritional vitamin D is less efficacious in the suppression of PTH levels and in 
improving or maintaining the status of bone histology in dialysis patients.
46
  Precursors to 
active vitamin D are found in food and ultraviolet light exposure.
21
  In healthy individuals, a 
series of enzymatic reactions convert these precursors to the calcitriol/active vitamin D3 
molecule.
21
   The conversion of nutritional vitamin D (25-(OH)D3) to active vitamin D 
(1,25(OH)2D3) occurs due to the 1-α-hydrolase enzyme located in the mitochrondria of 
proximal tubular cells of the kidney.
27
  With declining renal function, the kidney becomes 
less able to perform 1α-hydroxylation, the final reaction response for the synthesis of active 
vitamin D, and PTH levels rise.
21
  
IV rather than oral vitamin D formulations were the predictors of interest for the work 
presented herein.  IV vitamin D is preferred for hemodialysis patients because these 
medications can be easily administered during dialysis sessions while oral forms are 
generally most appropriate for patients with CKD.
27
  Although the route of administration 
will vary with patient-provider preference, IV administration is advantageous for several 
reasons.  Foremost, higher peak blood concentrations result given the lack of hepatic first-
pass metabolism with IV administration.
27
  By bypassing the gastrointestinal tract, IV dosing 
may decrease the risk of hypercalcemia.
27
  Lastly, similar to the issues encountered with 
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patient intake of most oral medications, prescribers must consider the decrease in medication 
efficacy associated with patient non-adherence of oral vitamin D therapy.
27
  
Evidence regarding optimal treatment of bone mineral disorders in dialysis patients is 
scant with guidance predominantly provided by the opinion-based National Kidney 
Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for 
Bone Metabolism and Disease in Chronic Kidney Disease (K/DOQI).
47
  Decisions to 
administer vitamin D sterols are guided by PTH levels, with physicians urged to concurrently 
consider serum calcium and phosphorous levels.
48
  IV vitamin D should be given to dialysis 
patients with a PTH level greater than 300pg/mL in order to suppress PTH levels to the target 
range of 150pg/mL to 300pg/mL.
47
  The K/DOQI disseminates guidelines three opinion-
based algorithms for the management of vitamin D sterols based on either serum calcium, 
phosphorous or intact PTH levels. Appendix 1 depicts the guideline based on dialysis patient 
intact PTH levels.
47
 
2.2.2  Calcitriol 
Calcitriol administration in dialysis patients has been associated with elevated serum 
calcium and phosphorous concentrations and also low bone turnover (hypodynamic bone 
disease).
44
  Nine chronic hemodialysis patients were administered 2µg of IV calcitriol three 
times a week for ten weeks.
49
  Following therapy, baseline PTH levels were reduced from 
902 +/- 126 pg/mL to 466 +/- 152 pg/mL (p< 0.01).
49
  
2.2.3  Paricalcitol 
Paricalcitol, a biologically active, manufactured vitamin D analog, is used to prevent 
and treat SHPT associated with ESRD.
39
  IV paricalcitol gained FDA approval in 1998 while 
the oral form was approved in 2005.
50
  Paricalcitol decreases PTH levels by suppressing PTH 
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release and preventing PTH synthesis.
39
  Additionally, the drug promotes bone 
mineralization and intestinal calcium and phosphorous absorption.
39
  In multicenter, 
prospective trials of greater than 12 months, paricalcitol reduced PTH levels by 
approximately 59% to 82%.
51
  In hemodialysis patients, a 0.24mcg/kg bolus IV 
administration of paricalcitol has a mean elimination half-life of 19.9 hours. 
39
  
The efficacy of paricalcitol has been evaluated in numerous clinical trials with the 
majority of trials comparing paricalcitol users to patients receiving placebo. Three double-
blind, placebo-controlled, dose-escalating, randomized, multicenter trials of 78 hemodialysis 
patients treated for 12 weeks found a significant decrease in iPTH levels from 795 ± 86 to 
406 ± 106 pg/mL (p< 0.001).
52
  Long-term studies of paricalcitol have confirmed these 
findings. In an open-label, multicenter, 13-month study of 164 hemodialysis patients, IV 
paricalcitol administered at a dose of 0.04-0.394µg/kg 2-3 times per week rapidly and 
effectively suppressed iPTH levels.
53
  Mean iPTH levels reached designated target levels of 
100-300 pg/mL, going from a baseline mean of 628.3 +/- 27.65 pg/mL to 295.3 +/- 25.69 
pg/mL.
53
   Paricalcitol has been shown to suppress PTH levels even in in patients with 
protracted SHPT resistant to calcitriol therapy.
54
 
2.2.4  Doxercalciferol 
Doxercalciferol is a synthetic vitamin D agent that is converted to the biologically 
active form of vitamin D2, 1-α-hydroxy-vitamin D2 through the hepatic metabolic, post 
administration.
30
  Doxercalciferol, brand name Hectorol, is available as an 4µg/2mL solution 
or a 2µg/1mL solution for IV injection.
55
  Although the ideal dose of doxercalciferol must be 
tailored to the individual needs of each dialysis patient, the recommended starting dose is 
4µg, bolus injections three times per week.
55
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Both intermittent oral and IV doxercalciferol therapy effectively suppress iPTH levels 
but IV doxercalciferol does so with less instances of hypercalcemia and hypophosphatemia.
56
 
2.2.5   Clinical and economic differences of vitamin D formulations 
The first available vitamin D analog, calcitriol, can effectively lower serum PTH 
levels.
57
  However, calcitriol has also been shown to increase serum calcium levels by 
inducing intestinal calcium absorption and bone resorption.  The risk of both hypercalcemia 
and coronary artery calcification may increase when calcitriol is used simultaneously with 
calcium-based phosphorous binders or dialysate with high calcium concentrations.
57
  The 
vitamin D2 analogs, paricalcitol and doxercalciferol, are vitamin D analogs also considered 
mainstream therapy among dialysis patients.
57
  Both vitamin D2 analogs, like calcitriol, can 
effectively lower PTH levels but do so with a smaller effect on serum calcium and 
phosphorous concentrations compared to calcitriol.
57
  Unlike calcitriol, paricalcitol is 
considered a selective VDR activator, indicating that the administration of paricalcitol results 
in less activation of vitamin D receptors in the gastrointestinal tract, invariably leading to 
reduced calcium and phosphorous absorption.
44
 
Several studies have demonstrated equivalent or even superior PTH level suppression 
with the use of these paricalcitol or doxercalciferol compared to calcitriol.
58
  A 2007 meta-
analysis of randomized controlled trials of chronic kidney disease patients actually 
demonstrated both potentially positive and detrimental effects of paricalciltol and 
doxercalciferol.  Paricalcitol and doxercalciferol were shown to significantly reduce PTH 
levels by about 11pmol/L (100 pg/mL) but they also simultaneously increase phosphorous 
levels.
58
  Reduced PTH levels may correspond to a decrease in patient mortality risk by 
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approximately 5% to 10% over a 3 year span but the increase in phosphorous concentrations 
may increase mortality by an equivalent amount.
58
  
Sprague and colleagues performed the first double-blind, randomized, multicenter 
study of 263 hemodialysis patients at 27 facilities in the United States, The Netherlands, 
Spain, and Switzerland to assess the comparative effectiveness and safety of paricalcitol 
versus calcitriol,.
59
  Dosed at a 4:1 paricalcitol to calcitriol ratio, paricalcitol decreased PTH 
concentrations more rapidly compared to calcitriol.
59
  From baseline, paricalcitol treated 
patients achieved at least a 50% mean reduction in baseline PTH levels at week 15 compared 
to week 23 for patients receiving calcitriol.
59
  The authors found no statistically significant 
differences in the incidence of hyperphosphatemia in paricalcitol versus calcitriol treated 
subjects, a finding contrary to previously published studies comparing the two drugs.
59
 
However, compared to calcitriol subjects, patients receiving paricalcitol experienced lower 
hypercalcemic episodes (18% versus 33%, p=0.008) and fewer elevated calcium-
phosphorous product incidences.
59
 
Also, in a study by Dobrez and colleagues, approximately 94% of paricalcitol-treated 
patients remained on the therapy whereas only 58.7% of patients who initiated with calcitriol 
stayed on the drug, suggesting that paricalcitol may be better tolerated.
39, 60
 
In addition to the clinical differences between the three IV vitamin D formulations, 
there remain economic and cost variations in administering the drugs.  There are over 
570,000 prevalent ESRD patients as of December 31, 2009, a 2.1% increase than in the 
previous year.  Although patterns of IV vitamin D formulation use and dose effects have 
never been explored within this growing population, cost data from the 2011 USRDS annual 
report provides a strong indication of potential racial and geographic disparities in use.
3
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Approximately $509 million was spent on IV vitamin D therapy in 2009, accounting for 
18.3% of the $2.78 billion spent on all injectable medications for dialysis patients that year.
3
  
In 2009, per person per year costs were greatest for paricalcitol ($1,926), followed by 
doxercalciferol ($1,326) with calcitriol annual per person costs lowest at $456.
3
  
2.2.6  Factors currently associated with vitamin D use 
Compared to patients receiving calcitriol, patients administered paricalcitol were 
more likely to be black, have an arteriovenous fistula, and have higher baseline serum levels 
of calcium, phosphorus, and PTH. Paricalcitol treated patients were also less likely to be 
diabetic.
61
 Paricalcitol use has been found to be greatest in the southern region of the 
country.
60
 
Cost data suggests racial and geographic differences in vitamin D use.  In 2009, IV 
vitamin D per person per year Medicare expenditures for black patients was $1,846 
compared to $1,059 for white patients, constituting a 74% difference. This difference in 
Medicare medication costs by race, however, seems only to be specific to IV vitamin D with 
relatively similar costs observed for other injectable medications across races.
3
  For instance, 
in 2009, per person IV iron Medicare expenditures for whites and blacks were $789 and 
$814, respectively, representing only a 3% difference.
3
  Similar to geographic patterns 
observed with ESA and IV iron costs, the USRDS annual reported showed that the lowest per 
person per year costs of IV vitamin D were in the western portion of the country while the 
highest costs were found in the East and along the Gulf Coast region.
3
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2.3  Adjunct therapies  
In addition to vitamin D, therapy for the regulation of PTH levels and to maintain 
mineral homeostasis also includes oral phosphate binding agents, calcimimetics and 
parathyroidectomies.
62
  Serum concentrations of phosphorous are reduced with oral 
phosphate binding agents like calcium, sevelamer, lanthanum, magnesium and aluminum.
62
  
Phosphate binders are frequently prescribed to dialysis patients to control the deleterious 
effects of elevated phosphorus levels, hyperphospatemia.
40
  Calcimimetic agents actively 
reduce PTH secretions without simultaneously increasing calcium and phosphorous levels.
62
 
Sensipar, Cinacalcet HCL, the only U.S. Food and Drug Administration (FDA) approved 
calcimimetic agent, is available in oral form as a daily treatment of hypercalcemia in ESRD 
patients with  SHPT or parathyroid carcinoma.
62
  Sensipar increases the sensitivity of the 
calcium-sensing receptor on parathyroid glands to extracellular calcium.
63
  Sensipar was able 
to suppress iPTH levels in a phase 3, multicenter, randomized, placebo-controlled, double-
blind study of dialysis patients independent of treatment with traditional SHPT therapies.
64
 
The subsequent decrease in calcium levels directly decrease PTH levels.
63
  
Parathyroidectomies, the oldest SHPT treatment, are perhaps the least preferred 
option.  Surgery to remove the parathyroid glands, usually performed in patients with 
recalcitrant SHPT, is accompanied by numerous potential risks and complications.
62
  In 
addition to the traditional risks associated with anesthesia, following surgery, patients may 
experience severe hypocalcemia, permanent hypoparathyroidism, or require additional 
surgery.
62
 
It is important to note that in the general population, anti-osteoporosis agents such as 
bisphosphonates are used to prevent bone disorders.
65
  Bisphosphonates are not generally 
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prescribed to dialysis patients because of safety concerns over toxicity related to impaired 
renal excretion
66-68
, and bone disease in dialysis patients is often due to SHPT and other 
forms of renal osteodystrophy, including osteomalacia and adynamic bone disease
4
, which 
effect fracture risk independent of bone density.   
  
2.4  Renal osteodystrophy and fractures in End Stage Renal Disease  
2.4.1  Epidemiology of renal osteodystrophy  
Renal osteodystrophy is an overarching label for both high-turnover bone disorders 
termed osteitis fibrosa cystica and low-turnover disorders such as osteomalcia and adynamic 
bone disease.
30
  Specifically, renal osteodystrophy can present itself in any of five 
histopathological forms including osteitis fibrosa, osteomalcia mixed lesions, mild lesions, 
and adynamic bone disease.
69
  Often a consequence of SHPT, osteitis fribrosa, the most 
common form of renal osteodystrophy, is characterized by increases in bone formation, 
resorption and marrow fibrosis.
27
   On the contrary, in addition to low bone-specific alkaline 
phosphatase levels, adynamic bone disease is characterized by low iPTH levels below 
200pg/mL and decreased bone formation.
70
  
At this juncture, it is important to differentiate renal osteodystrophy from 
osteoporosis.  The bone histology in renal osteodystrophy is characterized by bone 
remodeling and is best diagnosed with a bone biopsy.
70
   Osteoporosis, contrarily, is a 
systematic skeletal disease defined by low bone mass and deterioration of bone tissue.
71
  
In sum, disturbances in the vitamin D-PTH axis and disturbances in PTH, calcium, 
phosphorous, and vitamin D regulation lead to renal osteodystrophy.
72
  Both high and low 
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bone turnover characterize renal osteodystrophy as the disease can be classified broadly into 
osteitis fibrosa, osteomalcia, adynamic bone disease, and mixed osteodystrophy.
72
 
2.4.2  Clinical and economic burden of fractures 
ESRD patients have been observed to be at increased risk of fractures relative to those 
without renal impairment.
73
  Patients with ESRD are 4.4 to 14 times more likely to 
experience a hip fracture compared to individuals in the general population.
16
  These 
estimates, however, were derived using data solely from Caucasian incident dialysis patients 
within the USRDS between 1989 and 1996.
74
  The incidence of any fracture is approximately 
20 per 1000 patient years on dialysis with a three-to-four fold increased risk of hip fracture 
reported for ESRD patients.
75, 76
  Dialysis patients who have never had a kidney transplant 
and those who have undergone transplantation have an observed hip fracture incidence rate 
of 2.9 fractures and 3.3 fractures per 1,000 person-years, respectively.
73
  
 The average or median time to fracture following dialysis initiation is informative for 
this analysis to serve as a benchmark to assess whether time to first fracture, the dependent 
variable in Cox regression models, is reduced with the administration of vitamin D.  
Published studies, however, currently do not explicitly provide this data.  Although we do not 
have information regarding the mean or median time to fracture since dialysis initiation, we 
can infer from a few studies that time since dialysis initiation (dialysis vintage) is associated 
with an increased risk of fracture.
74, 77
  Alem and colleagues stratified patients into four 
vintage categories (3 months-1 year, 1-2 years, 2-4 years, and greater than 4 years.
74
  The 
authors found that fracture incidence rates increased by 2.7-fold when comparing patients in 
the shortest versus longest vintage category among males and increased by about two-fold 
among females.  Fractures dramatically increase one’s likelihood of death and the one-year 
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mortality rate following a hip fracture has ranged from about 15 to 40% in the general 
population.
78
  In the US, there are over a quarter of a million hip fractures every year 
resulting in 14% to 36% mortality in the first year following fracture.
79
  Coco and colleagues 
reported a hip fracture incidence rate of 13.9 per 1,000 patient-years among a cohort of 1,272 
patients within outpatient dialysis facilities in New York between 1988 and 1998.
80
  
Mortality one year subsequent to the hip fracture event was by far greater among dialysis 
patients when compared those in the general population.  A 64% one-year mortality rate was 
found among the dialysis cohort compared to a 20% one-year mortality rate in the general 
population.
80
  
A population based cohort study by Mittalhenkle and colleagues found that, among 
U.S. incident dialysis patients between 1995 and 2000, hip fractures were associated with a 
2.15 time increase in the incidence rate ratio for all-cause mortality.
81
  After experiencing a 
hip fracture, dialysis patients had a one-year survival rate of approximately 50%.
81
  Among 
patients with no history of cardiovascular disease, the risk of cardiovascular events was 40% 
greater and the risk of cardiovascular mortality was 84% greater among dialysis patients who 
sustained a fracture compared to those who did not, respectively.
81
   
The subsequent morbidity following hip fractures is also remarkably high with 
surviving patients experiencing decreased functional ability even several months post 
fracture.
79
  Following a fracture, patients may need care at a skilled nursing facility and 
assistance with mobility, and personal care including needing help with self dressing and 
bathing.
79
 
73, 74, 77, 82-84
  In the general population, a hip fracture is associated with permanent 
disability and admission to long-term nursing facilities.
78, 85
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 There is a substantial economic burden associated with the occurrence and treatment 
of fractures in the US.  Using a Markov state-transition model, Burge and colleagues 
predicted the incidence and costs associated with osteoporosis-related fractures in the general 
population of the US from 2005 to 2025.
86
  The investigators predicted an incidence of two 
million fractures in 2005 at a cost of $17 billion with hip fractures accounting for 72% of 
total costs but only 14% of the overall distribution of fractures.
86
  By 2025, the incidence of 
fractures is expected to increase by 48%, contributing to $25.3 billion in costs.
86
 
 Furthermore, there is strong evidence that there is interstate variability in both the 
incidence and economic burden of fractures in the United States.  Also using a Markov state-
transition model of osteoporosis-related fractures, King and colleagues highlighted the 
geographic and hospital fracture care pattern differences in five states.
87
  In 2000, mean 
hospital charges for hip fractures ranged from $16,700 in Massachusetts to $29,500 in 
California.
87
  The disparity in mean charges was not explained by the length of stay 
associated with hip fracture hospital admissions.
87
  The fracture incidence estimated in 2005 
ranged from 199 per 10,000 in California to 266 per 10,000 in Massachusetts.
87
  In 2005, 
total costs attributable to fractures varied from $270 million in Arizona to $1,434 million in 
California.
87
 
   In the dialysis population, an episode of hip, vertebral, and pelvic fracture was 
associated with a total cost of $20,810 (SD=$16,743), $17,063 (SD=$26,201), $14,475 
(SD=$19,209), respectively.
88
  Total costs were primarily attributable to hospitalizations and 
skill nursing facility care with 65%-74% of costs due to hospitalizations and 11%-21% 
caused by costs accrued during skilled nursing facility stays.
88
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 Although this analysis did not explore variations in the cost of fractures among 
dialysis patients, it does contribute to the literature by documenting the burden of fracture 
related hospitalizations in the hemodialysis population. 
2.4.3  Factors associated with fractures 
Hemodialysis patients are susceptible to the risk factors for fracture observed among 
individuals in the general population but also experience additional risk factors attributable to 
their disease.  The following section describes the risk factors for fracture observed in the 
general population and then summarizes the current literature investigating the risk factors 
for fracture among the dialysis population. 
Fracture risk is multifactorial and risk factors related to falling, bone strength, and 
clinical characteristics have been identified.
89
  In the general population, approximately 90-
97% of proximal humerus fractures and greater than 95% of hip fractures are due to falls.
89, 90
  
Approximately 40% of dialysis patients fall per year, likely contributing to the increased 
fracture risk in this population.
91
  The relationship between low vitamin D levels, muscle 
weakness, falls and subsequent fracture risk has yet to be elucidated.
91
  Frail patients and 
those who are not physically active are more likely to fall.
90
  Certain medical conditions can 
also increase one’s risk of falls and subsequent fracture.  Diabetic patients, for instance, are 
more likely to fall due to gait impairment, peripheral neuropathy and poor visual acuity.
90
  
Epileptic seizures and side effects like dizziness and sleepiness associated with anti-epilectic 
drugs may also increase one’s fall and fracture risk.90   
Clinical characteristics such as age, female sex, Asian or white ethnicity and cigarette 
smoking are also strong predictors of fracture in the general population.  For instance, 
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decreased bone mineral density and a 50% greater lifetime risk of hip fracture has been 
attributed to smoking.
89
 
Several explanations have been advanced to attempt to explain the excess risk of hip 
fractures observed among ESRD patients when compared to the general population. 
Concomitant conditions associated with ESRD such as metabolic bone disease, 
hypogonadism, avascular necrosis, and chronic acidosis may engender bone loss among this 
population, increasing one’s risk of fracture.74  
Using USRDS data in a population-based cohort study, Stehman-Breen and 
colleagues investigated the risk factors for hip fracture among ESRD patients.
92
  The authors 
found that Caucasian race, female sex, lower BMI, age, and peripheral vascular disease were 
all independently associated with an increased risk of fracture.
92
  Specifically, compared to 
whites, black ESRD patients demonstrated a 42% lower risk of hip fracture (adjusted RR 
0.58; 95% CI 0.37-0.91).
92
   A two-fold or greater increase in the risk of hip fracture was 
independently associated with peripheral vascular disease (adjusted RR 1.94; 95% CI 1.29-
2.92), female sex (adjusted RR 2.26; 95% CI 1.48-3.44) or a BMI less than 23 (adjusted RR 
2.51; 95% CI 1.65-3.82).
92
  Interestingly, clinical parameters such as iPTH, aluminum, 
calcium and phosphate were not associated with the risk of hip fracture in the study.
92
 
Disparities in incidence and mortality rates have been observed across race and sex 
with white dialysis patients experiencing the greatest incidence of hip fracture.
80
  Women 
incurred the greatest burden of hip fractures with an incidence rate of 24.1 per 1,000 patient-
years compared to 11.7 per 1,000 patient-years in male dialysis patients.
80
   The overall 
incidence of hip fracture has been confirmed to be less among men than women in a study by 
Alem and colleagues.
74
  The authors observed an overall fracture incidence rate of 7.45 per 
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1000 person-years among men but a 13.63 per 1000 person-years rate among women.
74
 
White patients, those with higher alkaline phosphatase levels and  PTH levels less than 195 
pg/dL are all significant predictors of hip fractures.
80
   
 Vertebral fractures are more prevalent in female, diabetic hemodialysis patients over 
the age of 65 (32.3%) in comparison to hemodialysis patients without diabetes (13.2%) after 
adjustment for age, dialysis vintage and several laboratory parameters.
82
  The impaired bone 
formation and low bone turnover observed in type 2 diabetics, including those with ESRD, 
may be due to abnormalities in vascular function.  Complications induced by microvascular 
issues in diabetics may decrease blood supply to bone cells which in turn may interfere with 
osteoblast function.
82
  Other possible explanations for the observed increase in fractures 
among diabetic hemodialysis patients include factors that may induce falls such as impaired 
sight, gait and balance from diabetic retinopathy and cataracts.
82
  The study was conducted 
among a relatively homogenous population of hemodialysis patients maintained at Shirasagi 
Hospital in Japan and, therefore, race was not included as a risk factor in the analyses. 
 This analysis contributes to the current medical literature regarding the risk factors for 
fractures among dialysis patients by specifically examining the association between vitamin 
D exposure and fracture risk. 
 
 
2.5   Vitamin D therapy and non-skeletal and skeletal outcomes 
 
2.5.1  Vitamin D therapy and non-skeletal outcomes  
The relationship between vitamin D therapy and non-skeletal outcomes like 
hospitalization and mortality has been explored with varying results depending on the 
robustness of methodologies used.  
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In a retrospective study of 11,443 adult hemodialysis patients, Dobrez and colleagues 
were the first and only researchers to date to examine the relationship between specific 
vitamin D therapies and several hospitalization outcomes.
60
  Compared to calcitriol users, 
patients who initiated dialysis on paricalcitol were 14% less likely to be hospitalized 
(HR=0.863, p<0.0001), had 6.84 fewer hospitalization days per year (p<0.0001) and 0.642 
fewer hospital admissions per year (p<0.0001).
60
  The reduced hospitalization days from the 
use of paricalcitol at the start of dialysis therapy may result in a potential cost savings of 
between $7,699 to $11,000 per year.
60
  It should be noted that these study estimates were 
rather conservative given that a greater percentage of paricalcitol treated patients in the study 
had abnormally high baseline iPTH and more comorbidities in comparison to calcitriol-
treated patients.
60
 
In a study of 14,967 chronic hemodialysis patients at a not-for-profit dialysis facility, 
Tentori and colleagues investigated the relationship between specific vitamin D formulations 
and mortality.
57
  Compared to doxercalciferol-treated patients, individuals treated with 
paricalcitol did not demonstrate a survival advantage.
57
  Paricalcitol treated patients had a 
mortality rate (death/100 patient-years) of 15.3 (95% CI 13.6-16.9; p<0.0001), virtually 
identical to the mortality rate of 15.4 (95% CI 13.6-17.1; p=0.0003) observed among patients 
treated with doxercalciferol.
57
  Contrarily, patients administered calcitriol exhibited a 
significantly worse mortality rate of 19.6 (95% CI 18.2-21.1) compared to those treated with 
other vitamin D analogs.
57
  The poorer mortality outcomes associated with calcitriol were 
also reflected in unadjusted hazard models but the mortality differences between 
doxercalciferol and paricalcitol versus calcitriol were not statistically significant in models 
that adjusted for various laboratory parameters.
57
 
  
49 
A significant 7-17% adjusted risk reduction in all-cause mortality has been observed 
among regular vitamin D users in comparison to non-users with the greatest reductions found 
in patients where dialysis sessions were shorter.
93
  In 2003, Teng and colleagues published a 
historical cohort study comparing the three year survival of 67,399 long term hemodialysis 
patients who were treated with either paricalcitiol or calcitriol at for-profit dialysis centers 
between 1999 and 2001.
61
  Paricalcitol treated patients experienced a significantly lower 
mortality rate (0.180 per person-year) compared to patients receiving calcitriol (0.223 per 
person-year).
61
  In adjusted Cox propotional-hazards models, paricalcitol treatment conferred 
a 16% survival advantage (95% CI 10-21%) compared to calcitriol treatment.
61
  Teng and 
colleagues also published a historical cohort study in 2005 of 51,937 incident hemodialysis 
patients within a large, for-profit organization.
94
  Patients administered any vitamin D 
formulation had a 20% survival advantage compared to patients who did not receive vitamin 
D, a result that was consistent among patients at all levels of serum calcium, phosphorus and 
PTH.
94
  Mean dose per administration of paricalcitol and calcitriol has been found to be 
approximately 4.3 µg and 1.1 µg, respectively.
61
  Consistent with the majority of studies of 
vitamin D analogs, Teng et al. did not assess the effect of dose on mortality outcomes. 
With regards to mortality, a study of dialysis patients within a not-for profit facility 
found that paricalcitol-treated and doxercalciferol-treated patients were identical in their risks 
for all-cause and artherosclerotic cardiovascular disease.
57
  Mortality risk was higher among 
patients receiving calcitriol compared to paricalcitol or docercalciferol, but the magnitude of 
the differences in mortality risks varied depending on whether models had been adjusted for 
important covariates like race.
57
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There is recent controversy regarding whether the use of vitamin D generally confers 
a survival benefit to dialysis patients.  No survival advantage was found among patients 
administered vitamin D therapy when models rigorously controlled for previously 
unmeasured confounding variables such as underlying health status.
95
 
Furthermore, Shinaberger and colleagues presented one of the only studies suggesting 
a dosage-response association between increasing weekly doses of paricalcitol and survival.  
Shinaberger and colleagues followed 23,727 hemodialysis patients served at DaVita. Inc 
outpatient clinics who received only paricalcitol as vitamin D therapy.
96
  As the weekly dose 
of paricalcitol per unit of serum PTH increased, patients experienced better survival.
96
  The 
dosage-response association of paricalcitol with greater survival suggests that dose is an 
important, yet frequently neglected factor that may have a direct impact on patient outcomes.  
Confounding by indication may have plague previous studies that found the converse, the 
association of lower survival rates with higher doses of IV vitamin D.  Patients with elevated 
PTH levels, worse SHPT, and who ultimately were more likely to die were likely given 
higher doses of vitamin D.
96
  
The reduced hypercalcemic and hyperphosphatemic effects of paricalcitol have been 
hypothesized to be among one of the major reasons why the drug has been observed to have 
a survival benefit in dialysis patients when compared to other vitamin D formulations.
44
 
2.5.2  Vitamin D therapy and skeletal outcomes 
Studies suggest that vitamin D therapy has an effect on skeletal outcomes.  A 
randomized controlled trial of 60 peritoneal, pediatric patients concluded that calcitriol and 
doxercalciferol were equivalent in their ability control serum PTH levels and suppressing 
bone formation rates.
97
  Compared to calcitriol, paricalcitol likely does not inhibit osteoclast 
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activity at therapeutic doses, an observation that may explain the lower calcemic effects of 
paricalcitol in comparison to calcitriol.
98
 
Using rat models, Jokiharaa et al. found that paricalcitol effectively treated renal-
insufficiency induced bone mineral loss and bone mechanical competence.
99
  Forty-five rats 
were either randomized to a 5/6 nephrectomy or Sham-operation initially and then rats were 
further randomized later to either uremic control or paricalcitol treatment.
99
  Uremic control 
rats were observed to have an 8.1% and 6.6% decrease in bone mineral density at the femoral 
neck and midshaft, respectively, but the paricalcitol treated rats did not experience similar 
bone mineral density changes.
99
 
2.5.3  Relationship between clinical parameters, secondary hyperparathyroidism treatment 
and skeletal outcomes 
The exact relationship between SHPT, PTH, bone disease, and fracture risk remains 
unclear.  Although the relationship is well established in the healthy population, there are 
large discrepancies in the association between bone mineral density and fractures in dialysis 
patients.
4
  For instance, bone density measured at the lumbar spine has been predictive of 
fractures but no associations were found between fractures and bone density measured at the 
femoral neck.
4
  Furthermore, dialysis patients are also at greater risk compared to the general 
population for several metabolic bone diseases, such as osteomalacia and adynamic bone 
disease, that effect fracture rates independent of alterations in bone density.
4
 
SHPT and changes in PTH levels may be associated with bone disease and a range of 
bone morphologies collectively known as renal osteodystrophy among patients with kidney 
impairment.
100
  PTH, considered a surrogate indicator of bone turnover, predicts the 
histologic bone disease type.
31
  The main forms of osteodystrophy (osteitis fibrosa cystica, 
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adynamic bone disease, and osteomalacia) may be linked to an increased risk of fracture in 
ESRD patients due to changes in bone turnover, mineralization, and volume, but the link has 
yet to be established in the literature.
100
  Patients with relative hyperparathyroidism, 1-84 
PTH less than 150 pg/mL, are predisposed to adynamic bone disease, occurring in 
approximately 30% of hemodialysis and 50% of peritoneal dialysis patients.
31
  Contrarily, 
osteitis fibrosa is associated with 1-84 PTH levels greater than 500pg/mL.
31
  Evidence 
suggests that fracture rates among dialysis patients may vary by type of renal osteodystrophy.  
In a study of 31 dialysis patients, Piraino and colleagues found a higher rate of 0.2 
fractures/year among patients with low bone turnover osteodystrophy when compared to 
osteitis fibrosis patients with a fracture rate 0.1 fractures/year.
101
  
The exact relationship between PTH levels and underlying bone disease has yet to be 
established and the ability to diagnose bone disorders is currently inadequate.
72
  Several 
studies have been unable to find a definite link between reduced bone density and PTH 
levels.
75
  In one of the few studies modeling the effect of clinical parameters on fracture risk, 
Danese et al. examined the relationship between serum calcium, phosphorus, and PTH levels 
and the risk of hip, pelvic, and vertebral fractures among dialysis patients.
88
  The adjusted 
relative hazard associated with PTH levels was U-shaped , decreasing from a maximum then 
progressively increasing, for both vertebral and hip fractures.
88
  Other researchers have 
concluded that the increased PTH levels associated with vitamin D deficiency lead to high 
bone turnover which in turn causes cortical bone loss and low bone density, both of which 
cause hip fracture.
5
  
It is very important to note that the relationship between PTH levels and bone 
diseases have been derived overwhelmingly based on studies of white dialysis patients and, 
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therefore, associations may not necessarily hold for black dialysis subjects.
31
  However, 
previously published studies do provide researchers some insight into the potential 
association of several covariates with fracture risk among all dialysis patients.  
 In sum, the heterogeneous pathology of bone disease contributes greatly to the 
complexity and uncertainties associated with solidifying the causal relationship between 
vitamin D deficiency, SHPT, PTH levels, bone disease, bone density, and fracture risks in 
ESRD patients.  In a population-based study of ESRD patients, Caucasian ethnicity, older 
age, female gender, peripheral vascular disease, and lower BMI were found to be 
independent predictors of hip fractures.
92
  Although the aforementioned risk factors have 
been established, no studies thus far have examined the association between vitamin D dose 
and fracture risk among dialysis patients.  Given that white patients are generally at a greater 
risk for fracture in the hemodialysis population, it was important to discern whether the 
magnitude of the association between IV vitamin D and fractures varied by race. 
 The study conducted herein attempted to address the question of whether IV vitamin 
D actually affected the hard-endpoint of fracture risk outside of the drug’s established 
influence on PTH levels and surrogate indicators of bone disease.  
Clinical parameters 
 Clinical parameters such as hemoglobin levels (g/dL), albumin levels (g/dL), PTH 
levels (pg/mL), transferrin saturation (TSAT, %), phosphorous levels (mg/dL), calcium 
levels (mg/dL), and ferritin levels (ng/mL) have been documented to have an effect on the 
observed morbidity, mortality, or fracture risk found in dialysis patients.  These clinical 
parameters were not available in the USRDS.  However, it is important to discuss these 
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surrogate markers of bone histology since they play a role in dictating the influence of 
vitamin D exposure on fractures. 
Although there have been some studies indicating that the relative risk of death and 
hospitalization among ESRD patients is inversely associated with hemoglobin levels,
102
 
recent findings suggest that targeting higher hemoglobin levels with erythropoietin-
stimulating agents may confer no benefit or actually increase the risk of harm to anemic 
CKD patients.
103-107
  Transferrin saturation (TSAT) levels (normal: 20%-30%) and serum 
ferritin levels (normal >150ng/ml) are commonly used measures of iron deficiency and renal 
anemia- an independent risk factor for heart disease and mortality in ESRD patients.
108, 109
  
With regards to albumin levels, hypoalbuminemia (low serum albumin levels) has been an 
established marker of morbidity, mortality, nutrition, inflammation and plasma volume in 
dialysis patients.
110
  
Calcium, phosphorous, and PTH levels are three of the most important clinical 
parameters involved in bone-mineral homeostasis and overall ESRD patient health.  In a 
nationally representative incident dialysis cohort, Melamed and colleagues found that 
elevated phosphate levels were independently associated with all-cause mortality but 
elevated calcium and PTH levels were only associated with all-cause mortality in time-
dependent models.
111
  No consensus has been reached regarding the influence of PTH levels 
on fracture outcomes. Using data from the Dialysis Morbidity and Mortality Study (DMMS) 
Waves 1 to 4, Danese and colleagues found no association between calcium and phosphorus 
concentrations and the risk of fracture and a weak association was found  between PTH 
concentrations and the risk for hip and vertebral fractures.
88
  Coco and colleagues determined 
that, compared to patients with higher PTH levels, patients with lower serum PTH levels 
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were more likely to experience a hip fracture (p < 0.006).
80
  In contrast, Stehman-Breen and 
colleagues did not find a statistically significant relationship between iPTH levels and the 
risk of hip fractures.
112
  
 
 
2.6  Conceptual Framework 
2.6.1  Andersen’s Behavioral Model of Health Services Use 
The hypotheses and inclusion of variables presented in this dissertation were guided 
by Andersen’s Behavioral Model of Health Services Utilization.  Overall, the model posits 
that the use of health care services is contingent upon the predisposition to use health care 
services, variables that enable or restrict use, and the need for those services.
113
  Initially 
published in the 1960’s to aid in assessing the predictors dictating the use of health services 
by families, the model has undergone significant revisions over the last few decades in order 
to account for novel issues in health system delivery and research.
7
 
 The first iteration of the model in the 1960s focused on measuring the multifaceted 
aspects of healthcare access including “potential access,” the presence of enabling factors 
and “realized access,” referring to when health care services are actually used.113 
Figure 3. Andersen’s behavioral model of health services use 
 
Source: Andersen RM. National health surveys and the behavioral model of health services use. Med Care. Jul 
2008;46(7):647-653. 
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The most recent version of the model is depicted in Figure 3 and incorporates macro 
level factors influencing health behavior.  Contextual characteristics represent the aggregate 
health system, organizational, community- and provider- level determinants of health 
services use.
113
  With this latest iteration of the model, a different set of variables are 
assigned to the predisposing, enabling, and need categories, differentiating contextual and 
individual characteristics.  At the aggregate level, contextual characteristics include 
predisposing factors like community structure, enabling factors like number of medical 
facilities and need factors like community disability rates that impact individual health 
services use.  
At the individual-level, predisposing characteristics refer to demographic (e.g., age, 
gender), social structure (e.g., race, education, occupation), and health belief related factors.
7
  
Enabling characteristics at this level include financial and organizational factors such as 
whether an individual has a regular source of care, income, and whether an individual has 
health insurance.  Need characteristics describe both perceived and evaluated indicators of an 
individual’s health that include factors such as number of illnesses and mental health status. 
 Predisposing, enabling, and need population characteristics subsequently determine 
health behavior, comprising of personal practices, use of health services, and processes of 
medical care.
113
  Personal practices include diet, tobacco use, exercise and other self-care 
activities that affect an individual’s health.  Use of health services include doctor and 
emergency room visits and processes of medical care describe prescriptions, test ordering 
and other activities that define the interaction between providers and patients.
113
 
Finally, the health outcomes component, similar to the needs component, measures 
both perceived hand evaluated health status.  Perceived health status measures patient or a 
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proxy’s measure of patient well-being, quality of life, and functionality.114  Evaluated health 
outcomes, contrarily are based on professional judgments and established health care 
standards.
114
  Additionally, the health outcomes component contains a measure of patient 
satisfaction with the care they have received and is driven by, among a myriad of other 
factors, a patient’s assessment of wait times, the quality of the patient-provider relationship, 
and inconveniences of travel time.
114
    
2.6.2  Proposed Conceptual Framework 
Figure 4 presents the conceptual model that was used to guide this research. The 
model, adapted from Andersen’s Behavioral Model of Health Services Utilization, frames 
each predictor within key model components.  The adapted model is revised to include 
relevant factors dictating medication use in dialysis facilities and to fit the research question 
herein.  Among the differences from the latest iteration of Andersen’s model include the 
omission of the feedback loops and reverse arrows that serve to illustrate the recursive nature 
and simultaneity of each model component.  Instead, our simplified, revised model 
emphasizes the direct associations between factors that predict vitamin D use and fracture 
outcomes.  Health beliefs, perceived health and consumer satisfaction are traditional 
measures in the model, frequently measured through patient reported outcome instruments, 
and are not available in our dataset but displayed in the conceptual model for completeness. 
 
 
 
  
 
 5
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Figure 4. Proposed conceptual framework  
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 Furthermore, the final phase of Andersen’s model depicts contextual characteristics 
defined as aggregate health organization, community, and provider level variables.
113
  We 
believe that, given the limited availability of community level factors in our data sources, 
these contextual characteristics were best modeled as enabling characteristics under the 
“organization” subheading.  For example, our data are unable to capture the effects of 
governmental policies, environmental pollutants, and other general environmental factors 
that may influence health-related outcomes and patient medication use.   
The predisposing characteristics included in our model capture demographic factors 
such as age and sex.  The social structure subheading of the predisposing characteristics 
component encompasses the myriad of factors that dictate social status in one’s community, 
affect an individual’s coping strategies, and dictate the health and viability of one’s physical 
environment.
7
  Patient race is, thus, included in the social structure category of the model. 
Race has been included in the model because black patients have been reported to have a 
62% lower fracture risk in comparison to white patients.
73
  Black hemodialysis patients have 
also been observed to be more likely to be administered IV vitamin D compared to white 
patients.
33
  Socioeconomic status is included in the model for completeness but not included 
in our dataset. 
Enabling characteristics, as the name implies, represent the resources that must be 
available for use of health care services to occur.  Both individual financing variables such as 
an individual’s Medicaid eligibility and organizational factors were captured.  In addition to 
health insurance that directly affects whether patient’s have a usual source of care, dialysis 
facility-level structural features such as profit status, chain affiliation and size are also 
included.  
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Moreover, need characteristics include the individual’s perceived need inasmuch as 
need can be altered by an individual’s mutating health education, and financial ability to 
afford health care.  We were able to only measure an individual’s evaluated need as 
exemplified by objective measures like comorbid conditions and not whether a patient had a 
history of falls. 
Population characteristics (predisposing, enabling, and need) are linked to health 
behaviors that ultimately influence health outcomes.  Health behaviors consist of personal 
health practices, use of health services, and processes of medical care.  Measurable personal 
health practices of the ESRD population such as exercise and healthy eating habits are not 
readily available in the USRDS dataset.  
 Andersen’s model effectively captures the effect of predisposing, enabling, and need 
characteristics on IV vitamin D use and the association between vitamin D use and fractures. 
Measures of vitamin D exposure fall under both the use of health services and processes of 
medical care categories.  In-center hemodialysis patients receive IV medications during in-
center sessions from health care providers within their dialysis facility.  The nature of ESRD 
care means that the use of health care services is intrinsically intertwined with processes of 
dialysis care.  The use of health care services is reflected in the patient’s choice to attend 
dialysis sessions while the administration of IV medications during dialysis reflects a process 
of care.   
 Lastly, the health outcomes component of the synthesized model depicts the outcome 
variable for Aim 2, fracture risk.  The hypothesized relationship between the ecological level 
measures of vitamin D exposure, covariates, and fracture outcomes are depicted in Appendix 
2.
  
 
CHAPTER III 
RATIONALE FOR METHODS USED TO ASSESS FRACTURE RISK 
 
 The following chapter provides a broad review of the methodological approaches 
used to investigate phenomena in nephrology, the biases certain approaches attempt to 
mitigate, and presents the rationale for the statistical approach employed in this dissertation.  
Aim 1 of this dissertation is purely descriptive and provides evidence of the secular patterns 
of use of vitamin D among hemodialysis patients over a decade.  Aim 2 investigates the 
association between vitamin D exposure and fracture risk among incident hemodialysis 
patients.  This chapter serves as a precursor to the methodology chapter and provides the 
justification for our choice of a retrospective cohort study using the grouped-treatment 
approach for Aim 2 to assess fracture risk whereby vitamin D exposure was measured at the 
facility-level and the fracture outcome was measured at the individual-level.  We begin with 
a historical comparison of randomized controlled trials (RCTs) versus non-experimental 
studies in explaining the importance of our use of an observational study and then justify the 
use of the grouped-treatment approach to address concerns regarding confounding by 
indication. 
 
3.1  Justification for the use of observational studies 
To begin with, although randomized controlled trials  are often deemed the most 
robust study design when examining treatment effects, they are not without their
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challenges.
115
  As in our study, performing an RCT is likely inappropriate and unethical. 
Given the known pharmacological benefits of IV vitamin D therapy in the treatment of SHPT 
among dialysis patients, it would be unethical to withhold vitamin D treatment in any 
attempts to establish a counterfactual when investigating the association between vitamin D 
exposure and fracture risk in a RCT.  Also, studying the unintended effects of vitamin D 
exposure on fractures may be inappropriate since the outcome of interest may occur over a 
relatively long time span, a potentially cost-prohibitive issue for RCTs.  
 Additionally, RCTs are generally plagued by the presence of effect modification, 
preventing study results from being generalizable to different subgroups or patients who do 
not fit the study’s eligibility criteria.116  In the analysis herein, we were are able to bypass this 
issue and perform subgroup analyses whereby the association between vitamin D exposure 
and fracture risk wasexamined within age, sex, and race strata.  Calculating stratum-specific 
relative risks is further advantageous as a means of controlling for confounding.
117
   
 Results derived from observational studies have been found to be less prone to 
heterogeneity when compared to RCTs.
118
  Observational studies are more likely to include a 
varied patient case mix, with a spectrum of comorbidities and treatments that are 
personalized to the patient.
118
  In contrast, RCTs may not represent clinical practice due to 
stringent protocols and eligibility criteria.
118
 
 
3.2  Justification for the grouped-treatment approach 
 We performed an observational study using the two-level statistical (grouped-
treatment) approach, combining aspects of the individual-level analysis with those of an 
ecological study.  The following section begins with a description of the confounding by 
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indication issues leading to the decision to measure variables at different units of analysis for 
this study.  Then, both theoretical and empirical explanations are provided to justify the study 
approach. 
 To begin with, confounding by indication arises from the general notion that medical 
providers prescribe medications and perform procedures on patients with the most clinical 
need for treatment.
119, 120
  A similar phenomenon, confounding by disease severity, arises 
when sicker patients with a poor prognosis are prescribed higher doses of medications and 
given more treatment.  When treatment decisions are made because of medical indications 
and underlying prognoses that may not be fully accounted for in a model, a purportedly 
beneficial medication may appear to be positively associated with an adverse outcome.
119
  
Confounding by indication/disease severity is an especially salient threat to the validity of 
non-experimental studies of dialysis patients where the substantial morbidity and poor 
prognoses in this population may thwart the benefits of a medication.
119
  As an illustration, 
statins, prescribed to reduce the rates of cardiovascular events, are frequently prescribed to 
those perceived to be in greatest clinical need of these medications.
120
  Rather than 
demonstrating a reduction in cardiovascular events, statins may appear to cause them without 
adequate adjustment for cardiovascular risk factors.
120
 
In a RCT, confounding by indication or selection bias is mitigated through the 
randomization process, guaranteeing that the balance of patients in each arm is due the 
chance.
117
  Throughout the years, there have been substantial advancements in the execution 
of observational studies, especially in the identification of confounding variables and in the 
quality of secondary databases like the USRDS.
116
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 In this particular study, bias due to confounding by indication/disease severity would 
likely be present in an individual-level analysis because our data source does not contain 
PTH, calcium, and phosphorous levels.  These clinical variables are assessed as a 
nephrologist makes decisions to administer vitamin D and they are simultaneously measures 
used to assess the effect of vitamin D on serum makers post-administration.  
There has been growing interest in the use of different analytical approaches to 
mitigate the effects of confounding by indication in observational studies.  Of particular 
interest, ecological studies have been advanced as a means of addressing the aforementioned 
confounding issues with investigations into the subject published by researchers Wen and 
Kramer.
121
  To account for confounding by indication bias due to improper control of 
underlying processes influencing the association between vitamin D dosing practices and 
fracture risk, a grouped-treatment approach was used, combining aspects of both the 
ecological and individual-level units of analysis.  Since we do not have access to clinical 
variables like PTH levels influencing the prescription of vitamin D, measures of vitamin D 
exposure were modeled as ecological variables at the facility-level while covariates and 
dependent variables were modeled at the individual-level.  
Theoretically, the grouped-treatment approach used herein consisted of three variable 
types: the ecological predictor (X), individual-level covariates (x) and the individual-level 
outcome (y).
122
  The main ecological predictor, X, can have a cross-level effect on y in three 
ways: 1) X can directly affect y; 2) X can act as an effect modifier and modify the association 
between x and y; and 3) X can have an indirect effect by affecting x, which then affects y.
122
 
To futher justify the use of this approach, the differences between ecological and individual-
level analyses are described below. 
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Ecological analyses are characterized by studies with groups as the unit of analysis 
(both independent and dependent variables measured at the group level and where 
associations between independent and dependent variables across groups are measured).
123
 
Selection bias concerns within a particular center are not major concerns when employing an 
ecological analysis.  In contrast, individual-level studies, as the name implies, investigate 
associations between independent and dependent variables (both measured at the individual-
level) across individuals.
123
  Both approaches vary in the type of inferences and information 
generated.  Although assessing information on group characteristics, ecologic studies are 
void of data regarding the cross-classification of individual-level characteristics within 
groups.  For instance, the association between the percentage of drinkers in different 
rehabilitation groups and hospitalization rates can be assessed in an ecological study but the 
study will lack information regarding whether drinkers were actually more likely to be 
hospitalized within specific rehabilitation centers.  Contrarily, individual-level studies assess 
interindividual variation but frequently without assessing the characteristics of the groups 
that individuals comprise.
123
 
At the individual-level, treatment effects can be accurately obtained if using 
observational data with adequate clinical details and measures of disease severity and 
comorbidity.
121
  Although ecologic studies come with their own issues, an ecologic analysis 
is preferred for an assessment of the treatment effects of vitamin D because we believe that 
their advantages (relative immunity from confounding by indication) supersede potential 
ecological fallacy issues.  Furthermore, the proposed study question fits within Wen and 
Kramer’s description of research situations where it is appropriate to use an ecological level 
key independent variable.
121
  Specifically, they should be used when 1) there is limited 
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evidence of treatment efficacy from a randomized clinical trials; 2) there is limited evidence 
of treatment effectiveness in clinical practice; 3) confounding by indication is likely in an 
individual-level analysis; 4) across geographic areas, large variations in the use of the 
treatment exists; and 5) variations across geographic areas are believed to be due largely to 
practice style differences.  The principal premise is that the use of the treatment is driven by a 
provider’s particular practice style which varies by region, assuming that groups of patients 
are of similar in prognosis.
124
  The challenges of measuring practice style at the patient-level 
can be overcome with the key independent vitamin D-related variables measured 
ecologically.  
The grouped-treatment approach has been used successfully in epidemiological 
studies.  Using subarachnoid hemorrhage treatment as a case study, Johnston and colleagues 
compared an individual-level study with all variables at the patient-level, and an ecological 
study with all variables at an aggregated level, and a grouped-treatment approach to assess 
the association between in-hospital death and treatment type (endovascular therapy versus 
surgery).
124
  The authors found evidence of confounding by indication in the individual-level 
analysis given that trends in the individual and ecological models were in opposite 
directions.
124
  To combat this, the authors employed a grouped-treatment approach with the 
following elements: 1) in-hospital death as a binary, individual-level dependent variable, 2) 
an ecological independent variable (portion of cases treated by endovascular techniques) as 
the main predictor, and 3) covariates specified at the individual-level.  Unlike the individual-
level model, this two-level model suggested a strong association between institutional use of 
endovascular therapy and reduced in-hospital death risk.
124
  Johnston successfully 
demonstrated that confounding by indication was present at the individual level.  
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Endovascular therapy, given more to patients with a poor prognosis, resulted in a higher 
mortality risk and this bias was mitigated by the grouped-treatment approach.  The ecological 
treatment variable bypassed these individual-level treatment selection bias concerns.
124
 
The decision to use the grouped-treatment approach in this dissertation was driven by 
the knowledge that the United States Renal Data System (USRDS) dataset used to assess the 
association between vitamin D exposure and fracture risk in this work does not contain 
measures of biochemical parameters like PTH, phosphorous and calcium levels.  IV vitamin 
D is prescribed and indicated for the manipulation of these biochemical markers in the 
treatment of SHPT among hemodialysis patients.  Without these biochemical measures, an 
investigation of the association between vitamin exposure and fracture risk in an individual-
level analysis where all variables are measured at the patient-level would suffer from 
confounding by indication.  Confounding by indication may likely arise because the 
allocation of IV vitamin D treatment is not randomized but rather prescribed to the patient 
based primarily on their PTH levels.  Confounding by indication in a patient-level analysis 
would be evident if the treatment, in this case IV vitamin D, influenced PTH levels or any 
other marker of SHPT that fostered the use of treatment and IV vitamin D, at the same time, 
increased the risk of fracture, our outcome of interest.  With the grouped-treatment approach 
employed in this dissertation, the vitamin D treatment was measured at the facility-level 
while covariates and the fracture outcome were measured at the patient-level.  This approach 
allowed us to take advantage of the aforementioned relative immunity of ecological studies 
from confounding by indication with our ecologically measured treatment variable.  
Simultaneously, the advantages of increased power and precision were realized with 
outcomes and covariates specified at the individual level.   
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Lastly, the grouped-treatment approach was employed in this dissertation because it 
was well-suited for the study of our target population.  The grouped-treatment approach 
allows for pseudo-randomization whereby we assumed that patients received treatment 
within dialysis facilities in a way that randomized them to different vitamin D prescribing 
protocols.
125
  Hemodialysis patients are very unique in that patients are assigned to the 
dialysis facility nearest to their home residence and a dialysis facility’s vitamin D 
administration practices does not factor into the decision to attend a particular center.  This 
differs from hospitals, for instance, who may receive more patients with a certain condition 
because they have a particular expertise or procedure driving their reputation for superior 
treatment of the condition in question.  The grouped-treatment approach has been previously 
employed successfully in observational studies of hemodialysis patients
95, 126
, lending 
empirical credence to the methodology employed herein.  The following chapter provides 
details of the methods used to assess both study aims presented in this dissertation and 
explains how we operationalized the grouped-treatment approach in Aim 2.  
 
  
 
CHAPTER IV 
METHODS 
 
The goals of this retrospective cohort study were: 1) to describe patient-level, facility-
level, and state-level trends in the use and dosage of three vitamin D analogs among 
prevalent hemodialysis patients, and 2) to investigate the association between vitamin D 
exposure and fracture risk.  This section provides a detailed description of the data sources, 
study design, measurements, and statistical analyses that were used to examine each of the 
two specific aims.  This study was exempt from review by the University of North Carolina 
Institutional Review Board. 
 
4.1  Data source 
Secondary data for this study was derived from the United States Renal Data System 
(USRDS).  Data from years 1999-2008 were used to identify the study population and 
baseline covariates.  The USRDS is a registry that collects, analyzes, and distributes national 
data on all ESRD patients in the United Sates, irrespective of insurance coverage or age.  All 
Medicare Part A and B claims are also included within the USRDS Standard Analytical Files 
(SAFs).  In the following section, the relevant files within the USRDS are described in detail. 
Institutional claims within Medicare Part A are comprised of all inpatient, outpatient, 
skilled nursing facility, home health agency, and hospice claims.  Hospitalization data 
includes the admission source, length of stay, discharge destination, and associated diagnoses 
and procedures for each patient.  The Inpatient SAF contains final action claims data
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 submitted by inpatient hospital providers for reimbursement of facility costs.  These data 
include diagnosis (ICD-9 diagnosis), procedure (ICD-9 procedure code), Diagnosis Related 
Group (DRG), dates of service, reimbursement amount, hospital provider, and beneficiary 
demographic information.  The USRDS maintains these data in two files, an Institutional file 
with records at the patient-level and an Institutional Claims Detail file with records at the 
claim level. 
Medicare Part B Physician/Supplier claims include durable medical equipment 
charges along with physician services and supplies.  The file also contains final action claims 
data submitted by non-institutional providers.   Examples of non-institutional providers 
include physicians, physician assistants, clinical social workers, nurse practitioners, 
independent clinical laboratories, ambulance providers, and free-standing ambulatory 
surgical centers.  Data contained in this file includes diagnosis, procedural codes, dates of 
service, reimbursement amount, non-institutional provider numbers (e.g., UPIN, PIN, NPI), 
and beneficiary demographic information.  Each observation in this file is at the claim level.  
The USRDS Patient File contains information describing patient race, age, date of 
death, first service date, and other demographic characteristics. Death data are obtained from 
the CMS-2746 ESRD Death Notification Form, providing the date along with the primary 
and secondary causes of death for over 99% of patients.
3
   
 The USRDS Payer History File documents the sequence of payers for each patient 
including any change in Medicare status and dual Medicare/Medicaid eligibility.
127
  Patient 
transplant events are documented in the USRDS Transplant File.  The USRDS Facility File 
contains dialysis facility-level data derived from the CMS Annual Facility Survey (CMS-
2744, hereafter AFS), a survey that all centers are mandated to complete each calendar year.  
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In addition to facility-level characteristics such as geographic region, the file reports the 
number of patients being treated at all dialysis facility or treatment center at the end of each 
calendar year.
3
  
 The remaining sections of this chapter describe the study design and patient 
population, followed by a detailed description of the measurements and statistical analyses 
employed for each aim.   
 
4.2  Study design and cohort selection by aims  
Using USRDS data, we conducted a retrospective cohort, intention-to-treat analysis.  
Generally, the intention-to-treat design results in smaller observed treatment effects 
compared to observed estimates if all patients adhered to vitamin D therapy, thus tending to 
bias estimates toward the null.
128
  This section describes the study design for each aim.  After 
describing the study design, the process for cohort selection is described, including a detailed 
explanation by aim of the inclusion and exclusion criteria. 
4.2.1  Aim 1 
 The following section details the cohort selection process and overall study design 
used for Aim 1.  
Aim 1: To investigate patient-level, facility-level, and state-level trends in the use and 
dosage of three vitamin D analogs among prevalent hemodialysis patients. 
 Table 1 details the inclusion criteria that were used to define the study population. 
Table 1. Summary of Aim 1 cohort selection process 
Inclusion criteria 
Patients with Medicare as a primary payer throughout the study period  
In-center hemodialysis patients 
Patients with at least 90 days of hemodialysis following the initiation of renal replacement 
therapy 
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A retrospective cohort study was conducted to describe patient-level, facility-level 
and state-level secular patterns in the use and dosage of IV vitamin D formulations among 
prevalent hemodialysis patients in the USRDS dataset.  To be eligible, patients had to have 
Medicare as a primary payer at 90 days post hemodialysis initiation.  Medicare is considered 
the secondary payer for the first 30 consecutive months following dialysis initiation for 
individuals who were not already eligible for Medicare on the basis of age or disability prior 
to enrollment in the ESRD program.
129
  If this requirement was not enforced, patients with 
Medicare as a secondary payer would have limited or non-existent treatment and event data. 
Spurious rate calculations would have resulted as these patients contributed follow-up time to 
the denominator but limited event information to the numerator.
3
  Historically, the number of 
incident hemodialysis patients with Medicare as primary payer has decreased drastically 
from 95% in 1974 in the earliest years of the ESRD program to 74% in 2009, with the 
percentage of prevalent hemodialysis patients with Medicare as primary payer at 83% in 
2009.
3
 
 Additionally, patients must be an in-center hemodialysis patient.  Renal replacement 
therapy consists of either kidney transplantation or dialysis, a means of filtering waste from 
the blood in order to enable the body’s regulatory functions.130  There are two main forms of 
dialysis, hemodialysis that uses an apparatus to filter blood outside of the body or peritoneal 
dialysis that uses the lining of the abdomen to filter blood inside the body.
130
  Patients 
electing home hemodialysis with the support of trained health care professionals are provided 
home treatment 3 to 5 times a week for a period of 3 to 10 hours per session.  In contrast, in-
center hemodialysis, conducted at the hospital or a free-standing clinic, is administered 3 
times a week on alternating days (Mondays, Wednesdays, and Fridays or Tuesdays, 
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Thursdays, and Saturdays) with dialysis sessions averaging 3.5 to 4 hours.
131
  Since patients 
are administered IV medications during their respective dialysis sessions, only in-center 
hemodialysis patients were included to avoid any confounding arising from differences in the 
length of a dialysis session and frequency of medication administration. 
Furthermore, the analysis was restricted to only hemodialysis patients to account for 
potential differences in clinical outcomes and patient characteristics associated with each 
treatment modality.  Many studies have compared a range of outcomes among patients 
treated with in-center hemodialysis versus those treated with peritoneal dialysis, with 
conflicting results.  For instance, although some studies have documented a survival 
advantage for peritoneal dialysis patients in the first two years of dialysis
132, 133
, others have 
documented higher mortality rates associated with peritoneal dialysis. 
131
  Yet still, other 
studies have found no differences in the risk of death when comparing hemodialysis to 
peritoneal dialysis patients.  A recently published study using robust methodology and 
USRDS data found no significant differences in mortality risk among the treatment 
modalities during a 5 year follow-up period.
134
  In addition to the discrepancies in the 
medical literature regarding this topic, there is also evidence that diabetes, age, and 
comorbidity significantly modify the association between treatment modality and 
mortality.
135
 
Eligible patients were further required to be on hemodialysis for at least 90 days.  
Data obtained in the initial three months of therapy for an ESRD patient poses substantial 
difficulties for an investigator.  Foremost, in the first 90 days, providers are exploring various 
treatment modalities and therefore patients are more likely to switch from hemodialysis to 
peritoneal dialysis.  For instance, in 2009, the number of hemodialysis patients decreased by 
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14% from dialysis initiation to day 90.
3
  However, the number of peritoneal and transplant 
patients increased by 1.4% and 21%, respectively, from dialysis initiation to day 90.
3
 
Most importantly, the ESRD program entitles Medicare coverage to disabled patients under 
the age of 65.  Although peritoneal or home dialysis patients can bill Medicare immediately, 
in-center hemodialysis patients under 65 years old are not able to bill Medicare for 
hospitalizations or dialysis therapy until 90 days post their first dialysis service date.
3
  To 
ensure the capture of all claims for all eligible patients, this 90 day restriction was imposed. 
Figure 5 depicts the study design for Aim 1.  
 
Figure 5. Study design for Aim 1 
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 Prevalent and incident hemodialysis patients identified in the USRDS database from 
January 1, 1999 through December 31, 2008 meeting the aforementioned eligibility 
requirements were included in the analysis.  Patients who survived 90 days post dialysis 
initiation entered the follow-up period where vitamin D exposure (monthly/yearly vitamin D 
dose and formulation preference) were assessed.  Patients were censored if one of the 
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following events occurred: 1) death, 2) kidney transplantation, 3) Medicare was no longer the 
primary payer, and 4) switched to peritoneal dialysis.  Patients were administratively 
censored at the last date of available data on December 31, 2008.  Patients may have 
undergone dialysis at multiple facilities during the follow-up period.  This may occur for 
several reasons, including if a patient moved or if a patient transferred facilities because a 
particular facility’s shift offerings were more attractive.  We assumed that patients receive 
care at the dialysis facility in closest geographical proximity to their home residence.  
Therefore, we assumed that all switches occurred at random and we did not account for 
patient dialysis facility switches. 
 
4.2.2  Aim 2 
Aim 2: To investigate the association between vitamin D exposure and fracture risk by 
fracture type and among relevant subgroups among incident hemodialysis patients. 
 Table 2 details the inclusion and exclusion criteria that were used to define the final 
study population.  First, eligible patients were identified.  Then, we defined eligible facilities 
as those that serviced at least 5 eligible patients.  
Table 2. Summary of Aim 2 cohort selection process 
Inclusion criteria 
Patients with Medicare as a primary payer throughout the baseline and follow-up period 
Patients with at least 90 days of hemodialysis following the initiation of renal 
replacement therapy 
Incident hemodialysis patients 
In-center hemodialysis patients 
Patients who survived at least 270 days post-dialysis initiation  
Patients with at least 120 days of claims during the 180-day baseline period 
Exclusion criteria 
Patients younger than 18 years of age at dialysis initiation 
Patients who experienced a fracture during the 180-day baseline period 
Patients without a facility identified in the dataset 
Patients in a facility with <5 eligible patients 
  
76 
 The analysis was restricted to patients who initiated dialysis between October 1, 1999 
and March 1, 2004.  The oldest vitamin D formulation, calcitriol, was released in September 
1986. Paricalcitol and doxercalciferol were released over a decade later in April 1998 and 
June 1999, respectively.
27
  Patients were eligible to enter the baseline period on January 1, 
2000 given that all three vitamin D formulations were being administered at that time.  In 
March 2004, the FDA approved the use of cinacalcet hydrochloride (Sensipar), the only FDA 
approved calcimimetic for the treatment of SHPT in dialysis patients and hypercalcemia in 
patients with parathyroid carcinoma.
136
  In May 2004, cinacalcet became commercially 
available and approximately 10% of patients dialyzed by a large for-profit provider received 
the drug between August to October 2004.
137
  To avoid the effect of possible confounding 
due to this major therapeutic advancement in the treatment of SHPT, the effect of vitamin D 
exposure on fracture outcomes was assessed solely in a pre-calcimimetic cohort between 
January 1, 2000 and May 31, 2004.   We assumed very minimal use of cinacalcet in May 
2004 because of the lag that generally exists between the date a drug becomes commercially 
available and its adoption into dialysis treatment practice. 
Figure 6. Study design for Aim 2 
 
 
 
 
 
 
 
 
 
 
 
                                                       
 
X 
Start of dialysis 
90 days: Ensure 
capture of all claims 
180 days: Vitamin D 
exposure assessment 
Fracture 
Censoring 
12 months:  Follow-up period 
 
 
  
77 
Figure 6 depicts the study design for Aim 2.  Following the first 90 days of renal 
replacement therapy, incident, in-center hemodialysis patients were eligible, using a new-
user design.  The analysis was restricted to incident dialysis patients to ensure better 
measurement of factors that may differ systematically between groups of vitamin D users. 
Identifying patients at a common time point, at dialysis initiation, allows researchers to 
control for events occurring earlier in therapy that may predict a patient’s use of vitamin D 
and vitamin D dose.  Employing a new-user design with an inception cohort of incident 
hemodialysis patients is advantageous to avoid the considerable bias arising if fracture risk is 
assumed to vary with time. 
  Time-dependent biases associated with the inclusion of prevalent patients can be due 
to several factors.  Pharmacologic agents like IV vitamin D have both beneficial and 
detrimental effects with different induction periods.
138
  The inclusion of only incident 
patients prevents the under-ascertainment of fractures that occurred prior to therapy and 
before the follow-up period.  Also, if prevalent patients were included, there would be no 
means of accounting for early attrition and mortality of patients most susceptible to fracture 
events.
138
  During the 12 month follow-up period, the association between vitamin D 
exposure and time to first fracture was assessed with patients censored once any of the 
following events occured: 1) death, 2) kidney transplantation, 3) loss of Medicare as the 
primary payer, or 4) a switch to peritoneal dialysis.  Patients were administratively censored 
on May 31, 2004. 
 A 180 day baseline period to assess covariate values and vitamin D exposure was 
considered sufficient based on analyses conducted by Teng and colleagues.  In a study of 
51,037 chronic hemodialysis patients, 83% had started treatment with injectable vitamin D 
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within 180 days of dialysis initiation.
139
  To be eligible, patients must have survived at least 
270 days post dialysis initiation. This period includes the first 90 days of dialysis to ensure 
proper ascertainment of claims and the full 180-day baseline period.  Patients were further 
required to have at least 120 days of claims during the 180-day baseline period in order to 
ensure a sufficient number of records to assess vitamin D exposure and covariates.  
Patients younger than 18 years old were excluded from the analysis.  Age was 
assessed at dialysis initiation.  Pediatric and adolescent ESRD patients were excluded 
because treatment and diagnostic decisions vary substantially with the differing causes of 
disease, health outcomes, and comorbid conditions in pediatric versus adult dialysis 
patients.
140
  Among the clinical differences between the two patient populations, 
approximately 45% to 65% of pediatric patients are treated with peritoneal dialysis but only 
about 13% to 17% of adult ESRD patients are treated with this modality.
140
  Whereas the 
primary causes of ESRD in adults are hypertension and diabetes, the primary cause of the 
disease in children are cystic, hereditary and congenital diseases.
3
  In addition to the clinical 
challenges, the lack of nephrologists with pediatric specialization may lead to differences in 
treatment recommendations and outcomes when comparing adults and children.
140
   
Hip fractures among younger individuals are extremely rare and likely to be caused 
by trauma.
141
  In children, the incidence of hip fracture is less common compared to adults.  
Rather than due to physiological processes, pediatric fractures are likely induced by high 
energy traumas like motor vehicle accidents or falls from a substantial height.
142
  
 Patients who experienced a fracture during the 180-day baseline period were 
excluded.  The goal of this analysis was to determine the association between vitamin D 
exposure and a patient’s first observed fracture since the end of the baseline period.  Having 
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a prior hip fracture has been associated with a 70% greater adjusted odds ratio (AOR) of hip 
fracture (AOR=1.70, p=0.02) in a cohort of 12,782 hemodialysis patients across 12 
countries.
77
   Among the same group of patients, having experienced a hip fracture was 
highly predictive of incurring a new fracture (RR=4.52, p<0.001).  We decided to exclude 
patients with a prior history of fracture instead of controlling for this variable as a potential 
confounder because, among other criteria, a potential confounder must not be an effect of the 
exposure (IV vitamin D in this case) and it must not be a factor in the causal pathway of 
experiencing a fracture.
117
   In this study, having a previous history of fracture is likely in the 
causal pathway describing the effect of IV vitamin D use and the risk for experiencing a 
subsequent fracture.  Lastly, patients without a corresponding facility identified in the dataset 
were excluded.  Since vitamin D exposure was assessed at the facility-level, an indicator for 
the corresponding facility for each patient was crucial to allow for the aggregation of the 
patient-level variables to the facility-level. 
4.2.3 Sample size  
 After employing all eligibility criteria, the cohort selection process was complete.  
The number of eligible patients for this aim varied over time from approximately 220,000 in 
1999 to over 300,000 in 2008. A flowchart diagram for Aim 1 is not presented because of 
this variability in the number of eligible patients over time.  
 Figure 7 presents the sample size determination flow chart diagram for Aim 2.  
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Did not have Medicare as a primary payer at baseline 
N= 62,955 
 
N= 239,193 
N= 218,769 
Incident dialysis patients between  
01/01/00-12/31/08 
 
N= 888,714 
ELIGIBLE FACILITIES 
N= 4,021 
Not an in-center hemodialysis patient at baseline 
N= 20,424 
N= 155,814 
Not an incident patient between 01/01/00-05/31/04 and did 
not survive at least 270 days post dialysis initiation  
N= 649,521 
ELIGIBLE PATIENTS 
N= 135,958 
 
N=138,640  
N= 136,864 
Not >18 years old at dialysis initiation 
N= 343 
 
N= 155,471 
Did not have at least 120 days of dialysis claims at 
baseline 
N= 14,157 
 N= 141,314 
Experienced a fracture at baseline 
N= 2674 
 
Did not have a facility identified in dataset 
N= 1776 
 
In a facility with < 5 patients 
N= 906 
 
Figure 7.  Sample size determination flow chart for Aim 2 
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4.3  Measurements 
 This section describes the operationalization of the key measures of vitamin D 
exposure for Aim 1 and Aim 2, the fracture outcome for Aim 2, and covariates for Aim 2 
using USRDS data.   
4.3.1  Vitamin D formulations and dose 
 Table 3 describes the chemical name, dosage form, dosage range, and frequency of 
administration for each IV vitamin D formulation.  According to guidelines, calcitriol doses 
should range from 0.5-5µg and paricalcitol dosing based on iPTH levels range from 2.5-
15µg.
143
  Specifically, calcitriol should initially be dosed at 1-2µg, with dose increases of 
0.5-1µg at 2-4 week intervals if necessary.
144
  Paricalcitol dosed at 2.5–5.0 μg is 
recommended for iPTH levels of 300–600 pg/mL, 6.0–10 μg, for iPTH levels of 600–1000 
pg/mL, and 10–15 μg for iPTH levels greater than 1000 pg/mL.143  The initial recommended 
dose of doxercalciferol is 4µg bolus administrations 3 times per week with dose increases of 
1-2µg at 8-week intervals if iPTH levels do not reach target ranges.
55
 
Table 3. Description of IV vitamin D formulations 
Drug Chemical Name Dosage Form Dosage 
Range
a
 
Frequency of 
Administration
b
 
Calcitriol 
(Calcijex) 
1,25-
dihydroxyvitamin 
D3 
1 and 2 μg/mL in 
1 mL ampuls 
0.5-5 μg 3 times/wk 
Paricalcitol 
(Zemplar) 
19-nor-1,25-
dihydroxyvitamin 
D2 
5 μg/mL in 1 and 
2 mL vials 
2.5-15 μg 3 times/wk 
Doxercalciferol 
(Hectorol) 
1α-hydroxyvitamin 
D2 
2 μg/mL in 1 and 
2 mL ampuls 
2-8 μg 3 times/wk 
Source: Hudson JQ: Secondary hyperparathyroidism in chronic kidney disease: Focus on clinical consequences 
and vitamin d therapies. Ann Pharmacother 40: 1584-1593, 2006
143
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Table 4 presents the Healthcare Common Procedure Coding System (HCPCS) codes 
that were used to identify each formulation within the USRDS.  Calcitriol use was identified 
using HCPCS codes J0635 (1µg) and J0636 (0.1µg).  The codes J2500 (5µg) and J2501 
(1µg) were used to identify paricalcitol and J1270 (1µg) identified doxercalciferol use.  
These codes were derived from Medicare Part A institutional claims. 
 
Table 4. HCPCS codes to identify IV vitamin D formulations 
HCPCS Code Formulation Dose 
J0635 Calcitriol  1µg 
J0636 Calcitriol .1µg 
J2500 Paricalcitol 5µg 
J2501 Paricalcitol 1µg 
J1270 Doxercalciferol 1µg 
Source: St. Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ: Effects of monthly dose and regular 
dosing of intravenous active vitamin d use on mortality among patients undergoing hemodialysis. 
Pharmacotherapy 29: 154-164, 2009 
 
A dose ratio of 1:4 for calcitriol to paricalcitol has been shown to be effective in 
treating SHPT without significant variations in phosphorous or calcium levels.
145
  A dosing 
conversion factor of 0.57:1 for doxercalciferol to paricalcitol was found to maintain 
equivalent suppression of iPTH levels among a cohort of 27 chronic hemodialysis patients.
146
  
Using these dosing conversions established in clinical practice, the calcitriol-equivalent 
dosing conversion factor for calcitriol to doxercalciferol was determined to be 1:2.28 
(4*calcitriol=paricalcitol; paricalcitol=doxercalciferol/0.57; therefore 
4*calcitriol=doxercalciferol/.57). 
4.3.2  Vitamin  D exposure by aims 
Aim 1: Vitamin D exposure measured at the individual, facility and state level 
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 At the individual-level, the following vitamin D exposure variables were assessed: 
vitamin D use (yes/no) and average vitamin D dose per month. Vitamin D use was measured 
as a dichotomous variable indicating whether a patient was administered any dose of vitamin 
D in the respective month of measurement.  Vitamin D administration is not accurately 
captured during hospital stays.  Because of this, inpatient days were subtracted from patient 
time at risk during the month of interest.  Patients with zero vitamin D administered during 
the month or year of interest were classified as a non-vitamin D user for that respective time 
period. Average vitamin D dose represented the mean dose of any vitamin D formulation 
administered to patients during the respective month or year of interest.  Vitamin D use and 
average vitamin D dose were measured monthly and yearly for all eligible patients between 
January 1, 2000 and December 31, 2008.  
 At the facility-level, the following vitamin D-related variables were assessed: the 
percentage of vitamin D users per facility per month and average vitamin D dose per patient 
per month in each facility in the months between January 1, 2000 and December 31, 2008. 
The percentage of vitamin D users per month within each facility indicated the percentage of 
patients within a facility administered any dose of vitamin D, irrespective of formulation, in 
the respective month of analysis.  The average vitamin D dose per patient per month in each 
facility indicated the mean dose of any vitamin D agent, irrespective of formulation, 
administered to patients in each facility during the respective month of interest.  Facility-
level vitamin D formulation preference by calendar year was also tabulated (Appendix 4).  At 
the state level, the following measures of vitamin D exposure were assessed: the percentage 
of vitamin D users per state per year and average vitamin D dose per patient per year within 
the respective state.  Analogous to the facility-level analysis, the unadjusted proportion of 
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vitamin D users per year was defined as the number of vitamin D users per year in each state 
divided by the number of eligible dialysis patients in the state of interest.  The average 
vitamin D dose per patient per year in each state indicated the mean dose of any vitamin D 
formulation administered to all patients per year in the state of interest. 
Aim 2: Vitamin D exposure measured as ecological variables at the facility-level 
 The key measures of vitamin D exposure for Aim 2 were ecological variables 
measured at the facility-level during the 180-day baseline period: 1) the non-case-mix 
adjusted proportion of vitamin D users in each facility; 2) the case-mix adjusted proportion of 
vitamin D users in each facility; 3) the non-case-mix adjusted average vitamin D dose per 
patient in each facility; 4) the case-mix adjusted average vitamin D dose per patient in each 
facility; and 5) whether a facility was in the highest quartile of case-mix adjusted average 
vitamin D dose per patient in each facility.  The “case-mix adjusted proportion of vitamin D 
users” variable and the “case-mix adjusted average vitamin D dose per patient” variable 
required the use of statistical modeling techniques to create.  Therefore, detailed descriptions 
of both variables are provided in the section entitled “Analyses used to create case-mix 
adjusted measures of vitamin D exposure.”  Each measure of vitamin D exposure was 
modeled separately in regression analyses.  A detailed description of each vitamin D-related 
variable follows. 
 Foremost, at the individual-level, vitamin D use was a dichotomous variable 
indicating whether the patient received any dose of vitamin D during the baseline period.  
When aggregated to the facility-level, the non-case-mix adjusted proportion of vitamin D 
users within each facility was modeled as a continuous variable measuring the proportion of 
patients within a facility administered any dose of vitamin D, irrespective of formulation, 
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during the 180-day baseline period.  It is important to emphasize that while vitamin D use 
(yes/no) at the individual-level is a dichotomous variable, when aggregated to the facility-
level, the percentage of vitamin D users within each facility was a continuous variable.   
Although this variable measures the number of vitamin D users relative to number of 
patients in each facility, the variable does not indicate a facility’s predilection to prescribe 
vitamin D.  Employing a strategy reported by Tentori and colleagues, the case-mix adjusted 
proportion of vitamin D users at a facility was estimated to reflect a facility’s propensity to 
prescribe vitamin D.
95
  The creation of this variable is described in the “Analyses used to 
create case-mix adjusted measures of vitamin D exposure” section below. 
Furthermore, the non-case-mix adjusted average vitamin D dose per patient in each 
facility indicated the mean vitamin D dose administered per patient in each facility during the 
180-day baseline period, irrespective of vitamin D formulation.  Analogous to the case-mix 
adjusted proportion of vitamin D users, the case-mix adjusted average vitamin D dose per 
patient in each facility is described in the “Analyses used to create case-mix adjusted 
measures of vitamin D exposure” section.  
The last measure of vitamin D exposure indicated whether a facility was in the 
highest quartile (75
th
 percentile) of average vitamin D dose per patient.  This was based on 
the distribution of the average vitamin D dose per patient among all eligible facilities.  To 
ameliorate potential multicollinearity issues, each measure of vitamin D exposure was 
modeled separately in statistical analyses (described in the “Statistical analyses by aims” 
section).  
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4.3.3  Fracture outcomes 
 Table 5 lists the ICD-9 codes that were used to identify fractures by site.  Fractures in 
any diagnoses field in any one of four broad fracture categories were identified: 1) vertebral; 
2) pelvis/hip; 3) other [femur, lower leg (tibia, fibula, patella & ankle), ribs/sternum, 
humerus, scapula & clavicle (shoulder/upper arm), or forearm/wrist]; and 4) any of the above 
fracture types.   
Table 5. Diagnostic codes used to identify fractures 
  Fracture Category ICD-9 Codes 
1 Vertebral 733.13, 805.xx, 806.xx 
2 Pelvis/hip (femoral neck) 733.14, 808.xx, 820.xx 
3 Other Femur: 733.15, 821.xx 
Lower leg: 733.16, 822.x, 823.xx, 824.xx 
Ribs/sternum: 807.0x-807.1x, 807.2-807.3 
Shoulder/upper arm: 733.11, 810.xx, 811.xx, 812.xx 
Forearm/wrist: 813.xx, 814.xx 
4 Any Any of the above ICD-9 codes 
 
The four broad categories of fractures delineated in Table 5 represent the most 
common and most economically burdensome fracture types.  Of note, this classification, 
therefore, excludes the following fractures in the 800-829 fracture series: fractures of the 
skull and facial bones (800.xx – 804.xx), ill-defined bones of trunk (809.xx), fractures of the 
metacarpals & phalanges (fingers) (815.xx-817.xx), ill-defined fractures of upper limb 
(818.xx), multiple fractures of upper limb (819.xx), fractures of tarsal, metatarsals, phalanges 
(toes) (825.xx – 826.xx), multiple, ill-defined fractures of lower limb (827.xx), multiple 
fractures of upper and lower limb (828.xx), and unspecified fractures (829.xx). 
 Some studies of osteoporotic fractures have excluded pathologic fractures under the 
presumption that these fractures are caused by localized processes such as malignancy or 
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infection that are not related to the bone disorder of interest.
147
  Pathologic fractures were not 
excluded in this analysis.  A study of U.S. Medicare beneficiaries repudiated the rationale for 
the exclusion of pathologic fractures by demonstrating that epidemiological analyses using 
administrative data substantially underestimate the burden of fractures with the exclusion.
147
 
In contrast to a closed fracture, an open fracture is where the bone breaks and pierces 
through the skin.
148
  Open fractures, classified with ICD-9 codes like 821, 820.3x 820.9, 
821.1x, 821.3x, 822.1, and 805.3, have sometimes been excluded from epidemiological 
analyses because these fractures are generally associated with major trauma.
149, 150
  For the 
purposes of this analysis, both open and closed fractures were assessed because of the 
difficulty in determining whether a fracture in claims data was induced by disease (or a 
traumatic fall subsequent to bone disease) or due to a traumatic event like a motor vehicle 
accident. 
The outcome for Aim 2 was fracture risk.  To assess fracture risk, the dependent 
variable, time to first fracture, was measured during the one-year follow-up period 
immediately following a hospitalization for a fracture event (see “Study design and eligibility 
criteria by aims” section below).  A detailed description of the outcome variable follows. 
 As delineated in detail in the section below, patient time at risk began at the 181
st
 day 
following the end of the 180-day baseline period and ended with the occurrence of a 
censoring event.  To assess fracture risk, time-to first fracture was the dependent variable and 
defined as a continuous measure in Cox proportional hazards models representing the time in 
days from the end of the baseline period to the date of hospitalization for the first fracture 
event. 
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 Table 6 presents an overview of the key independent variables and outcome measure 
for Aim 2.  
Table 6. Overview of key independent and outcome variables for Aim 2 
Variable Description Type Unit of 
Analysis 
Independent variables measured during 180-day baseline period 
Non-case-mix adjusted 
proportion of vitamin D 
users 
Proportion of patients within a 
facility administered any dose of 
vitamin D  
Continuous  Facility-level 
Case-mixed adjusted 
proportion of vitamin D 
users 
Patient and facility case-mix 
adjusted proportion of patients at 
a facility prescribed any dose of 
vitamin D 
Continuous Facility-level 
Average vitamin D dose 
per patient  
Mean vitamin D dose 
administered per patient in each 
facility  
Continuous Facility-level 
Whether a facility is in 
the highest quartile of 
case-mix adjusted 
average vitamin D dose 
Whether a facility is in the 75th 
percentile of case-mix adjusted 
average vitamin D dose per 
patient  
Dichotomous Facility-level 
Dependent variable measured during 1-year follow-up period post-fracture hospitalization  
Time to first fracture Time in days from the end of the 
baseline period to the date of the 
first fracture event. Time to first 
fracture is the dependent variable 
and fracture risk (the probability 
of fracture among patients in the 
exposure group relative to those 
who were not exposed to the key 
vitamin D variable) is the 
parameter estimate that results 
after performing Cox regression 
analyses 
Continuous Patient-level 
 
 
4.3.4  Covariates 
 Covariates were defined a priori and 6 vectors of variables were delineated: 
demographic characteristics, comorbidities, disease history characteristics, facility 
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characteristics, functional status markers, and treatment characteristics.  Details regarding the 
coding definition and source file for each variable can be found in Appendix 3.  The choice 
of covariates was based on published literature describing predictors of fractures in both the 
general and dialysis population.  For instance, Jadoul and colleagues substantiated that risk 
factors for fractures in dialysis patients include female sex, older age, non-black race, and 
having a prior kidney transplant.
77
  
Demographic characteristics  
Age, sex, and race described patient demographic characteristics.   Age at dialysis 
initiation, sex, and race were derived from the USRDS Patient File.  Patients were assigned 
to one of four age categories: 18-44, 45-64, 65-74, and ≥ 75 years old.  As the modal group, 
patients 65-74 years old were chosen as the reference category.  Several studies have 
documented an increased incidence of hip fracture with increasing age in both the dialysis 
and general population.
74, 80
 
With regards to sex, women have an estimated 64% greater risk of hip fracture when 
compared to men and black patients have been reported to have a 62% lower risk in 
comparison to white patients.
73
  In fact, Mitterbauer and colleagues developed a predictive 
model positing that the independent variables of age and sex sufficiently predict fractures 
occurring within 1 year of hemodialysis treatment.
76
 
 Black individuals in the general population have been shown to have increased bone 
mass in comparison to white individuals and SHPT may actually be a causal factor.
151
  The 
increased bone mass may be attributed to changes in the vitamin D-endocrine system 
including greater tubular reabsorption of calcium and greater circulating levels of 
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1,25(OH)2D.
151
  Possibly in part due to the increased bone mass observed among blacks, 
whites have been observed to have the greatest incidence of hip fractures.
80
 
Medicaid eligibility at dialysis initiation was categorized as a binary variable. 
Approximately 22% of new dialysis patients are eligible for Medicaid services; with the rate 
of eligibility increasing to 32% as the high costs of medical care depletes patient financial 
resources.
152
  It is important to control for Medicaid eligibility given that systematic 
differences have been documented when Medicaid-enrolled and non-Medicaid incident 
dialysis patients are compared.  Incident ESRD patients with Medicaid coverage are 
generally younger, female, minority, have functional limitations, or are prone to risk factors 
associated with adverse health outcomes.
152
 
Comorbidities 
 The presence of comorbid conditions within the ESRD population presents a major 
therapeutic challenge for nephrologists and they must be controlled for because these 
conditions independently predict poor patient health outcomes.  The analyses controlled for 
the presence of any of the following comorbid conditions or procedures during the baseline 
period: acute myocardial infarction (MI), anemia, autoimmune disorder, coronary artery 
bypass graft (CABG) performed/ stent/ percutaneous transluminal coronary angioplasty 
(PTCA) placement, cancer, chronic obstructive pulmonary disease (COPD)/asthma, diabetes 
mellitus, gastrointestinal bleed, human immunodeficiency virus (HIV)/ acquired 
immunodeficiency syndrome (AIDS), hypertension, hyperthyroidism, ischemic heart disease, 
liver disease, neurologic disorder, obesity, other heart disorder, peptic ulcer disease, 
peripheral vascular disease, pneumonia, psychiatric disorder, pulmonary circulation disorder, 
stroke, and substance use disorder.  Patients were categorized as having an autoimmune 
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disorder at baseline if they had any claim with the diagnoses of inflammatory bowel disease, 
psoriasis, lupus, or rheumatoid arthritis/collagen vascular diseases. Cardiovascular 
abnormalities, including ischemic heart disease, hypertension, and peripheral vascular 
disease, arguably, present the greatest clinical challenge. Table 7 lists the diagnostic codes 
that were used to identify each type of comorbid condition. 
 
Table 7. Diagnostic codes used to identify comorbidities 
Diagnosis ICD-9 codes  
Acute MI 410 
HIV/AIDS 042-044  
Anemia 280.0-281.9, 385.9 
Autoimmune disorder 564.1, 695.4, 696.0-696.1, 710, 710.0, 714, 
720, 725 
Cancer
a
 140-172, 173.3, 173.9-175.9, 179-199, 200-
201, 202.0-202.3, 202.50-203.01, 232.9, 
233.0, 233.1, 338.3, 799.4, 203.8, 238.6, 
273.3, 300.29, 789.51, 795.82, V10, V67.2 
COPD/Asthma 490-496, 505, 506.4      
Diabetes mellitus 250 
Gastrointestinal bleed 578 
Heart-related procedure CABG/stent/PTCA placement 
ICD-9 Codes: 
00.66, 36.06, 36.07 
HCPCS Codes: 
33510-33519 (excluding 33515), 92982, 
92985, 92980 
Hypertension 401-405 (excluding 
402.11,402.91,404.11,404.13,404.91,404.93)
b
 
Hyperthyroidism 242 
Ischemic heart disease 411-414 
Liver disease 070.32, 070.33, 070.54, 456.0, 456.1, 456.20, 
456.21, 571.0, 571.2, 571.3, 571.4, 571.5, 
571.6, 571.8, 571.9, 572.3, 572.8, V42.7 
Neurologic disorder 331.9-332.0, 333.4, 333.5, 334, 335, 340, 341, 
345.0, 345.1, 345.4, 345.5, 345.8, 345.9, 
348.1, 348.3, 780.3, 784.3 
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Table 7. Diagnostic codes used to identify comorbidities 
Diagnosis ICD-9 codes  
Obese 278.00-278.01 
Other heart disorder 402.11, 402.91, 404.11, 404.13, 404.91, 
404.93, 420-429, 785.0, V45.0, V53.3, 0932, 
7463, 7464, 7465, 7466, V422, V433  
Peptic ulcer disease 530.2, 531-534, V12.71     
Peripheral vascular disease 440-443, 447.1, 557.1, 557.9, V43.4 
Pneumonia 481-486 
Psychiatric disorder 295-298 
Pulmonary circulation disorder 415-417 
Stroke 434.01, 434.11, 434.91, 435-438, V12.54 
Substance use disorder 303-305 
Source: Brookhart,  Freburger, et al. paper that is currently under review 
a 
The listed ICD-9 codes identify the following broad types of cancers: Codes 140-172= malignant neoplasms of 
the lip, oral cavity, pharynx, digestive organs, peritoneum, respiratory organs, intrathoracic organs, bone and 
articular cartilage; Code 173.3= malignant neoplasm of skin of other and unspecified parts of face; Codes 
173.9-175.9= malignant neoplasm of the skin (unspecified), female breast and male breast; Codes 179-199= 
malignant neoplasm of genitourinary organs and other/unspecified sites; Codes 200-201= lymphosarcoma, 
reticulosarcoma, other specified malignant tumors of lymphatic tissue, and Hodgkin’s disease; Codes 202.0-
202.3= nodular lymphoma, mycosis fungoides, and Sezary’s disease; Codes 202.50-203.01= Letterer-Siwe 
disease, malignant mast cell tumors, peripheral T cell lymphoma, other lymphomas, other and unspecified 
malignant neoplasms of lymphoid and histiocytic tissue; Code 232.9=carcinoma in situ (unspecified); Code 
233.0= carcinoma in situ of the breast; Code 233.1= carcinoma in situ of the cervix uteri; Code 338.3= 
neoplasm related pain; Code 799.4= cachexia; Code 203.8= other immunoproliferative neoplasms; Code 
238.6= neoplasms of plasma cells; Code 273.3= Macroglobulinemia; Code 300.29=Other isolated or specific 
phobias; Code 789.51= malignant ascites; Code 795.82=elevated cancer antigen 125 ; Code V10= personal 
history of malignant neoplasm; Code V67.2= cancer chemotherapy follow-up. 
b
 These codes are excluded from the definition of hypertension because they define hypertensive heart disease. 
Because of this, these codes are a part of the “other heart disease” category. 
 
Many of the comorbidities associated with older age are clinically manifested in the  
ESRD population.
153
  The frailty, loss of muscle mass, inactivity, and other indicators of 
physical decline found in ESRD patients but traditionally intrinsic to older patients, may lead 
to the 5% to 8% of falls that result in fractures.
154
  The prevalence of cardiovascular, 
pulmonary, gastrointestinal, and other disorders contributing to polymorbidity have been 
associated with a high incidence of falls and subsequent severe femoral fractures.
154
  Acute 
illnesses like pneumonia have been associated with an increased risk of falls, especially 
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among older adults.
155, 156
  We controlled for psychiatric disorders because conditions such as 
dementia, depression, and schizophrenia have been associated with an increased risk of 
fracture.
157
  
Disease history characteristics 
Primary cause of ESRD and prior history of parathyroidectomy were controlled for as 
disease history characteristics. 
 Each patient’s primary cause of ESRD was categorized into four groups: diabetes 
mellitus, hypertension, glomerulonephritis, and other.  Diabetes, hypertension, 
glomerulonephritis and all other causes of ESRD are coded as separate identifiers in claims 
found in the USRDS Patient File.  Diabetes served as the reference category as the most 
frequent cause of renal failure.  The “other” category captured patients whose renal failure 
was caused by polycystic kidney disease or another genetic or urologic disease.   
The leading cause of ESRD in the United States is diabetic nephropathy due to type 2 
diabetes followed by hypertension.
158
  The cause of ESRD in administrative claims data 
within the USRDS is a reflection of the physician’s clinical understanding of 
pathophysiology of a patient’s renal disease.  It should be noted that the clinical diagnoses in 
administrative forms may not accurately represent the true underlying cause of the 
progression of renal insufficiency.
159
  Establishing the true cause of ESRD is a difficult 
endeavor given the complexity of the disease.  For instance, hypertension is a proven cause 
of ESRD but hypertension can be a complication of kidney disease as well.
160
 Malignant 
hypertension can induce renal failure while primary renal diseases may cause 
hypertension.
160
  Also, the cause of ESRD may be a series of processes occurring 
simultaneously including repeated kidney infection, hypertension, and diabetes mellitus.
159
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For this patient, compelling a nephrologist to choose one single underlying cause of disease 
may lead to errors and may simply reflect the physician’s diagnostic preferences.159  While 
the validity of the cause of ESRD variable merits further research, it has been shown to be a 
clinically relevant measure.  The primary cause of ESRD has been observed to indicate 
discrepancies in ESRD mortality rates.  For example, compared to patients without diabetes 
as the primary cause of ESRD, diabetes as a cause of renal failure has been associated with a 
higher relative risk of mortality (RR 1.55; 95% CI 1.36-1.80; p<0.001).
161
 
 A parathyroidectomy is often the therapeutic modality of last resort among patients 
whose SHPT is unable to be managed with pharmacological options.
20
  Because of this, 
having had a parathyroidectomy performed provides an important indication of SHPT 
severity.
20
  When compared to matched control subjects, a parathyroidectomy in chronic 
hemodialysis patients has been associated with a 32% lower risk for hip fracture (95% CI 
0.54-0.86;  p=0.001) and a 31% lower risk for any fracture (95% CI 0.57-0.83; p<0.001).
14
  
Among other possible mechanisms, a parathyroidectomy can act to lower fracture risks in 
three main ways: 1) a parathyroidectomy can mitigate the effects of high-turnover bone 
lesions, thereby decreasing long term fracture risk by improving bone quality; 2) a 
parathyroidectomy induces a swift uptake of phosphorous and calcium by the skeleton which 
may have a protective effect on fractures; and 3) a parathyroidectomy may lower fracture risk 
by improving a patient’s bone strength and bone mineral density.14  Table 8 describes the 
diagnostic and procedural codes that were used to identify parathyroidectomies. 
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Table 8. Diagnostic and procedural codes used to identify parathyroidectomies 
Diagnosis or procedure description ICD-9 or CPT code 
Complete parathyroidectomy  6.81 (ICD-9) 
Other parathyroidectomy  6.89 (ICD-9) 
Parathyroidectomy or exploration of 
parathyroid(s) 
60500 (CPT) 
Parathyroidectomy or exploration of 
parathyroid(s); re-exploration  
60502 (CPT) 
Parathyroidectomy or exploration of 
parathyroid(s); with mediastinal exploration, 
sternal split or transthoracic approach  
60505 (CPT) 
Yost Engineering, Inc.: Epicoder. http://healthcare.yostengineering.com/epicoder. Accessed 
November 15 2011 
 
Facility characteristics 
Data regarding all dialysis facilities were derived from the USRDS Facility File and 
measured during the baseline period.  The analysis controlled for the following facility-level 
covariates: profit status, practice setting, chain affiliation, size, and region. 
 Facilities were categorized into two groups based on profit-status: for-profit and not-
for-profit.  There is conflicting evidence regarding the potential effect of facility profit status 
on patient outcomes.  Numerous studies have been conducted under the hypothesis that for-
profit dialysis facilities put their patients at risk because they may have an economic 
incentive to use fewer resources.
162
  For instance, Devereaux and colleagues concluded that 
private for-profit dialysis centers were associated with an increased risk of death (RR 1.08; 
95% CI, 1.04-1.13; p<0.001).
163
  Contrarily, Frankenfield et al. found that facility profit 
status did not have an effect on intermediate outcomes like hematocrit levels and Brooks and 
colleagues found no relationship between dialysis center profit status and patient survival.
162, 
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164
  Although the evidence may be conflicting, it was important to control for the potential 
impact of facility profit-status on patient outcomes. 
Facility practice setting was categorized as freestanding or hospital-based facilities.  
Hospital-based facilities are located within or are associated with a hospital while 
freestanding facilities function independently of hospitals.  Although providing a greater 
variety of dialysis services compared to free-standing facilities, hospital-based dialysis 
facilities tend to be less efficient providers of care given the complex salary and benefit 
structures associated with hospitals.
165
 
 According to the USRDS, a chain is defined as a corporation operating 20 or more 
dialysis facilities in two or more states.
127
  The exact number of chains in the USRDS 
database can thus vary annually with the addition of new facilities and due to chain mergers 
and acquisitions.  Each patient was categorized into one of the top six largest dialysis chains 
during the study period.  The top 3 largest chains were determined based on the number of 
dialysis facilities affiliated with each chain.  Compared to smaller chains and independent 
facilities, larger dialysis chains may benefit from lower costs due to economies of scale.  
Dialysis chains may also differ in the quality of care provided to patients, their use of inputs 
(e.g., number of staff and available dialysis machines), patient-case mix if one chain tends to 
treat sicker patients, and chains may differ in organizational maturation (learning by doing 
effects).
166
 Facilities were categorized into three groups of small, medium and large based on 
the number of patients each facility served.   
 Facilities in the lowest quartile after tabulating each facility’s patient volume were 
considered small (18 or fewer patients), facilities in the highest quartile of patient volume (44 
or more patients) were considered large, and facilities in between serving 19-43 patients were 
  
97 
considered medium. Compared to hemodialysis patients in smaller facilities, patients in 
larger dialysis facilities are more likely black, elderly, dialysis patients for greater than 2 
years, and more likely to have adequacy measures (e.g., urea reduction ratio) performed.
164
  
Both large and small facility size have also been associated with negative health outcomes, 
however.  Adherence to hemodialysis regimens are vital to patient health with skipping 
dialysis sessions associated with higher hospitalization rates and greater phosphate levels.
167
  
Small dialysis units, defined in one study as less than 30 patients per unit, have been found to 
generally have higher patient mortality rates compared to larger facilities, suggesting that 
small dialysis providers may cater to a disproportionate number of high risk patients.
168
  
 Four geographical regions (Northeast, Midwest, South, and West) of the US were 
delineated based on the location of each patient’s dialysis facility using Census Bureau 
Regions and Divisions.
169
  Differential rates of fracture have been observed to vary by 
fracture type and geographical region.  Hip fracture rates are generally higher in the southern 
portion of the US and lower in the north.
15, 170
  The reason for the observed regional 
differences in fracture rates remains unclear but some suggested hypotheses include risk 
factors that are more prevalent in the south when compared to the north.  Some hypotheses 
include geographical variations in the presence of nutritional deficiencies, sunlight exposure, 
dietary fluoride consumption, and factors like poverty and rural location that are strongly 
associated with diet.
170
  
The Northeast region consisted of the New England and Mid-Atlantic states of 
Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, 
Rhode Island, and Vermont.  The Mid-West region consisted of Illinois, Indiana, Iowa, 
Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota and 
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Wisconsin. The Southern region consisted of Alabama, Arkansas, Delaware, the District of 
Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, 
Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia.  The Western 
region consisted of Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, 
New Mexico, Oklahoma, Oregon, Texas, Utah, Washington and Wyoming. 
Functional status markers 
 The analysis accounted for the presence of a personal assistance aid as a marker of 
functional status.  Table 9 details the procedural codes used to identify claims for 
wheelchairs, walkers/canes, and modified bathroom equipment including claims for 
replacement parts for all three technologies.  Patients with any claim during the baseline 
period for any of the three personal assistance technologies were coded as “1” for present in a 
binary variable. 
Table 9. Procedural codes used to identify personal assistance aids 
Personal assistance aid Healthcare Common Procedure Coding 
System (HCPCS) codes 
Use of wheelchair E0950 – E1228, E1230, E1240 – E1298 
Use of walker/cane E0130, E0135, E0140, E0141, E0143, E0144, 
E0147, E0148, E0149, E0105, E0100 
Use of modified bathroom equipment E0240 – E0248 
 
A study of 4,952 dialysis patients within the USRDS found an independent 
association between the inability to ambulate and the relative risk of hip fracture (RR 1.84; 
95% CI 1.10-3.06;p=0.019) but this relationship was not statistically significant in age, 
gender, and race adjusted analyses.
112
  The ability to transfer was independently associated 
with an increased risk of hip fractures (HR = 3.0, 95% CI = 1.2–7.2) in a study of community 
dwelling, disabled, older adults.
171
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Treatment characteristics 
The presence of a fistula was included as a treatment characteristic.  Complications 
arising from vascular access issues are a leading cause of the morbidity observed in dialysis 
patients.
172
  The vascular access variable accounted for whether a dialysis patient had an 
arteriovenous fistula (hereafter fistula) placed during the 180-day baseline period.  The three 
primary forms of vascular access are the native arteriovenous fistula, arteriovenous fistula 
graft and central vein catheter.
172
  The presence of a fistula was assessed using the 
Institutional Claims File and the HCPCS codes in Table 10 below. 
Table 10. Procedural codes used to identify fistula creation   
Fistula creation Healthcare Common 
Procedure Coding System 
(HCPCS) codes 
Arteriovenous anastomosis, open; by upper arm cephalic 
vein transposition 
36818 
Arteriovenous anastomosis, open; by upper arm basilic 
vein transposition 
36819 
Arteriovenous anastomosis, open; by forearm vein 
transposition 
36820 
Arteriovenous anastomosis, open; direct, any site (e.g., 
Cimino type) (separate procedure) 
36821 
Creation of arteriovenous fistula by other than direct 
arteriovenous anastomosis (separate procedure); 
autogenous graft 
36825 
Creation of arteriovenous fistula by other than direct 
arteriovenous anastomosis (separate procedure); 
nonautogenous graft (e.g., biological collagen, 
thermoplastic graft) 
36830 
 
Vascular access is important because early fistula placement is indicative of early 
nephrology care.  Early nephrology care has in turn been associated with better management 
of comorbid conditions and adequate treatment of disturbances like renal-based anemia.
173
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In comparison to other access types, catheter use is least favorable and has been associated 
with an increased risk of central venous stenosis, thrombosis, inadequate dialysis, and 
infections like bacteremia, osteomyelitis, and endocarditis.
174
  Among prevalent dialysis 
patients in Georgia, North Carolina and South Carolina, the adjusted odds of mortality were 
greater among patients dialyzed with a catheter compared to those dialyzed with a fistula 
(OR 1.4; 95% CI 1.1-1.9).
174
  Fistula use, the  preferred access type, compared to grafts, have 
a higher patency rate, lower rate of infection, and lower cost.
173
  
  
4.4  Statistical analyses by aims 
This section begins with a description of the statistical analyses that was used to 
create the case-adjusted vitamin D ecological variables introduced in the previous section.  A 
description of all statistical analyses used by study aim follows.  All statistical analyses were 
performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC).  
 
4.4.1  Analyses used to create case-mix adjusted measures of vitamin D exposure 
Mixed-effects models were used to create the two case-mixed adjusted key vitamin D 
exposure variables. The general equation of the mixed-effects model was: 
 
In this equation, i indicates the patient-level units of observation, j indicates the 
facility-level units of observation, and the subscript 0 indicates a constant term for the 
corresponding units.
175
  The within facility correlation among the patient-level units is 
indicated by u0j, the random effect. 
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To estimate the case-mix adjusted proportion of vitamin D users within each facility, 
we used a mixed-effect logistic regression model, an advantageous method when attempting 
to account for random variation.  The outcome of the mixed-effect logistic regression model 
was a dichotomous variable indicating whether each patient received any dose of vitamin D 
during the 180-day baseline period (yes/no).  The model adjusted for age (18-44, 45-64, 65-
74, and ≥ 75 years old), sex, race (white, black, and other), and primary cause of ESRD 
(diabetes mellitus, hypertension, glomerulonephritis, and other) as fixed effects.  Indicators 
for each patient’s facility were included as random effects. 
The case-mix adjusted proportion of vitamin D users at a facility (i.e., the percentage 
of patients at a facility prescribed vitamin D) was modeled as a normally distributed random 
intercept that represented the expected level of vitamin D treatment at each facility.  In other 
words, an intercept was generated for each facility and that intercept represented the facility-
specific vitamin D prescribing rate (the facility-specific case-mix adjusted proportion of 
vitamin D use).  The distributions of the variables were graphed and the correlation between 
the non-case-mix and case-mix adjusted variables measuring the proportion of vitamin D 
users within each facility were assessed using a Pearson correlation coefficient (Appendix 5).  
The distribution of values for the intercept produced from the mixed-effects logistic 
regression model prior to additional adjustment is depicted in Appendix 9.  The number of 
patients in a facility with each case-mix adjusted measure of vitamin D exposure was 
graphed (Appendix 6).  
To estimate the case-mix adjusted average vitamin D dose per patient in each facility, 
we used a mixed-effect linear regression model.  The outcome of this mixed-effect linear 
regression model was each patient’s average vitamin D dose during the 180-day baseline 
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period.  The model adjusted for age, sex, race, and primary cause of ESRD as fixed effects.  
Indicators for each patient’s facility were included as random effects. 
The case-mix adjusted average vitamin D dose per patient in each facility was 
modeled as a normally distributed random intercept and represented the expected average 
vitamin D dose per patient at each facility during the 180-day baseline period.  In other 
words, an intercept was generated for each facility and that intercept represented the facility-
specific vitamin D dosage rate for each patient.  The distributions of the variables were 
graphed and the correlation between the non-case-mix and case-mix adjusted variables 
measuring the average vitamin D dose per patient within each facility were assessed using a 
Pearson correlation coefficient (Appendix 5). 
  A detailed description of all case mix characteristics can be found in the “Covariates” 
section.  Specifically, both models adjusted for age, sex, race, Medicaid eligibility, the 
presence of various comorbidities (arteriosclerosis heart disease, cancer, cardiac 
dysrhythmia, cerebrovascular accident/TIA, COPD, congestive heart failure, diabetes, 
gastrointestinal bleeding, HIV/AIDS, hypertension, liver disease, other cardiac disorders, and 
peripheral vascular disease), primary cause of ESRD, prior history of parathyroidectomy, 
facility characteristics (profit status, practice setting, chain affiliation, size and region), use of 
personal assistance aids, the presence of a fistula, and calendar year. 
4.4.2  Aim 1 
 This section presents an overview of all statistical analyses to be used for Aim 1.  
Aim 1: To describe patient-level, facility-level and state-level trends in the use and 
dosage of three vitamin D analogs among prevalent hemodialysis patients. 
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Descriptive statistics, stratified by year, vitamin D use, and average vitamin D dose 
were presented for each major demographic characteristic (e.g. age, race, and sex).  Annual 
percentages of patients treated with vitamin D were charted.  The monthly and yearly 
percentage of patients treated with vitamin D was tabulated by key baseline covariates 
including age, race, sex and primary cause of ESRD. 
Average vitamin D dose per patient at baseline was estimated by dividing the total 
dose administered to each patient by the total number of eligible patients.  For the purposes 
of this analysis, we focused only on outpatient days at risk.  Since we focused on facility 
practice patterns and to account for missing information during hospitalizations, inpatient 
hospital days were subtracted from total days at risk for each calendar month.  The average 
annual vitamin D dose per users of each formulation were computed for all study years.  
Facility vitamin D formulation preference by year was tabulated and the results are presented 
in Appendix 4. Geographical trends in vitamin D use were described using the SAS PROC 
GMAP feature to depict the average vitamin D dose administered per patient per year at the 
state level.  The PROC GMAP feature allows SAS users to graph two or three dimensional 
color maps by combining map and response data.
176
 
 
4.4.3  Aim 2 
 This section describes the hypotheses for Aim 2, presents an overview of the main 
statistical approach used and explains the statistical analyses that were used to examine the 
association between vitamin D exposure and fracture risk. 
Aim 2: To investigate the association between vitamin D exposure and fracture risk by 
fracture type and among relevant subgroups among incident hemodialysis patients.  
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Null Hypotheses 
H10: There is no association between the non-case-mix proportion of vitamin D users within 
a dialysis facility and fracture risk. 
H20: There is no association between the case-mix adjusted proportion of vitamin D users 
within a dialysis facility and fracture risk. 
H30: There is no association between the non-case-mix average vitamin D dose per patient 
within a dialysis facility and fracture risk. 
H40: There is no association between the case-mix adjusted average vitamin D dose per 
patient within a dialysis facility and fracture risk. 
H50: There is no association between high case-mix adjusted average vitamin D doses per 
patient at the facility-level (the 75th percentile) and fracture risk. 
Alternative Hypotheses 
H1a: The non-case-mix adjusted proportion of vitamin D users within a dialysis facility is 
negatively associated with fracture risk. 
H2a: The case-mix adjusted proportion of vitamin D users within a dialysis facility is 
negatively associated with fracture risk. 
H3a: The non-case-mix adjusted average vitamin D dose within a dialysis facility is 
negatively associated with fracture risk. 
H4a: The case-mix adjusted average vitamin D dose within a dialysis facility is negatively 
associated with fracture risk. 
H5a: High case-mix adjusted average vitamin D doses per patient at the facility-level (the 
75
th
 percentile) are negatively associated with fracture risk. 
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The absolute standardized difference was used to compare baseline characteristics 
between vitamin D users and non-vitamin D users.  Significant imbalance of baseline 
characteristics between groups was indicated by an absolute standardized difference (ASD) 
greater than 10.
177
  Descriptive statistics were used to describe patient-level demographic and 
clinical characteristics by quartiles of the case-mix adjusted proportion of vitamin D users 
measure (Appendices 7 and 8). 
Assessing fracture risk  
Cox proportional hazards modeling was used to assess the independent association of 
each vitamin D-related predictor and fracture risk for fracture type and for any fracture. 
Separate cox proportional hazards models were constructed to assess the association of each-
vitamin D exposure with fracture risk by subgroups of age (<65 versus ≥ 65 years old), sex, 
and race (black versus non-black) (Appendix 14).  The dependent variable for all the Cox 
proportional hazards models was time to first fracture.  The general form of the regression 
equation used was: 
 
h𝑖 t = h0 t + exp⁡(β1 demographic charactertistics x𝑖1 +β2 comorbidities x𝑖2 +
β
3
 disease history characteristics x𝑖3 +β4  facility characteristics x𝑖4 +
β
5
  functional status marker x𝑖5 +β6  treament history characteristics x𝑖6 +ε) 
 
where i=individual observation, x=covariate, t=time, k=number of covariate
178
 
The Cox proportional hazards model, also known as Cox regression, is a 
semiparametric model that is among the most widely used methods for multivariable survival 
analysis.  It has several advantages in comparison to other approaches including its 
predecessor, the parametric model.
179
  Foremost, Cox regression does not require information 
  
106 
regarding the underlying distribution of survival times such that the same regression model 
can be used to analyze standard gamma, Weibull, log-normal or any of a range of survival 
distributions.
179
  Secondly, the model allows for the inclusion of time-varying factors within 
the regression.
179
  Moreover, as the name indicates, the hazard function for any two 
individuals is assumed to be constant, allowing the investigator to estimate necessary 
parameters without the need to specify a baseline hazard function.
179
  
The Efron method was used to handle ties.  Ties are defined as instances where two 
or more patients have the same study time value.
179
  Like the Breslow and Exact method, the 
Efron method assesses the true time ordering of patients with equal study times.
179
  The 
Efron method differs in its use of a numeric approximation to simply derive an estimate 
rather than assuming ties occurred sequentially or considering all possible orderings.
179
  
The proportional hazards assumption was verified using the Kolmogorov-type supremum 
tests based on 1,000 simulations (Appendix 10).   
Kaplan-Meier methods were used to derive time to fracture curves depicting 
interaction between race and vitamin D user status (Appendix 11), sex and vitamin D user 
status (Appendix 12), and age and vitamin D user status (Appendix 13) at the individual-
level.  Moreover, it is extremely important to correct for autocorrelated data within a Cox 
regression.  The Cox regression model assumes that independent observations, and, 
therefore, data from the same unit (patient-level data from individuals grouped within 
facilities) violates this assumption and engenders several major consequences.  At the first 
level is patient-time data, nested in the patients who in turn are nested within dialysis 
providers at the third level (Figure 8).
180
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Patient-time refers to the very common repeated measures issue found in longitudinal 
data where outcome values measured repeatedly over time within the same patient will likely 
be correlated.
181
 A practical example of this phenomenon can be seen in a pre-test/post-test 
experiment where the pre-test and post-test data are very much correlated because they are 
being collected from the same individual. With regards to this analysis, a patient’s likelihood 
of experiencing an initial fracture is likely very much correlated with that same patient’s 
likelihood of experiencing a second fracture at a later point in time.  
 
 
Figure 8. Levels of analysis when studying ESRD population 
 
 
 
 
 
 
These “patient-time” issues are nested within patient-level characteristics that have an 
influence on the outcome of interest.  In this case, individual-level factors such as patient 
frailty, demographic characteristics, and disease history, for instance, all impact that 
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particular patient’s likelihood of experiencing fractures.  Patients then regularly attend 
dialysis facilities.  Characteristics associated with the dialysis provider such as their profit-
status, number of patients served, and geographic location additionally interact with these 
patient-level characteristics in predicting one’s likelihood of experiencing fractures.  If these 
auto-correlated data issues within a Cox proportional hazards model are ignored, tests of 
statistical significance may be inaccurate as standard errors would be biased downward while 
test statistics produced by the model would be biased upward.
179
  
In order to avoid the effect of possible clustering, we used a robust sandwich estimate 
of the covariance matrix.
182
  Separate models were constructed to independently model the 
association between each measure of vitamin D exposure and fracture risk.  Each fracture 
type was a separate outcome. 
Results from Cox regression models were expressed as hazard ratios (HR) with their 
corresponding 95% confidence intervals (CI).  Statistical significance was assigned to p-
values less than 0.05.  
  
4.5  Sensitivity Analyses  
 To determine the robustness of our results, sensitivity analyses were performed to 
assess the effect of varying the value of certain key parameters.  Foremost, we assessed 
results after varying the length of the study period from January 2000-May 2004 to January 
2000-December 2008 (Appendix 16).  Secondly, for the fracture-related outcomes of Aim 2, 
the effect of varying the length of the baseline period was examined.  We reviewed the length 
of the exposure period among observational studies investigating the association between IV 
vitamin D and outcomes among hemodialysis patients (Appendix 18).  This provided the 
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rationale for comparing demographic and clinical characteristics by facility quartile of the 
case-mix adjusted proportion of vitamin D users (Appendices 19-21).   We also assessed the 
association between IV vitamin D exposure and fracture risk when the length of the baseline 
period has been changed to 30 days, 90 days, and 365 days, respectively (Appendix 22).  
 
  
 
CHAPTER V 
STUDY 1 RESULTS: TRENDS AND VARIATIONS IN INTRAVENOUS VITAMIN D 
USE AMONG HEMODIALYSIS PATIENTS IN THE UNITED STATES 
 
5.1  Overview 
 Injectable vitamin D agents are commonly used to manage secondary 
hyperparathyroidism in dialysis patients.  Yet, there are little data documenting the trends 
and geographic variations in the use of these agents in large, representative samples.  We 
sought to describe patterns and variations in the use of vitamin D formulations (calcitriol, 
paricalcitol, doxercalciferol) in hemodialysis patients. We studied patients in the United 
States Renal Data System (USRDS) between January1999 and December 2008 with 
Medicare as a primary payer. Annual percentages of patients treated with each type of 
formulation were tabulated by race, sex, and age at dialysis initiation.  The geographical 
distribution of vitamin D dose per patient was mapped at the state level.  Intravenous vitamin 
D use has increased sharply from 1999 to 2008 with 83.9% of patients treated with any 
vitamin D formulation in 2008.  The use of calcitriol has declined since 1999, going from 
being administered in 58.6% of patients in 1999 to 1.8% in 2008.   
 
This chapter presents the results in manuscript form for Aim 1. An overview, introduction, 
methods, results and discussion of the study are provided.  This study sought to describe patient-
level, facility-level, and state-level trends in the use and dosage of three vitamin D analogs by 
relevant patient subgroups.  Study 1 was published in the journal Renal Failure in 2013 
(Beaubrun AC, Brookhart MA, Sleath B, Wang L, Kshirsagar AV. Trends and Variations in 
Intravenous Vitamin D Use among Hemodialysis Patients in the United States. Renal Failure. 
2013;35(1):1-8).
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Paricalcitol was found to be the overwhelmingly preferred formulation during the study 
years.  In 2008, the average dose among black patients was 84% greater than among white 
patients (136 mcg versus 73.6 mcg).  Higher doses of vitamin D were administered to 
patients in the southern region of the country.  Vitamin D use has increased and parallels the 
rise in use of paricalcitol and doxercalciferol.  Given the variations in use and known 
pharmacologic differences in vitamin D formulations, future research should focus on 
whether the formulations differentially affect patient outcomes. 
 
5.2  Introduction 
 Secondary hyperparathyroidism (SHPT), characterized by elevated parathyroid 
hormone (PTH) levels, is a common complication found in hemodialysis patients
.2
  SHPT 
induced changes in bone histology coupled with increased serum phosphorous and calcium 
levels, have all been implicated as factors partially responsible for the increased morbidity 
and mortality observed in hemodialysis patients in comparison to individuals in the general 
population.
30 
 The suppression of PTH levels through activated vitamin D therapy has been 
central to the treatment of SHPT in the dialysis population.
2 
 Vitamin D therapy helps to 
maintain appropriate mineral metabolism, prevents bone disease, and minimizes loss of bone 
strength and fractures.
18
  Additionally, treatments for SHPT aim to prevent the numerous 
extraskeletal complications that may be associated with the high cardiovascular morbidity 
observed in end-stage renal disease (ESRD). 
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Currently there are three commonly prescribed intravenous (IV) vitamin D therapies: 
calcitriol (1α,25-dihydroxyvitamin D3; Calcijex, Abbott Laboratories, North Chicago, IL, 
USA), paricalcitol (19-nor-1α,25-dihydroxyvitamin D2; Zemplar, Abbott Laboratories) and 
doxercalciferol (1α-hydroxyvitamin D2; Hectorol, Genzyme).  There have been several 
studies describing patient-level predictors of vitamin D use in the dialysis population.
60, 61
  
These studies have  found that dialysis patients administered vitamin D are generally 
younger, more likely to be black, and were more likely to have a fistula or graft.
95 
 However, 
to date, studies reporting temporal trends in the use of IV vitamin D formulations have been 
conducted using small sample sizes and none have graphically depicted geographic patterns 
of vitamin D use.
183
   
 In the present study, we address this gap in the literature.  Using data on US 
hemodialysis patients in Medicare’s ESRD program between January 1, 1999 and December 
31, 2008, we report patterns in IV vitamin D dosing and formulation choice over time and 
across geographic regions. 
 
5.3  Methods 
5.3.1 Data source 
 Data were extracted from the United States Renal Data System (USRDS).  The 
USRDS contains detailed demographic and treatment information including the date of 
dialysis initiation for all patients beginning renal replacement therapy.  All Medicare Part A 
and B claims are also included within the USRDS dataset, including diagnosis and procedure 
codes for inpatient and outpatient visits.   
  
113 
5.3.2  Study design and patient population 
 The study cohort consisted of prevalent hemodialysis patients of all ages between 
January 1, 1999 and December 31, 2008.  Patients were required to have Medicare as a 
primary payer for the duration of the follow-up period.  Patients were eligible if hemodialysis 
was their initial mode of renal replacement therapy and no adjustments were made to account 
for any later switches in treatment modality.  
5.3.3  Patterns of vitamin D use assessment 
Medicare Part A outpatient revenue files were used to identify IV vitamin D 
administered to hemodialysis patients.  Healthcare Common procedure Coding System 
(HCPCS) J codes were used to identify vitamin D claims.  Calcitriol use was identified using 
HCPCS codes J0635 (1mcg) and J0636 (0.1mcg).  The codes J2500 (5mcg) and J2501 
(1mcg) were used to identify paricalcitol and J1270 (1mcg) identified doxercalciferol use.  
 The mean annual vitamin D dose of each formulation per patient was computed for 
all study years for all patients and by race.  A patient was defined as a vitamin D user during 
each study year if they were administered any dose of any of the three formulations. 
Variations in IV vitamin D use were assessed according to the annual percentage of patients 
treated with any vitamin D formulation by race, sex and age at dialysis initiation (<18, 18-34, 
35-44, 45-54, 55-64, ≥65).  Race was classified as “white” or “black”. 
 To obtain the total and mean annual doses of vitamin D administered to each patient, 
annual doses of paricalcitol and doxercalciferol administered to each patient were converted 
to calcitriol-equivalent doses according to conversion ratios derived by St.Peter and 
colleagues. (4.6:1 for paricalcitol:calcitriol and 3.1:1 for doxercalciferol:calcitriol).
93  
Since 
the administration of vitamin D to hemodialysis patients may not be accurately captured 
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during hospital stays, annual vitamin D dose during the total number of outpatient days 
during the year was tabulated.  The number of hospitalization days per year per patient 
remained constant from 1999 to 2008 and, therefore, restricting our exposure period to only 
outpatient days should not impact our results.  
5.3.4 Statistical analyses 
 All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., 
Cary, NC).  Descriptive statistics were used to tabulate the percentage of vitamin D users per 
year by subgroup, total, and mean annual doses of vitamin D.  Geographical trends in vitamin 
D were described using the SAS PROC GMAP option to depict the mean vitamin D dose 
administered per patient at the state level.  The PROC GMAP feature allows SAS users to 
graph two or three dimensional color maps by combining map and response data.
176
 
Geographical trends were presented among the whole eligible patient population of blacks 
and whites and also among only black patients to elucidate any racial influences on 
geographical variations in annual vitamin D dose per patient.  
 This study was exempt from review by the University of North Carolina at Chapel 
Hill Institutional Review Board. 
 
5.4  Results 
 Table 11 describes the baseline characteristics of the prevalent hemodialysis cohort in 
years 1999-2008.  The study population consisted of 225,022 patients in 1999 and 315,608 
patients in 2008.  The mean patient age was consistently 59 years old (SD=17) throughout 
the 10-year study period. There were 52.0% males in 1999, increasing to 54.3% in 2008.  
The percentage of white and black patients remained consistent during the 10 year study 
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period at approximately 57% and 37%, respectively.  Diabetes as the primary cause of renal 
failure increased from 41.1% of the study population in 1999 to 44.7% in 2008 while 
glomerulonephritis as the primary cause of renal failure decreased from 14.1% of patients to 
11.4%.  Approximately 29% of all patients reported hypertension as the primary cause of 
renal failure in all study years. 
Table 11. Baseline characteristics of patients between 1999-2008 
      Cause of ESRD 
Year N Mean 
Age
a
 
(SD)  
Male 
(%) 
White 
(%) 
Black 
(%) 
Hypertension 
(%) 
Diabetes 
(%) 
GN
b 
(%) 
1999 225,022 59.0 
(17.0) 
52.0 56.5 37.8 29.9 41.1 14.1 
2000 235,917 59.1 
(17.0) 
52.2 56.7 37.6 29.6 41.7 13.8 
2001 250,940 59.3 
(17.0) 
52.3 57.0 37.2 29.4 42.5 13.3 
2002 268,680 59.6 
(17.0) 
52.8 57.4 36.9 29.4 42.9 13.0 
2003 278,938 59.6 
(16.9) 
53.0 57.3 36.9 29.4 43.4 12.6 
2004 291,255 59.6 
(16.9) 
53.4 57.2 36.9 29.5 43.7 12.3 
2005 301,534 59.5 
(16.9) 
53.7 57.2 36.7 29.4 44.1 12.1 
2006 304,273 59.4 
(16.9) 
53.9 57.1 36.9 29.3 44.4 11.8 
2007 307,919 59.2 
(16.9) 
54.2 57.0 37.0 29.2 44.5 11.6 
2008 315,608 59.1 
(16.8) 
54.3 57.0 37.0 29.2 44.7 11.4 
a
Age at dialysis initiation 
b
Primary or secondary glomerulonephritis 
 
 Figure 9 depicts the annual percentage of patients treated with each vitamin D 
formulation from January 1999 to December 2008.  IV vitamin D use has increased sharply 
from 1999 to 2008 with 58.6% of patients treated with any vitamin D formulation in 1999 to 
approximately 84% treated with any vitamin D formulation in 2008.  The use of calcitriol has 
  
116 
declined since 1999, going from being administered in 58.6% of patients in 1999 to 1.8% in 
2008.  Paricalcitol was the overwhelmingly preferred formulation.  Between 2000 and 2008, 
the annual percentage of patients administered paricalcitol increased from 35.6% to 66.3%. 
Paricalcitol use peaked at 65.2% of patients in 2003, declined slightly to 59.7% of patients, 
then again increased to 66.3% in 2008.  Doxercalciferol use in the hemodialysis cohort began 
in 2002 with 10% of patients administered the drug, steadily increased to a peak of 28.8% of 
patients treated with doxercalciferol in 2006 and has begun to slightly decline to 23.7% of 
patients treated in 2008. 
 
 
Figure 9. Annual percentage of patients treated with intravenous vitamin D by 
formulation 
 
 
Figure 1. Annual percentage of patients treated with IV vitamin D by formulation.
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 The annual percentage of patients treated with vitamin D by race is presented in 
Figure 10.  In 1999, approximately 26% of the total patient population was black vitamin D 
users while 29% of vitamin D users were white.  Both the percentage of white and black 
vitamin D users increased steadily from 1999 to 2008.  Approximately 34% of the prevalent 
patient population was black vitamin D users in 2008 and the percentage of white vitamin D 
users increased to 45%.   
 
 
 
Figure 10. Annual percentage of intravenous vitamin D users by race 
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Racial variations in vitamin D dose are shown in Table 12.  In 1999, when calcitriol 
was the only IV formulation administered, white patients received an average dose of 47.7 
mcg while black patients received approximately 46% more vitamin D at an average dose of 
70 mcg.  Black patients were administered nearly twice as much vitamin D than white 
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patients annually between 2000 and 2006.  In 2007, black patients received 88% more 
vitamin D than white patients (average dose 129.7 mcg for blacks versus 69.l mcg for whites) 
and in 2008, black patients received 84% more vitamin D than white patients (average dose 
136 mcg versus 73.6 mcg). 
 
Table 12. Mean annual IV vitamin D dose 
(mcg) administered per patient by race 
Year                 Race 
 White Black 
1999 47.7   69.6 
2000 45.1   92.8 
2001 53.0 104.3 
2002 59.0 117.7 
2003 51.9 113.0 
2004 55.6 117.9 
2005 61.1 121.4 
2006 65.9 127.9 
2007 69.1 129.7 
2008 73.6 136.0 
 
Figure 11 depicts the annual percentage of patients administered vitamin D by sex. 
Approximately 30% percent of all patients were male vitamin D users in 1999.  In 2008, 
about 45% of all patients were male vitamin D users.  
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Figure 11. Annual percentage of intravenous vitamin D users by sex 
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Approximately 1% of all patients were vitamin D users under 18 years old and this 
remained constant between 1999 and 2008.  Approximately 5% of all patients and 7% were 
between 18 and 34 years old in 1999 and 2008, respectively.  Approximately 12% of patients 
were vitamin D users between 55 and 64 years old in 1999 and increased to 18% in 2008 
while approximately 25% of patients were vitamin D users at least 65 years old in 1999, 
increasing to 33% in 2008.  
 Annual trends in the mean dose administered of each vitamin D formulation among 
the users of that respective formulation are listed in Table 13.  The average annual calcitriol 
dose per calcitriol user has declined over the past decade, reflecting the decreased 
administration of the formulation.  In 1999, on average, 94.9 mcg (SD=3,458) of calcitriol 
was administered per calcitriol user.  In 2008, the average calcitriol dose per calcitriol user 
was 69.8 mcg (SD=87.6).  With regards to paricalcitol, the average annual dose per 
paricalcitol user increased from 7.97 mcg (SD=4.49) in 1999 to 105 mcg (SD=118) in 2008. 
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The average annual dose of doxercalciferol per doxercalciferol user also increased steadily 
from 1999 to 2008. 
 
Table 13. Mean annual IV vitamin D dose (mcg) administered per patient by 
formulation 
 Calcitriol Paricalcitol Doxercalciferol 
Year  Mean Dose (SD) Mean Dose (SD) Mean Dose (SD) 
1999              94.9 (3,458)         7.8 (4.49)                  0.0 (0.0) 
2000                74.8 (320.3)     79.5 (431)                  0.0 (0.0) 
2001              70.6 (216.0)      99.4 (389)                  0.0 (0.1) 
2002              74.3 (150.3)    108.0 (552)                     6.3 (42.9) 
2003               81.2 (1,802)     90.6 (144)                      8.4 (32.1) 
2004               72.6 (146.1)        91.6 (124.8)                  89.3 (158) 
2005             73.4 (93.2)     95.8 (195)               95.5 (85.7) 
2006                 78.4 (92.7)     97.0 (110)                 103.0 (137) 
2007             78.2 (97.2)     96.6 (103)                  107.0 (120) 
2008                 69.8 (87.6)   105.0 (118)                  112.0 (111) 
 
 Geographical trends in the average annual dose of vitamin D administered per patient 
among all eligible patients are depicted in Figure 12.  In 1999, only 7 states had a mean 
annual dose of vitamin D per patient greater than 60mcg (South Dakota, Minnesota, Iowa, 
Kentucky, Delaware, Mississippi, and South Carolina) with patients administered the highest 
vitamin D doses in South Dakota and Kentucky.  In contrast, 18 states had an average annual 
vitamin D dose per patient greater than 60mcg in 2000 with 4 of the 6 states with average 
doses between 80mcg and 100mcg clustered in the south (Louisiana, Mississippi, Alabama 
and South Carolina).  The highest doses of vitamin D per patient were administered in 
California, northeast, and southern region of the country in 2002.  In 2002, Delaware, South 
Carolina, Mississippi and Kansas had an average annual vitamin D dose per patient greater 
than 100mcg. In 2008, 14 states had a mean yearly vitamin D dose per patient greater than 
100 mcg (Connecticut, New Jersey, Delaware, Maryland, Virginia, North Carolina, South 
Carolina, Tennessee, Georgia, Alabama, Mississippi, Louisiana, Texas, and Illinois).  Figure 
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13 depicts geographical trends in the average annual vitamin D dose per patient among only 
black patients.  When the population was restricted to only black patients, in 2008, only 5 
states (Idaho, Montana, Utah, Colorado, and South Dakota) had an average annual vitamin D 
dose per patient less than 100 mcg. 
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Figure 12. Annual intravenous vitamin D dos per patient by state among both white and black patients, 1999-2008 
Figure 4.   Annual Vitamin D Dose per Patient by State Among Both White and Black Patients, 
1999-2008.
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Figure 13. Annual intravenous vitamin D dos per patient by state among only black patients, 1999-2008 
Figure 5.   Annual Vitamin D Dose per Patient by State among Only Black Patients, 
1999-2008.
1999 2000 2001 2002
2003 2004 2005 2006
2007 2008
Vitamin D Dose/Patient (mcg)
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5.5  Discussion 
 This study investigated secular trends and variations in the administration of specific 
vitamin D analogs in hemodialysis patients.  The data suggest that there have been a 
substantial increase in the use of vitamin D among hemodialysis patients in the United States 
between 1999 and 2008.  As of 2008, approximately 84% of the USRDS population used IV 
vitamin D. With regards to formulation-specific patterns of utilization, calcitriol use has 
declined sharply since 1999.  In contrast, paricalcitol was the most frequently administered 
formulation in the United States with 66.3% of patients treated with the analog in 2008. 
Doxercalciferol use declined steadily since its peak usage of 28.8% of patients in 2006.  
 The study presented herein is unique in its use of a relatively large population of over 
300,000 patients in the most recent years of available data until 2008.  It should be noted that 
the Dialysis Outcomes and Practice Patterns Study (DOPPS), a prospective cohort study of 
hemodialysis patients in 19 countries, released recent data regarding trends in IV vitamin D 
formulation use and dose in the US.
183
  Unlike this study, however, DOPPS investigators 
based their observations on a relatively small sample of less than 4,000 US dialysis patients. 
Consistent with the results of this study, the DOPPS study reported that in August of 2010, 
85.3% of the sample used only paricalcitol, 13.6% used only doxercalciferol, and 1.0% used 
only calcitriol.  However, in December 2011, the percentage of patients using only 
paricalcitol decreased to 55.5%, doxercalciferol users increased to 44.2% and the percentage 
of calcitriol users was 0.1%.  
 Clinical differences between the three formulations may explain the changes over 
time in IV vitamin D formulation choice. The first available vitamin D analog, calcitriol, can 
effectively lower serum PTH levels.
57
  However, calcitriol administered in dialysis patients 
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has been associated with elevated serum calcium and phosphorous concentrations.
44
  The risk 
of hypercalcemia may increase when calcitriol is used simultaneously with calcium-based 
phosphorous binders or dialysate with high calcium concentrations.
57
  The vitamin D2 
analogs, paricalcitol and doxercalciferol, are also considered mainstream therapy among 
dialysis patients.
57
  Both vitamin D2 analogs, like calcitriol, can effectively lower PTH levels 
but do so with a smaller effect on serum calcium and phosphorous concentrations compared 
to calcitriol.
57 
 Several studies have demonstrated equivalent or even superior PTH level 
suppression with the use of either paricalcitol or doxercalciferol compared to calcitriol.
58
 
 The preponderance of paricalcitol use within the hemodialysis population as 
demonstrated by the data, however, does not decrease the need to explore the comparative 
effectiveness of IV vitamin D agents. A meta-analysis of randomized controlled trials of 
chronic kidney disease patients demonstrated both potentially beneficial and detrimental 
effects of vitamin D compounds like paricalcitol and doxercalciferol introduced into the 
market after calcitriol. Paricalcitol and doxercalciferol vitamin D compounds were shown to 
significantly reduce PTH levels by about 11pmol/L but they also simultaneously increase 
phosphorous levels.
58
  Reduced PTH levels may correspond to a decrease in patient mortality 
risk by approximately 5% to 10% over a 3 year span but the increase in phosphorous 
concentrations may increase mortality by an equivalent amount.
58
 
The most striking differences in vitamin D use were found in comparisons of annual 
vitamin D dose per patient between black and white patients.  Although the percentage of 
black patients receiving vitamin D was less than the percentage of white patients over the 
past decade, black patients have continued to receive nearly twice as much of the drug in 
comparison to whites.  This greater use is possibly a result of pervasive vitamin D deficiency 
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associated with individuals with darker pigmented skin.  In the general population, 90% of 
Mexican Americans and nearly all non-Hispanic blacks (97%) currently suffer from vitamin 
D deficiency.
34 
 Additionally, black hemodialysis patients generally have higher intact PTH 
levels in comparison to other races.
19
  Gupta and colleagues reported an average PTH level of 
641.7 in black and 346.0 in white dialysis patients.
31
  Therefore, the greater severity of SHPT 
among black patients may be associated with the greater vitamin D dose administered to 
these individuals in comparison to whites. 
 Our findings are consistent with the finding by Kalantar-Zadeh and colleagues 
demonstrating that African Americans had twice the odds of receiving a higher dose of 
paricalcitol (>10µg/week) than other races in a study of ESRD patients in a large dialysis 
organization.
184 
 Also, the greater administration of IV vitamin D to black dialysis patients is 
reflected in cost figures from the 2011 USRDS Annual Data Report. In 2008, IV vitamin 
costs were 78% greater for black compared to white patients within the prevalent dialysis 
population with vitamin D costs reaching $1,824 per patient per year for blacks.
3
  
 Moreover, since 1999, higher doses of vitamin D per patient were found in the 
southern region of the United States in states like Mississippi, Louisiana, and Alabama. 
St.Peter and colleagues have also reported geographic variations in injectable drug use 
among the dialysis population.
185
  For instance, the authors found the greatest use of IV iron 
in Alaska and eastern Texas while the lowest percentages of IV iron were found in the central 
region of the country.
185
  Patient, facility and policy level factors contributing to the 
geographic differences in injectable drug administration to hemodialysis patients merits 
further investigation.  More research is needed to investigate how the greater administration 
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of vitamin D doses to black patients or individuals with higher body mass indexes impacts 
the observed regional differences in vitamin D administration.  
 The study has important limitations.  Since Medicare Part A data within the USRDS 
is collected primarily for administrative purposes, we can not know whether the amount of 
vitamin D dose billed actually reflects the amount of vitamin D received for each patient.  
The dosage reflected in vials billed for a particular formulation may not accurately capture 
partial doses administered.  Also, administration of vitamin D is guided primarily by patient 
serum PTH levels, a variable not available in the USRDS.  
 Our data suggest that the frequency and doses of vitamin D are increasing.  Patterns 
of prevalent vitamin D use at different times over a decade, shows that while use of vitamin 
D in general has increased, calcitriol and doxercalciferol use have both decreased while 
paricalcitol emerged, at least temporarily, as the dominant formulation.  Recent controversy 
regarding the therapeutic effects of vitamin D in ESRD has sparked interest in the 
comparative effectiveness and safety of vitamin D formulations.  Given the increase in dose 
and variation in use of these formulations, more research is needed to investigate the 
comparative differences in patient health outcomes resulting from the use of paricalcitol 
versus doxercalciferol versus calcitriol.
  
 
CHAPTER VI 
STUDY 2 RESULTS: INCREASING USE OF INTRAVENOUS VITAMIN D MAY 
NOT REDUCE FRACTURE RISK AMONG HEMODIALYSIS PATIENTS 
  
6.1  Overview 
              The administration of intravenous (IV) vitamin D therapy has been central to the 
treatment of secondary hyperparathyroidism (SHPT) and other bone mineral disorders; 
however its clinical benefits are not clear. The objective of this analysis was to examine the 
association between IV vitamin D exposure and fracture risk among hemodialysis patients, 
by fracture type.  A retrospective cohort study was conducted using Medicare claims from 
the United States Renal Data System.  Incident hemodialysis patients between 01/01/2000 
and 05/31/2004 who survived at least 90 days post the initiation of dialysis therapy entered a 
180-day baseline period where vitamin D exposure was assessed.  After the baseline period, 
the time to the first fracture hospitalization was assessed during a 12-month follow-up period. 
The key measures of vitamin exposure were ecological variables measured at the facility-
level during the baseline period: 1) the proportion of vitamin D users in each facility (derived 
using mixed-effects logistic regression); and 2) the average vitamin D dose per patient in 
 
This chapter presents the results in manuscript form for Aim 2. An overview, introduction, 
methods, results and discussion of the study are provided.  This study sought to examine the 
association between vitamin D exposure and fracture risk by fracture type and among relevant 
subgroups.  
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each facility (derived using mixed-effects linear regression).  Fractures were identified at the 
individual-level and grouped into four categories.  Multivariable Cox proportional hazard 
regression models adjusted for demographic, treatment, health status, and facility-level 
characteristics.  A total of 135,958 patients within 4,021 facilities were eligible for cohort 
inclusion.  No significant relation was observed between increasing vitamin D use or 
increasing vitamin D dose per patient at the facility-level and fracture risk for all fracture 
types in both crude and multivariable adjusted analyses.  Specifically, for any fracture, the 
hazard ratio (HR) in adjusted models for a facility’s proportion of vitamin D users was 1.10 
(95% CI 0.86-1.42) while the HR for a facility’s average vitamin D dose per patient was 0.99 
(95% CI 0.90-1.09).  In summary, increasing vitamin D use and increasing average vitamin 
D dose administered per patient within dialysis facilities did not have an observed beneficial 
association with fractures. 
 
6.2  Introduction 
In the end-stage renal disease (ESRD) population, fractures are common, costly, and 
associated with increased morbidity and mortality.
74, 80, 81, 88
  After experiencing a hip 
fracture, dialysis patients have a one-year survival rate of approximately 50%
81
 and patients 
experience 3-5 hospitalizations within 1 year of fracture.
189
  Secondary hyperparathyroidism 
(SHPT)-induced variations in bone histology and increased serum phosphorous and calcium 
levels, have all been implicated as factors in part responsible for the increased fracture risk, 
morbidity and mortality observed in hemodialysis patients.
30
  
Intravenous (IV) vitamin D is widely prescribed to hemodialysis patients for the 
treatment of SHPT and its use has increased over the past 10 years.
183, 186
  In 2008, 84% of 
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dialysis patients received IV vitamin D.
186
  During our study period, IV vitamin D 
reimbursement was based on the total units of the drug administered, a payment structure 
prompting large increases in vitamin D dosage and expenditure.
11
  With recent changes to 
reimbursement expected to foster substantial decreases in vitamin D dosage for cost-
efficiency purposes
1
, it is imperative that we understand whether variations in vitamin D 
dosage influence important clinical outcomes like fracture risk. 
Administration of IV vitamin D has been shown to be effective at suppressing the 
elevated serum parathyroid hormone (PTH) levels that characterize the SHPT,
5, 30, 187
 but the 
clinical benefit of IV vitamin D in the dialysis population remains unclear.  The existing 
trials of vitamin D are small and have limited follow-up and have mostly focused on the 
effects of vitamin D on PTH levels.
58
  It is unknown whether PTH is an adequate surrogate 
marker for fracture risk.
88, 112
  
 To address this gap in the evidence, we conducted a large-scale retrospective study of 
the effectiveness of IV Vitamin D therapy on fracture risk. We employed a statistical 
approach that uses variation in vitamin D usage practices across dialysis facilities as the basis 
of a natural experiment to account for expected strong confounding by indication bias.
124, 188
   
 
 
6.3  Methods 
6.3.1 Data source 
           Medicare claims were derived from the United States Renal Data System (USRDS), a 
registry that collects, analyzes, and distributes national data on all ESRD patients in the 
United States.   All Medicare Part A and B claims are included within the USRDS Standard 
Analytical Files (SAFs).  Institutional claims within Medicare Part A are comprised of all 
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inpatient, outpatient, skilled nursing facility, home health agency, and hospice claims.  
Medicare Part B Physician/Supplier claims include durable medical equipment charges along 
with physician services and supplies.  The USRDS Patient File contains information 
describing patient race, age, date of death, first service date, and other demographic 
characteristics.  The USRDS Facility File contains dialysis facility-level data derived from 
the CMS Annual Facility Survey (CMS-2744), a survey that all centers are mandated to 
complete each calendar year.  Death data was obtained from the CMS-2746 ESRD Death 
Notification Form, providing the date of death for over 99% of patients.
3
 
6.3.2 Study design and cohort selection criteria 
 We conducted a retrospective cohort study using USRDS data.  Incident, in-center 
hemodialysis patients within the USRDS dataset between January 1, 2000 and May 31, 2004 
who survived at least 90 days post the initiation of dialysis therapy entered a 180-day 
baseline period where vitamin D exposure and covariates were assessed (Figure 14).   
Figure 14. Study design diagram 
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           Patients were eligible if they had Medicare as a primary payer throughout the baseline 
and follow-up period, had at least 120 days of claims during the baseline period, and if they 
were older than 18 years of age at dialysis initiation.  Patients who experienced a fracture 
during the baseline period, patients without a facility identified in the dataset and patients in a 
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facility with less than 5 hemodialysis patients were excluded.  After the baseline period, the 
time to the first fracture hospitalization was assessed during a 12-month follow-up period. 
            In March 2004, the Food and Drug Administration (FDA) approved the use of 
cinacalcet hydrochloride
136
.  In May 2004, cinacalcet became commercially available and 
approximately 10% of patients dialyzed by a large for-profit provider received the drug 
between August to October 2004.
137
   To avoid possible confounding effects resulting from 
the availability of an alternative therapy for SHPT, the association between vitamin D 
exposure and fracture outcomes was assessed solely in a pre-calcimimetic cohort between 
January 1, 2000 and May 31, 2004. 
6.3.3  Measurement of vitamin D exposure 
 Vitamin D use was derived from Medicare Part A institutional claims and identified 
using Healthcare Common Procedure Coding System (HCPCS) codes J0635 (1µg) and J0636 
(0.1µg) for calcitriol, J2500 (5µg) and J2501 (1µg) for paricalcitol and J1270 (1µg) for 
doxercalciferol use.  Doxercalciferol and paricalcitol doses were converted to calcitriol-
equivalent doses using dosing conversions established in clinical practice (1:2.28 for 
calcitriol to doxercalciferol and 1:4 for calcitriol to paricalcitol). 
145, 146
  The key measures of 
vitamin D exposure were ecological variables measured at the facility-level during the 180-
day baseline period: 1) the case-mix adjusted proportion of vitamin D users in each facility; 
and 2) the case-mix adjusted average vitamin D dose per patient in each facility.  Employing 
a strategy reported by Tentori and colleagues, the case-mix adjusted vitamin D treatment 
variables reflect a facility’s propensity to prescribe vitamin D after accounting for various 
characteristics that may influence the dose and whether patients within a facility are 
administered the drug.
95
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 Mixed-effects logistic regression was used to estimate the case-mix adjusted 
proportion of vitamin D users within each facility.  The outcome of the model, adjusting for 
age, sex, race (white, black, or other), and primary cause of ESRD (hypertension, diabetes, or 
other), was a dichotomous variable indicating whether each patient received any dose of 
vitamin D during the 180-day baseline period with indicators for each patient’s facility 
included as random effects. Patients were assigned to the dialysis center most used 
throughout the study period.  An intercept was generated for each facility representing the 
facility-specific vitamin D prescribing rate (the expected level of vitamin D treatment at each 
facility).  The case-mix adjusted average vitamin D dose per patient, the expected average 
vitamin D dose per patient at each facility during the baseline period, was estimated using a 
mixed-effects linear regression model.  The outcome of the model was each patient’s average 
vitamin D dose during the 180-day baseline period.  The model, similarly, adjusted for age, 
sex, race, and primary cause of ESRD.   
6.3.4  Measurement of fracture outcomes 
The outcome variable was the time from the end of the baseline period to the first 
hospitalization for fracture measured at the individual-level during the 12-month follow-up 
period.  Fractures were identified using International Classification of Diseases, 9th revision 
(ICD-9) diagnosis codes and grouped into four categories: 1) vertebral; 2) pelvis/hip; 3) other 
[femur, lower leg (tibia, fibula, patella & ankle), ribs/sternum, shoulder/upper arm (humerus, 
scapula & clavicle) or forearm/wrist]; and 4) any of the above fracture types.  This 
classification excluded fractures of the hands and feet (due to minimal consequences of these 
fractures), fractures of multiple areas and of the skull/trunk (likely indicative of severe or 
blunt trauma), and ill-defined, unspecified factures.  
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6.3.5  Measurement of Covariates 
 Relevant confounding variables were ascertained based on published literature 
investigating predictors of fracture risk in both the dialysis and general population.  Age, sex, 
race (white, black, or other), and primary cause of ESRD were derived at dialysis initiation 
from the USRDS Patient File.  Patients were assigned to one of four age categories: 18-44, 
45-64, 65-74, and ≥ 75 years old.  As the modal group, patients 65-74 years old were chosen 
as the reference category.  Each patient’s primary cause of ESRD was categorized into four 
groups: diabetes mellitus, hypertension, glomerulonephritis, and other.   Diabetes served as 
the reference category as the most frequent cause of renal failure.  The “other” category 
captured patients whose renal failure was caused by polycystic kidney disease or another 
genetic or urologic disease.  Medicaid eligibility was derived at dialysis initiation from the 
USRDS Payer File.  
The USRDS Medicare Part A and Part B files were searched during the 180-day 
baseline period for the following comorbid conditions or procedures: acute myocardial 
infarction (MI), anemia, an autoimmune disorder, cancer, chronic obstructive pulmonary 
disease (COPD)/asthma, diabetes mellitus, gastrointestinal bleed, a heart-related procedure, 
human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS), 
hypertension, hyperthyroidism, ischemic heart disease, liver disease, neurologic disorder, 
obese, other heart disorder, peptic ulcer disease, peripheral vascular disease, pneumonia, 
psychiatric disorder, pulmonary circulation disorder, stroke, and substance use disorder.  
Patients were categorized as having an autoimmune disorder at baseline if they had any claim 
with the diagnoses of inflammatory bowel disease, psoriasis, lupus, or rheumatoid 
arthritis/collagen vascular diseases. A heart-related procedure was defined as any claim at 
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baseline with HCPCS codes in part A or par B indicating that a coronary artery bypass graft 
(CABG) was performed or that a stent or percutaneous transluminal coronary angioplasty 
(PTCA) was placed. 
Data on all dialysis facilities were derived from the USRDS Facility File and 
measured during the baseline period.  The analysis controlled for the following facility-level 
covariates: profit status, practice setting, chain affiliation, size, and region.  Facilities were 
categorized into two groups based on profit-status: for-profit and not-for-profit.  Facility 
practice setting was categorized as freestanding (facilities that function independently of 
hospitals) or hospital-based.  Each patient was categorized into one of the top three largest 
dialysis chains during the study period.  Facilities were categorized into three groups of 
small, medium and large based on the number of patients each facility served.  Facilities in 
the lowest quartile after tabulating each facility’s patient volume were considered small (18 
or fewer patients), facilities in the highest quartile of patient volume (44 or more patients) 
were considered large, and facilities in-between serving 19-43 patients were considered 
medium.  Four geographical regions (Northeast, Midwest, South, and West) of the US were 
delineated based on the location of each patient’s dialysis facility using Census Bureau 
Regions and Divisions.
169
   
Prior history of parathyroidectomy, use of personal assistance aids and the presence 
of a fistula were defined as the presence of a HCPCS code at baseline for any of the 
respective procedures of interest.  The use of personal assistance aids was defined as whether 
the patient had any claim at baseline for wheelchairs, walkers/canes, and modified bathroom 
equipment including claims for replacement parts for all three technologies.  
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6.3.6 Statistical analyses to assess fracture risk 
The absolute standardized difference was used to compare baseline characteristics 
between vitamin D users and non-vitamin D users.  Significant imbalance of baseline 
characteristics between groups was indicated by an absolute standardized difference (ASD) 
greater than 10.
177
 
Unadjusted and adjusted Cox proportional hazard regression analyses were performed 
to examine the independent association between vitamin D exposure and fracture for each 
fracture type.  Multivariable Cox models adjusted for age, sex, race, Medicaid eligibility, the 
presence of various comorbidities, primary cause of ESRD, prior history of a 
parathyroidectomy, facility characteristics, use of personal assistance aids and the presence 
of a fistula.  
Patients were censored once any of the following events occurred: 1) death, 2) kidney 
transplantation, 3) loss of Medicare as primary payer status, or 4) a switch to peritoneal 
dialysis.  Patients were administratively censored on May 31, 2004.  A robust estimate of the 
standard errors was computed that acknowledged the within-facility clustering of 
outcomes.
182
  All analyses were performed using SAS 9.2 (Cary, NC, USA). 
 
6.4  Results 
 A total of 135,958 patients within 4,021 facilities were eligible for cohort inclusion.  
Table 14 describes the demographic and clinical characteristics of the cohort by vitamin D 
user status.  Approximately 60% of the cohort was over 65 years old, 43.4 % were Medicaid 
eligible, 47.5% were female, with the majority served at a for-profit (79.4%) or freestanding 
facility (87.1%).  The most common comorbidities present were anemia (84.9%), 
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hypertension (79.9%), diabetes mellitus (59.1%), and a heart disorder (52.2%).  Differences 
were observed with respect to race when comparing vitamin D users to non-vitamin D users. 
Among vitamin D users, 57.3% were white, 38.0% were black and 4.8% were of another 
race.  Among non-vitamin D users, however, 76.0% were white, 18.5% were black and 5.5% 
were of another race. Compared to non-vitamin D users, vitamin D users were more likely to 
be Medicaid eligible or have anemia and less likely than non-users to have ischemic heart 
disease, peripheral vascular disease or a heart disorder.  
Table 14. Demographic and clinical characteristics of cohort by vitamin D user 
status 
Characteristics All (%) Vitamin D 
User (%) 
Non-
Vitamin D 
User (%) 
Absolute 
standardized 
difference  
N  135,958   95,705   40,253     - 
Age (years)     
   18-44          10.3         10.8            9.1   5.7 
   45-64          29.1         30.3          26.3   8.9 
   65-74          31.2         30.8          32.3   3.2 
   >= 75          29.4         28.2          32.3   8.9 
Race       
   White          62.8         57.3          76.0 40.6** 
    Black          32.2         38.0                    18.5 44.4** 
    Other            5.0           4.8            5.5   3.3 
Female          47.5         48.0          46.4   3.2 
Medicaid eligible          43.4         45.6          38.0 15.5** 
Comorbidities     
   Acute MI            4.5           4.3            5.1   3.8 
   Anemia          84.9         85.9          82.2 10.1** 
   Autoimmune disorder            3.4           3.2            3.7   2.7 
   Cancer          11.2         10.7          12.3   5.0 
   COPD/Asthma          19.1         18.2          21.3   7.8 
   Diabetes mellitus          59.1         58.5          60.3   3.7 
   Gastrointestinal bleed            5.6           5.2            6.3   4.7 
   Heart-related procedure            2.3           2.4            2.2   1.3 
   HIV/AIDS            1.1           1.1            1.1   0.0 
   Hypertension          79.9         79.9          79.9   0.0 
   Hyperthyroidism            1.0           1.0            0.9   1.0 
   Ischemic heart disease          38.3         36.8          42.0 10.7** 
   Liver disease            3.3           3.3            3.4   0.6 
   Neurologic disorder            7.6           7.2            8.6   5.2 
   Obese            4.1           4.3            3.6   3.6 
   Other heart disorder          52.2         50.6          56.0 10.8** 
   Peptic ulcer disease            3.8           3.7            4.3   3.1 
   Peripheral vascular disease          25.1         23.7          28.4 10.7** 
   Pneumonia          10.1           9.2          12.1   9.4 
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Table 14. Demographic and clinical characteristics of cohort by vitamin D user 
status 
Characteristics All (%) Vitamin D 
User (%) 
Non-
Vitamin D 
User (%) 
Absolute 
standardized 
difference  
   Psychiatric disorder            4.4           4.1            5.2   5.2 
   Pulmonary circulation 
disorder 
           3.1           3.0            3.4   2.3 
   Stroke          12.5         11.6          14.8   9.5 
   Substance use disorder            6.1           6.1            6.1   0.0 
Cause of ESRD     
   Diabetes mellitus          48.8         48.7          48.9   0.4 
   Hypertension          30.1         31.0          27.9   6.8 
   Glomerulonephritis            8.0           7.9            8.2   1.1 
   Other          13.2         12.4          15.0   7.6 
Parathyroidectomy            0.1           0.1            0.0   4.5 
For-profit          79.4         82.0          73.2 21.2** 
Free-standing          87.1         88.4          84.1 12.5** 
Chain     
   Chain #1          26.4         27.3          24.3   6.9 
   Chain #2          14.0         15.2          11.2 11.8** 
   Chain #3          13.4         14.8          10.1 14.3** 
   Other chain          46.2         42.7          54.4 23.6** 
Facility size     
   Small            9.3           8.9          10.4   5.1 
   Medium          44.3         44.3          44.2   0.2 
   Large          46.3         46.7          45.4   2.6 
Region     
   Midwest          22.2         21.1          24.7   8.6 
   Northeast          17.4         17.3          17.7   1.1 
   South          44.9         46.0          42.2   7.7 
   West          15.5         15.6         15.4   0.6 
Personal assistance aids            6.2           5.9           6.9   4.1 
Fistula          24.9         25.2         24.2   2.3 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized difference; 
COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; HIV/AIDS, human 
immunodeficiency virus / acquired immunodeficiency syndrome 
** An absolute standardized difference > 10 indicates significant imbalance of characteristic when 
comparing vitamin D users to non-vitamin D users 
 
  
Table 15 shows the observed incidence of fractures by whether, at the individual 
level, patients were administered any dose of vitamin D at baseline.  The overall incidence of 
any fracture was 51.68 per 1,000 Person-Years (PYs) with the highest incidence rate 
observed for pelvis/hip fractures at a rate of 26.18 fractures per 1,000 PYs.  Fracture 
incidence was greater among non-vitamin D users compared to vitamin D users overall.  The 
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incidence of vertebral and pelvis/hip fractures among non-vitamin D users was 
approximately 63.1% and 38.0% greater, respectively, than non-vitamin D users. 
Table 15. Fracture rates per 1,000 person-years by vitamin D user status 
Fracture Type All Vitamin D 
User 
Non-Vitamin D 
User 
Absolute 
standardized 
difference 
Any fracture 51.68 46.74 63.64 34.5** 
Pelvis/hip 26.18 23.56 32.51 20.0** 
Vertebral 12.47 10.52 17.16 19.3** 
Other
a
 16.78 16.08 18.46         6.3 
a
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist 
fractures 
** An absolute standardized difference > 10 indicates a significant imbalance in the characteristic when 
comparing vitamin D users to non-vitamin D users 
 
 
 No significant relation was observed between the proportion of vitamin D users or the 
average vitamin D dose per patient at the facility-level and fracture risk for all fracture types 
in both crude and multivariable adjusted Cox proportional hazard analyses (Table 16) [Full 
models in Appendices 23-30].  Specifically, for any fracture, the hazard ratio (HR) in 
adjusted models for a facility’s proportion of vitamin D users was 1.10 (95% CI 0.86-1.42) 
while the HR for a facility’s average vitamin D dose per patient was 0.99 (95% CI 0.90-
1.09).  Analyses modeling the non-case-mix adjusted vitamin D exposure variables and 
whether a facility was in the highest quartile of case-mix adjusted vitamin D dose generated 
very similar results (Appendices 15 and 16). 
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Subgroup analyses were performed to address potential residual confounding by race, 
sex, and age (Table 17).  There was no statistically significant relation observed between 
average vitamin D dose per patient and fracture risk for all fracture types among black 
patients. There was also no statistically significant association between average vitamin D 
dose per patient and fracture risk for all fracture types in a cohort of only female patients and 
a cohort of only patients over the age of 65.  
 
 
Table 16. Cox models of the association between measures of vitamin D exposure and 
fracture risk 
Fracture Type Proportion of Vitamin D 
Users
a
 
Average Vitamin D Dose 
per Patient
b
 
 HR (95% CI)
c
 HR (95% CI) 
Any   
    Crude 1.05 (0.82-1.34) 0.98 (0.87-1.11) 
    Adjusted
d
 1.10 (0.86-1.42) 0.99 (0.90-1.09) 
Pelvis/hip   
    Crude 0.96 (0.70-1.33) 1.04 (0.91-1.19) 
    Adjusted 1.05 (0.74-1.48) 1.05 (0.94-1.16) 
Vertebral   
    Crude 1.03 (0.65-1.63) 0.70 (0.37-1.34) 
    Adjusted 1.06 (0.64-1.74) 0.76 (0.41-1.40) 
Other
e
   
    Crude 1.39 (0.89-2.16) 0.98 (0.87-1.11) 
    Adjusted 1.33 (0.83-2.13) 0.95 (0.79-1.13) 
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease 
b
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal 
disease 
c
Hazard Ratio (95% CI) 
d
Cox models adjusted for age, sex, race, Medicaid eligibility, comorbidities, primary cause of ESRD, prior 
history of parathyroidectomy, facility characteristics, use of personal assistance aids, and the presence of a 
fistula. 
e
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist fractures 
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Table 17. Multivariable
a
 Cox models of the association between facility-level average 
vitamin D dose per patient
b
 and fracture risk among subgroups 
 Black Female Age ≥65 years 
 HR (95% CI)
c
 HR (95% CI) HR (95% CI) 
Any 0.91 (0.74-1.12) 0.86 (0.69-1.06) 0.97 (0.85, 1.12) 
Pelvis/hip 0.93 (0.71-1.21) 0.85 (0.65-1.11) 1.06 (0.95-1.19) 
Vertebral 0.50 (0.07-3.43) 0.47 (0.13-1.71) 0.38 (0.12-1.23) 
Other 0.93 (0.72-1.20) 0.91 (0.73-1.15) 0.85 (0.59-1.21) 
a
Cox models adjusted for age (except for the age subgroup analysis), sex (except for the sex subgroup analysis), 
race(except for the race subgroup analysis), Medicaid eligibility, the presence of comorbidities, primary cause of 
ESRD, prior history of parathyroidectomy, facility characteristics, use of personal assistance aids, and the presence 
of a fistula. 
b
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of ESRD 
c
Hazard Ratio (95% CI) 
 
 
6.5  Discussion 
We conducted a large-scale investigation of the association between IV vitamin D use 
and fracture risk among hemodialysis patients.  We found that increasing vitamin D use and 
increasing average vitamin D dose administered per patient within dialysis facilities did not 
have an observed beneficial association with fracture risk. Fractures are prevalent in the 
dialysis population and impose substantial clinical post-fracture consequences including high 
hospitalizations, mortality, and long-term care facility use.
189
  Even in an era of increasing 
vitamin D use and dosage, fracture incidence rates have remained relatively constant among 
hemodialysis patients.
190
   
Our results are consistent with a meta-analysis by Palmer and colleagues of 76 
randomized controlled trials of patients at all stages of renal failure. 
58
  They concluded that 
vitamin D was of “unproven efficacy” with regards to mortality, bone pain, vascular 
calcification, or need for parathyroidectomy with the exception of its effect on some 
biochemical indexes.
58
  None of the clinical trials included, however, were adequately 
powered to examine the effect of vitamin D therapy on fracture risk and resolution of bone 
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pain.
191
  Despite the limitations of the study (e.g., many of the trials were small and had short 
follow-up times), the results of the meta-analysis did indeed highlight the weakness of 
current evidence on pharmacological effects of vitamin D therapy in dialysis patients.  Our 
study helps to address this research gap and circumvented the sample size limitations of 
previously conducted trials of vitamin D. 
Our findings are important given that vitamin D is being  prescribed more liberally in 
dialysis patients in an attempt to manipulate PTH levels.
186
  However, we found that 
aggressive vitamin D use among dialysis facilities did not lead to improved fracture 
outcomes.  In the general population, clinical decision making has relied on consistent 
evidence from randomized control trials to guide treatment of patient-level outcomes based 
on biochemical endpoints.
192
  For instance, while low-density lipoprotein cholesterol and 
blood pressure have been demonstrated to be valid predictors of mortality and morbidity in 
the general population, there is no evidence in the renal population that vitamin D’s alteration 
of biochemical parameters such as PTH affects outcomes like fracture.
58
  The hazards of 
using surrogate markers to target pharmacologic treatments in dialysis patients has been 
demonstrated in recent years with the controversy regarding whether treating anemia by 
targeting higher hemoglobin targets with erythropoiesis-stimulating agents resulted in 
increased cardiovascular complication and mortality risk.
193
 
We observed a decreased risk of fractures among vitamin D users in descriptive 
analyses.  However, these associations were not present in Cox regression models adjusting 
for various demographic, clinical, and health-status related characteristics.  Even though 
black patients received over twice the amount of vitamin D as white patients, our analyses 
found no association between dose and fracture risk in a homogeneous, all-black patient 
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subgroup analysis.  The heterogeneous pathology of bone disease in ESRD patients 
contributes greatly to the complexity and uncertainties associated with solidifying the link 
between vitamin D use, PTH levels, SHPT, bone density, falls, demographic attributes (e.g., 
race) and fracture risk.   
 Given the non-experimental design, our study may have been subject to residual 
confounding from factors like frailty and underlying health status.  However, our analysis 
that examined the effect of facility practice patterns on outcomes was explicitly adopted to 
minimize confounding by patient-level variables.  Given that a dialysis patient’s facility is 
generally chosen based on the facility’s geographical proximity to a patient’s home residence 
and is not based on a dialysis facility’s SHPT management protocols, facility-level practice 
variability in the administration of vitamin D creates a potential natural experiment.  The 
grouped-treatment analytic approach presented herein assumed that patients were assigned to 
dialysis facilities in a manner that effectively randomized them to different vitamin D 
administration practices.
125
  Since we did not have access to clinical variables like PTH 
levels influencing the prescription of vitamin D, confounding by indication issues at the 
individual-level were mitigated with IV vitamin D exposure modeled as ecological variables 
that adjusted for the diversity in patient case-mix within a facility.  This approach has been 
successfully applied in studies of ESRD patients
95, 126
 and further incorporates the advantages 
of increased power and precision with outcomes and covariates specified at the individual-
level.
124
 
Also, we were unable to capture oral anti-resorptive medication use within the 
USRDS database but this is a minor limitation.  Bisphosphonates are not generally prescribed 
to dialysis patients because of safety concerns related to toxicity due to impaired renal 
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excretion
66-68
, and bone disease in dialysis patients is often due to SHPT and other forms of 
renal osteodystrophy.
4
 
Medicare claims within the USRDS are collected primarily for administrative 
purposes and, thus, the amount of vitamin D dose billed may not actually reflect the amount 
of vitamin D received for each patient.  The dosage reflected in vials billed for a particular 
formulation also may not accurately capture partial doses administered.
186
  Furthermore, our 
definition of fracture, based on ICD-9 codes, may be somewhat misclassified.  However, 
Fisher and colleague’s validation of hip fracture claims suggests that fractures in the 
Medicare population are well-ascertained.
194
   
In summary, the increased frequency of IV vitamin D administration and increases in 
the average vitamin D dose administered to dialysis patients has not yielded any observed 
reductions in fracture risk.  It should be strongly noted, however, our results does not obviate 
the need to continue to administer vitamin D therapy to ESRD patients given that it has been 
established that treatment alters serum concentrations of PTH, the primary determinant of 
bone turnover in patients with ESRD.
195
   Our study does not suggest that vitamin D should 
not be used as it is thought to have many pleiotropic effects, such as reduced risk of 
cardiovascular events and cancer.
196
  We conclude only that vitamin D should not be used 
with the expectation of reducing fracture risk.  Future research is needed to substantiate these 
results and improve our understanding on how to most appropriately dose IV vitamin, 
especially within the context of the diversity of patient characteristics in the dialysis 
population.  
  
 
CHAPTER VII 
DISCUSSION 
 
 The broad goal of this dissertation was to examine trends in the use and dosing of IV 
vitamin D and to examine whether vitamin D exposure was associated with fracture risk 
among hemodialysis patients.  Two manuscripts (Chapters 4 and 5) document the results of 
this research.  In Study 1, we sought to describe patient-level, facility-level, and state-level 
trends in the use and dosage of three vitamin D analogs among prevalent hemodialysis 
patients.  In Study 2, we sought to investigate the association between vitamin D exposure 
and fracture risk.  This concluding chapter synthesizes the findings from the two 
manuscripts, discusses clinical and policy implications of our work, highlights the strengths 
and weaknesses of the analyses, and provides recommendations for future research.  
 
7.1   Summary of findings 
In Study 1, we documented an increasing frequency in the prescription of vitamin D 
and increases in the doses administered to hemodialysis patients.  Paricalcitol was the 
overwhelmingly preferred formulation between 2000 and 2008. While doxercalciferol use 
only declined slightly from its peak, calcitriol use in the dialysis population is virtually non-
existent with less than 2% of patients administered the drug in 2008. 
In addition to an increase in the percentage of users administered vitamin D (84% of 
patients in 2008), the dose of vitamin D given increased steadily over the decade for both
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doxercalciferol and paricalcitol.  The annual dose per patient administered for calcitriol 
decreased drastically, reflecting its waning popularity.  In this dissertation, the inclusion of 
variables was guided by Andersen’s Behavioral Model of Health Services Use.  According to 
the model, predisposing, enabling and need factors are considered population characteristics 
that together interact to determine the use of vitamin D, the key health behavior we sought to 
describe in this study.  Temporal trends in vitamin D dosing were explored among the three 
subgroups of predisposing characteristics available in our dataset (age, sex, and race).  We 
found that racial variations in dose were most poignant with black patients administered over 
80% more vitamin D than white patients in 2008.  
Region was categorized as an enabling characteristic.  Geographical variations in the 
average vitamin D dose per patient administered were observed with the highest doses of 
vitamin D found in states clustered in the south and the east.  We attempted to decipher 
whether regional variations were due to the racial distribution of patients in the United States 
and observed that black patients were given high doses of vitamin D (i.e., greater than 
100mcg on average annually) in all but 5 states, suggesting that race may be a contributor to 
observed geographical dosing differences.  
In Study 2, we conducted a large, population-based analysis of the association 
between vitamin D exposure and fracture risk across various fracture types using Cox 
proportional hazard regression models.  While Study 1 was purely descriptive, the inclusion 
of variables in Study 2’s statistical analyses was also guided by Andersen’s Behavioral 
Model of Health Services Use.  A facility’s decision to administer vitamin D was considered 
both a process of care and the use of a medical service under the health behaviors component 
of the model.  Vitamin D treatment at the facility-level was hypothesized to directly, 
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positively influence our health outcome of interest, fracture risk.  However, we found no 
statistically significant association between facilities with high vitamin D use and patient-
level fracture risk for all fracture types including those at the pelvis/hip, vertebrae, and 
femur.  There was also no signification association between the average vitamin D dose per 
patient within a facility and fracture risk for all fracture types examined.  Our key measures 
of vitamin D exposure were case-mix adjusted, accounting for variations in patient attributes 
within a facility that may influence the facility’s vitamin D treatment decisions.  Pelvis/hip 
fractures were observed to be the most common followed by vertebral fractures. 
In individual-level comparisons of predisposing, enabling, and need characteristics, 
differences between vitamin D users and non-vitamin D users were found (as indicated by an 
absolute standardized difference greater than 10).  Whereas we did not observe imbalance 
with other predisposing characteristics, we observed significant differences in the racial 
distribution of vitamin D users versus non-vitamin D users.  As for enabling characteristics, 
significant imbalance was observed between vitamin D users and non-vitamin D users with 
respect to Medicaid eligibility along with the facility-level factors of profit status (for-profit 
vs. non-profit), practice setting (hospital-based vs. free-standing), and dialysis chain.  Finally, 
differences between vitamin D users and non-vitamin D users were also found with the 
presence of the following comorbidities reflecting need characteristics: anemia, ischemic 
heart disease, other heart disorder, and peripheral vascular disease.  We found significant 
imbalance between vitamin D users and non-vitamin D users with respect to only these 
comorbidities and there is no plausible explanation in the literature to currently elucidate why 
vitamin D use would vary by the presence of heart disorders and anemia (ubiquitous among 
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dialysis patients).  The potential association between vitamin D use, anemia, and heart 
disorders merits further research.  
 Stratified analyses restricting patients by age, sex, and race were used to examine the 
association between IV vitamin D use and fracture risk among all the predisposing 
characteristics.  Although we observed that there were more black patients who used vitamin 
D than those who did not, the relation between vitamin D dose per patient and fracture risk 
was not significant among a subgroup of only black patients.  There also was not a 
significant relation between vitamin D dose per patient and fracture risk among a population 
of only female patients or one of only patients older than 65 years.  A priori, we hypothesized 
that IV vitamin D use and dose would be associated with a decreased risk of fracture among 
black patients, an increased risk of fracture among female patients and an increased risk of 
fracture among the elderly.  Female sex and older age are documented risk factors for 
fracture among dialysis patients.
77
 Black patients, possibly because of greater bone mass, 
have been observed to be at a lower risk for fracture compared to white patients in both the 
general and dialysis population. 
 
7.2  Implications  
The use of IV vitamin D therapy is ubiquitous among dialysis patients and the dosage 
of vitamin D therapy administered has steadily increased over time.  Medicare policies are 
hypothesized to be the great catalyst driving the observed, aggressive increase in vitamin D 
use.  Recent changes to Medicare’s reimbursement process may greatly impact the use of IV 
vitamin D therapy among dialysis patients in the future.  During the study period explored in 
this dissertation, dialysis facilities were paid one composite rate by Medicare for routine 
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dialysis services on a per-treatment basis.
197
  Injectable drugs like vitamin D were billed 
separately on a fee-for-service basis based on the total units of the drug provided to 
patients.
197
  The new ESRD prospective payment system, implemented on January 2011, 
spawned from concerns that the fee-for-service billing structure for injectable drugs led to 
high expenditures, inefficiencies and excessive use of erythropoietin stimulating agents and 
vitamin D.
1
  Under the new payment system, routine dialysis services and injectable drugs 
are billed under one, case-mix adjusted, bundled rate.  This provides dialysis facilities with 
strong financial incentives to manage the administration of IV vitamin D more efficiently.
198
  
The use of IV vitamin D will likely decline, gradually replaced with the adoption of less 
expensive oral vitamin D supplementations like generic calcitriol.
199
  
 Given the expected changes in vitamin D administration with the new payment 
system, the large variations in vitamin D dosing observed during our study period and 
documented in Study 1 provided a unique opportunity to investigate the impact of IV vitamin 
D on a salient clinical endpoint.  Vitamin D use and dosage has increased even while fracture 
incidence rates have remained relatively constant among hemodialysis patients.
190
  In Study 
2, using the grouped-treatment approach employed by Johnston, Tentori and other 
researchers,
95, 124
 we investigated the association between increasing vitamin D use, 
increasing vitamin D dose, and fracture risk.  The two-level, grouped-treatment approach was 
applied in this study to combine the advantage of reduced confounding with vitamin D 
exposure measured at the ecological level and greater variable specification with confounders 
and outcomes assessed at the patient-level.
124
  In contrast, rather than examining the effect of 
treating an individual dialysis patient with vitamin D, this approach allowed us to answer two 
questions: 1) “Is treatment at a dialysis facility utilizing IV vitamin D therapy more 
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frequently associated with reduced fracture risk, regardless of how an individual patient is 
treated?”; and 2) “Is treatment at a dialysis facility utilizing greater doses of IV vitamin D 
therapy associated with reduced fracture risk, regardless of the dose given to an individual 
patient?”  
 We did not find a statistically significant association between increasing vitamin D 
use or increasing vitamin D dose at a facility and fracture risk.  It would be valid to conclude 
that, given a choice, there would be no difference in a particular dialysis patient’s fracture 
risk if he or she transferred from a facility with relatively high vitamin D use to one with low 
vitamin D use.  However, given our analytical approach, our results can not indicate whether 
that same patient should be treated with vitamin D or whether certain doses of vitamin D 
would alter that patient’s fracture risk.  The results from this dissertation can not provide 
guidance regarding who should receive vitamin D therapy; it suggests only that having the 
option to transfer to a facility with high vitamin D use and dosage may not have any 
influence on that patient’s fracture outcomes.  We urge the nephrology community to 
reevaluate IV vitamin D dosing practices to ensure that any clinical decision to raise the dose 
of vitamin D for a particular patient is based on sound medical evidence.  Our empirical 
observation that vitamin D use increased drastically during a time of relatively unchanged 
fracture rates
190
 and our statistical analysis of the association between vitamin D exposure 
and fracture risk strongly suggest that the clinical benefit of vitamin D with respect to 
fracture risk among hemodialysis should be heavily questioned.   
Renewed and wide-ranging interest in the potential beneficial effects of vitamin D 
may entice nephrologists to incorrectly deem vitamin D a panacea for hemodialysis patients 
and entertain the use of the drug beyond established indications and guidelines.
95
  IV vitamin 
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D is standard in the treatment of SHPT, regulation of calcium and phosphate levels, and in 
the management of bone-mineral metabolism disturbances.  Vitamin D also has recognized 
pleiotropic effects including inhibiting the proliferation of cancer cells, defending against 
microbial infections, and preventing cardiovascular events.
200, 201
  
Vitamin D’s potential beneficial biological effects on the immune, inflammation, renin–
angiotensin systems and various other pathways triggered a number of observational studies 
that documented a survival advantage for hemodialysis patients administered IV vitamin D.
57, 
139
  Unfortunately, these analyses failed to properly account for confounding by unmeasured 
variables like underlying health status.  Employing the grouped-treatment approach used in 
this dissertation and other advanced statistical techniques, Tentori and colleagues did not find 
a survival advantage among hemodialysis patients administered vitamin D, suggesting that 
prior observational studies should be interpreted with much caution.
95
  Like the caution that 
should be exercised if deciding to use vitamin D to enhance survival prospects, dialysis 
healthcare providers should be equally reluctant to administer vitamin D at greater doses in 
an attempt to manipulate fracture risk. 
 As the nephrology community awaits the results of well-conducted studies to address 
the uncertainties regarding the clinical benefit of vitamin D, clinicians and healthcare 
providers compelled to use vitamin D with the intent of reducing fracture risks should be 
reminded that there is currently no evidence to substantiate the treatment decision.  Results 
generated from our analysis concurs with a meta-analysis of randomized clinical trials of 
vitamin D use in dialysis patients concluding that vitamin D had no beneficial effect on 
patient-level outcomes such as mortality and hospitalization.
58
  With respect to vitamin D and 
fractures among dialysis patients, a meta-analysis of the 4 randomized clinical trials with 
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fracture as a secondary outcome found that IV vitamin D had no clinical benefit (Effect size 
1.0 [0.06, 15.41]).
191
  
Given the lack of previous research in this area, findings from this population-based 
study addresses an important issue facing a growing population of ESRD patients.  Fractures 
are important markers of morbidity among dialysis patients and post-fracture consequences 
are substantial.
189
  The suppression of PTH levels with IV vitamin D therapy has been central 
to the treatment of SHPT and other bone mineral disorders in renal failure,
187
 but the clinical 
benefit of vitamin D with respect to fractures has yet to be elucidated.  The lack of evidence 
regarding the beneficial effect of vitamin D to curtail the frequency of fractures, however, 
does not overshadow the years of well-established literature documenting the value of the 
medication.  Our study adds to the cadre of evidence that may be used to guide future 
research agendas for analysts that might eventually inform decision-making by policymakers 
and healthcare providers.  A summary of recommendations for future research directions is 
presented in section 7.5. 
Moreover, the findings from our descriptive analyses also add to the nephrology 
literature.  Region was observed to be an important enabling factor.  The observed state-to-
state variations in vitamin D use and dosing practices found in Study 1 are consistent with 
Freburger and colleagues’ observations of the greater use of injectable drugs like 
erythropoietin stimulation agents and iron among hemodialysis patients in the southeastern 
region of the United States.
198
  Variations in vitamin D use in the dialysis population may be 
influenced by the same factors that have been found to increase Medicare spending in the 
general population such as provider profit-seeking behavior, organization of practices, or 
unmeasured markers of health status.
202
  Geographic differences in vitamin D use may also 
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be due to regional variations in facility practice management or reflective of the trends in 
demography and Medicare spending observed in the general population.
203, 204
  The results 
from this dissertation provide justification for large-scale analysis of reimbursement policies, 
scrutiny of factors perpetuating geographical differences and surveys into whether 
geographic variations in clinical care translate into regional differences in dialysis patient 
outcomes.  We need to better under how enabling characteristics like facility region interact 
with demographic, clinical, environmental factors to influence variations in facility 
management of injectable medications.  
Also, race was included in our analysis as a predisposing factor partially determining the 
use of dialysis services and a patient’s exposure to vitamin D in dialysis facilities.  Racial 
differences in utilization practices and vitamin D dosing are striking.
186
  Black patients 
receive nearly twice as much vitamin D as white patients, even though the percentage of 
black patients receiving vitamin D is less than the percentage of white patients receiving the 
drug.
186
  The new Medicare reimbursement system does not include race as a case-mix 
adjuster and, therefore, the payment system does not sufficiently reflect the higher cost to 
dialysis facilities to treat black patients.
205
  Facility viability and patient access to care may 
be significantly impacted if the payment system does not incorporate race and other drivers 
of facility cost differences.  However, this consideration is counterbalanced by the need for 
an appropriate racial classification and a greater understanding of whether racial variations in 
vitamin D are due to biological mechanisms or reflect discretionary facility practice 
patterns.
205
  The higher PTH levels found in black dialysis patients are among many factors 
dictating the pathology of renal osteodystrophy in dialysis patients and more studies are 
needed to ensure that higher vitamin D doses in blacks actually reflect clinical need before 
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validating these racial dose variations with the payment system.
205
  Simultaneously, we need 
to ensure that racial discrepancies are not due to facility practices that can be readily 
improved to enhance the quality of care to all dialysis patients of all races.
205
  
Finally, falls are an important and potentially modifiable risk factor for fracture.
79
  
However, there have been very few studies examining fall prevention strategies among 
dialysis patients.  A study of one outpatient hemodialysis center found clinically and 
statistically significant reductions in the incidence of falls after implementing targeted 
interventions addressing key risk factors for falls.
206
  Although the etiology of falls is 
multifactorial, risk factors for falls include cognitive impairment with vision, balance, 
strength, and gait; the presence of environmental dangers within the dialysis facility, and the 
use of more than four medications.
206, 207
  The physical environment of an outpatient 
hemodialysis center may be hazardous.
79, 206
  Potential hazards include loose blood tubing 
lines, wet floors from water spillage or leakage, elevated scales, and limited visibility due to 
low ambient lighting to accommodate patient preferences for sleep during dialysis 
treatment.
206
  
There are strategies that hemodialysis facilities may employ to begin to curtail the 
burden of fractures in their patient population.  Outpatient dialysis facilities can begin with a 
comprehensive assessment to identify patients at high risk for falls.
79
  Patients deemed at 
high risk for falls could be required to use a wheelchair while inside the center, have 
mandatory assistance with transfers, and scheduled communication with a renal social 
worker to discuss at-home strategies to reduce the risk of falls.
206
  Also, evidence from the 
general population suggests that reducing the number of medications taken by a patient may 
decrease the risk of fracture.
79
  The high comorbidity burden among dialysis patients is 
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largely responsible for the widespread polypharmacy observed in this population.  A 
comprehensive medication review, with a keen focus on psychoactive medications, may be 
beneficial by prompting the discontinuation of superfluous medications.  In the general 
population, the risk of falls has decreased with the gradual discontinuation of 
benzodiazepines, anticonvulsants, antipsychotics and sleeping pills.
79, 207
  With regard to the 
physical environment of the dialysis center, the impact of replacing elevated scales with in-
ground scales and installing tractable floor mats on the risk of falls can be assessed.
79
  Other 
modifiable alterations within  the dialysis facility include the routine use of towels around 
dialysis machines to curb fluid leaks and the installation of rails in patient restrooms.
206
  
 
7.3   Study limitations 
This dissertation has limitations.  Foremost, despite adjustment for various patient- and 
facility-level risk factors for fracture risk, residual confounding may still persist.  The non-
experimental nature of this study compels caution in interpreting study results.  Study 2 was 
limited by the presence of residual confounding from unmeasured factors like bone strength, 
patient behavior, and nutrition management.  For instance, the data did not enable us to 
account for hypoalbuminemia in our analysis, a factor found to be a strong predictor of high 
morbidity among dialysis patients.
208
   
Another limitation is that death is likely a competing risk in all survival analyses 
performed.   An alternative outcome that alters the probability of the outcome of interest 
occurring is considered a competing risk.
209
  In this study, individuals who had a fracture 
experienced the outcome of interest at the date of fracture.  However, if an individual dies 
prior to experiencing a fracture but was susceptible to fracture due to IV vitamin D use, death 
  
156 
would have been a competing risk.  In the presence of competing risks, traditional Kaplan-
Meier and Cox regression estimates may overestimate fracture risk.
209, 210
   
A limitation inherent to all administrative claims-based analyses, data from our analyses 
were derived from claims submitted for reimbursement purposes,  not from medical record 
abstractions or clinical measurements.  Misclassification bias may be present in several forms 
in this analysis.  Although studies of Medicare claims have demonstrated adequate 
ascertainment of fractures,
194
  there remains a possibility that some fracture events were 
missed. 
We were able to measure the number of vitamin D units billed for a particular patient 
but the data do not indicate whether partial doses were delivered to the patient.  Also, we 
could not capture oral vitamin D or bisphosphonate use but this is a minor limitation given 
that bisphosphonates are not generally prescribed to dialysis patients due to renal safety 
concerns.
211
 
Consistent with prior reports using the grouped-treatment approach
212
, we observed 
relatively wide confidence intervals for the vitamin D ecological variables.  However, this 
can be expected since we are measuring vitamin D treatment with the use of aggregated 
proxies, causing some loss of precision. 
With respect to external validity, the results from this dissertation may not be 
generalizable to chronic kidney disease patients that are not undergoing dialysis, peritoneal 
dialysis patient, and patients who do not have Medicare as a primary payer.  Also, caution 
should be taken in generalizing study results to prevalent dialysis patients given the focus on 
incident dialysis patients who make up only approximately 20% of the total US hemodialysis 
population.
213
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Lastly, variations in the pathophysiology and severity of comorbid conditions and 
fractures were not assessed.  The addition of the severity grading of various comorbidities 
did not lead to increased prognostic power in studies of mortality in patients with ESRD,
214
 
suggesting that this limitation is minor and including the severity of comorbidities in our 
analyses likely would not have influenced our results significantly.  
 
 7.4  Study strengths  
The strengths of this dissertation outweigh its limitations.  The primary strength of this 
dissertation was our statistical approach.  We attempted to overcome confounding by 
indication/disease severity (i.e., sicker patients receive more treatment) and other 
methodological issues commonly present in non-experimental studies conducted at the 
individual-level with our statistical approach. We adopted a statistical approach aimed at 
minimizing confounding due to unmeasured variables that directly influence the decision to 
administer vitamin D and confounding due to the fact that patients prescribed vitamin D may 
be fundamentally different from those who are not administered the drug.  Confounding bias 
may be attenuated or even eliminated with the use of an ecological, grouped-treatment 
variable that is related to the patient’s treatment but weakly associated with unmeasured 
patient risk factors.
215
   
Researchers have longed cautioned against the use of ecological studies to make 
inferences at the individual-level in a phenomenon known as the ecologic fallacy.
216
  
Associations found at an aggregated unit of analysis may not necessarily hold true at the 
individual-level.
216
  However, in the presence of confounding at the individual-level, the 
relative immunity of ecological studies to confounding by indication may supersede any 
ecologic fallacy issues if variation in treatment utilization is driven by differences in practice 
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style.
121, 216
  To circumvent the deficits of ecological studies and to take advantage of the 
relative immunity of the approach from confounding by indication, we employed the 
grouped-treatment approach. Vitamin D use and dose were aggregated to the dialysis facility-
level while covariates and fracture outcomes were measured at the patient-level.
188
  
Confounding by indication bias was mitigated with the ecological treatment variable and we 
capitalized on the advantages of increased precision with observed confounders and 
outcomes at the individual-level.
124
 
We recognized that residual confounding may still persist, even after aggregating 
vitamin D treatment to the facility-level.  Our key vitamin D variables may have been 
confounded by demographic and clinical attributes of patients at a particular facility that may 
have influenced how that center decided to administer vitamin D.  It was important to ensure 
that our measurement of vitamin D exposure at the facility-level was capturing variations in 
vitamin D use and dose at a facility, independent of that facility’s patient case-mix.  A 
facility’s high use of vitamin D may actually reflect a clustering of patient’s with a 
preponderance of characteristics that merit higher vitamin D dosage.  For instance, a facility 
may serve a preponderance of black hemodialysis patients, generally administered higher 
doses of vitamin D compared to patients of other races.
186
  To this end, an additional strength 
of this dissertation was that we addressed this potential bias by creating case-mix adjusted 
measures of vitamin D exposure that reflected a facility’s propensity to prescribe vitamin D 
given the facility’s patient population. 
Our target population of hemodialysis facilities was a considerable strength. The 
validity of our approach is contingent upon the assumption that the pre-treatment prognosis 
of patients is not associated with the proportion of patients treated with vitamin D at a 
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dialysis facility.
212
  By way of explanation, the assumption relies on the fact that high-risk 
patients are not being transferred to particular dialysis facilities because of that facility’s 
vitamin D utilization practices.  Studies of dialysis facilities provide a unique opportunity to 
plausibly fulfill this rather restrictive assumption.  Unlike hospitals where patients are most 
often referred to the hospital most adept at providing the particular procedure or care needed, 
dialysis patients generally attend the dialysis center in closest geographical proximity to their 
residence.  Therefore, the vitamin D treatment practices of a dialysis facility do not play a 
role in the decision to attend a particular facility, providing us with the basis for a natural 
experiment and pseudo-randomization.  
Another strength of this dissertation was the use of a proxy for functional status to 
account for waning underlying health processes that may predict fracture risk.  Functional 
status was estimated using claims for personal assistance aids like wheelchairs, canes, 
walkers, and modified bathroom equipment.  Patients with ESRD experience many of the 
clinical manifestations of frailty found in patients without kidney disease such as declining 
physical function, comorbidities, and loss of muscle mass.
153
  Adverse outcomes like 
hospitalizations and death have been shown to be mediated by frailty
153
, but few prior studies 
have attempted to control for its possible effects. 
Additionally, this dissertation is unique in its exploration of different subgroups and 
multiple fracture types.  Study 1 explored temporal trends in vitamin D use and dosing by 
relevant subgroups.  Study 2 investigated the association between vitamin D exposure and 
fracture outcomes by fracture type and relevant subgroups.  Unlike our study, the Dialysis 
Outcomes and Practice Patterns Study (DOPPS), the most contemporary report of IV vitamin 
D use and dose in the United States, did not report variations in vitamin D use by race, age, 
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and sex subgroups and used a small sample size of less than 4,000 patients.
183
  Studies 
examining the incidence and factors associated with fracture risk have focused 
predominantly on hip fracture and were based on selective groups of patients.
73, 74, 77, 82-84
  
Our study assessed the association between vitamin D exposure and fracture by four fracture 
categories that represented the most clinically significant and costly types.    
Our use of USRDS files is the final major strength of this dissertation.  The USRDS 
captures data on every ESRD patient in the United States and contains the most detailed data 
on demographic attributes, diagnoses, treatment histories, hospitalizations and dialysis 
facility services.
217
  Our population-based study had a large sample size of over 130,000 
patients representing over 4,000 dialysis facilities nationwide.  
 
7.5  Recommendations for future research 
 The present analysis characterized the association between vitamin D exposure and 
fracture risk but it was not designed to establish causal inference.  A robust clinical trial can 
confirm the validity of our observed associations but these trials would likely be limited by 
under-ascertainment of fracture events and questions regarding clinical equipoise.  The 
impracticability of randomized controlled trials warrants the use of robust non-experimental 
studies to address this salient issue.  The following text proposes research questions, 
corresponding study designs, and data sources that could be employed in non-experimental 
studies to substantiate our results and address the current gaps in the nephrology literature.  
In the absence of clinical trial evidence, the grouped-treatment approach extends the 
natural experiment methodology commonly found in epidemiology by taking advantage of 
variations in practice policies to estimate the marginal effect of differences in treatment 
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selection.
218
  As in this dissertation, the grouped-treatment approach (where the main variable 
of interest is measured ecologically while outcomes are measured at the individual-level) is 
advantageous in epidemiological studies where individual-level factors like biochemical 
parameters that determine the decision to prescribe a medication are not readily available in 
the dataset of interest.  An individual-level analysis using a data source with adequate 
laboratory and biochemical measures could be conducted to substantiate whether there is 
indeed no association between vitamin D exposure and fracture risk among hemodialysis 
patients.  To this end, one could employ the approach used by Block and colleagues to 
investigate cardiovascular outcomes among hemodialysis patients.  Data from DaVita Inc., 
the second largest dialysis provider in the United States, could be linked using unique patient 
identifiers to the Centers for Medicare & Medicaid Services (CMS) ESRD database by the 
United States Renal Data System (USRDS) through a data licensing agreement.
219
  
Unlike using USRDS data alone, merged DaVita and USRDS data contain detailed 
laboratory values, IV medication use, home medication use, and vascular access information 
from DaVita while simultaneously providing relevant Medicare claims and hospitalization 
data from the USRDS for each patient.
219
  The DaVita dataset provides two distinct 
advantages.  Firstly, the data contain the important laboratory values of calcium, phosphorus, 
and PTH levels that are used to guide vitamin D administration.  Secondly, merged DaVita 
and USRDS data would allow researchers to measure exposure to cinacalcet, an oral 
calcimimetic also used to treat SHPT.  Our analysis was restricted to the years prior to the 
widespread use of cinacalcet to allow us the ability to ascertain the association between 
vitamin D and fracture risk without the effects of confounding from the administration of a 
drug also indicated to treat SHPT.  A retrospective cohort study using the most recent years 
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of available data could be conducted to assess the effect of vitamin D exposure on fracture 
risk with patient-level vitamin D prescription treated as a time-dependent variable.  Vitamin 
D exposure and covariates (e.g., baseline comorbidity, laboratory data, cinacalcet and 
phosphate binder use) could be measured during a 6-month baseline period.  Adjusted time-
dependent Cox proportional hazard regression models could be employed to assess 3-year 
fracture risk and eligible patients would be censored in the event of transfer out of DaVita, 
renal transplantation or loss to follow-up. 
Furthermore, a natural extension of the recommended study described above could be 
an investigation exploring the comparative effectiveness of IV vitamin D formulations with 
respect to fracture outcomes.  In this dissertation, we report the overwhelming use of 
paricalcitol between 1999 and 2008.  However, trends have changed in recent years and 
contemporary data of hemodialysis patients contend that doxercalciferol and paricalcitol are 
now being administered at relatively equal frequency, with calcitriol use now virtually non-
existent.
183
  It is unknown whether the pharmacological differences between these 
formulations translate into differential effects on important clinical outcomes like fracture 
risk. Using the aforementioned, linked USRDS and DaVita data, the comparative 
effectiveness of paricalcitol versus doxercalciferol with respect to fracture risk could be 
assessed with a retrospective cohort study.  A cohort of incident hemodialysis patients could 
be selected under the new user design. Following a 3-month waiting period for claim 
ascertainment post-dialysis initiation, vitamin D exposure (use and dosage) could be 
measured over a 6-month baseline period for patients treated exclusively with either 
paricalcitol or doxercalciferol.  Patients could be followed over 1 or 3 years and censored if 
they died, switched to another formulation, switched dialysis facilities, or underwent renal 
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transplantation.  Laboratory values could be averaged over the 6-month baseline period and 
controlled for within Cox proportional hazard regression models along with baseline 
comorbidity and clinical attribute data.   
Cinacalcet, also used to treat SHPT among dialysis patients, is currently covered 
under Medicare Part D but will be included under the new bundle as of January 2014.  Given 
that financial incentives may compel the substitution of IV vitamin D for the cheaper 
cinacalcet for certain patient populations in 2014, future studies are needed to investigate the 
comparative efficacy and safety of vitamin D versus these various therapeutic options with 
respect to fracture outcomes.  The secondary data needed to explore these issues will take 
years before becoming available to researchers and confirmatory studies will be required to 
ensure that the bone health of patients with ESRD is not compromised under the new 
payment system.  For now, the independent effect of cinacalcet on fracture risk could be 
assessed using the methodology published by Frankenfield and colleagues to allow for 
comparison with studies of vitamin D exposure and to inform future analyses post the 2014 
reimbursement policy changes.
220
    
Using CMS Medicare Part D data linked to USRDS files, a retrospective cohort study 
could be conducted with a point-prevalent cohort of adult hemodialysis patients alive 
between July 1, 2006 and December 31, 2006, the latter months of the calendar year of 
Medicare Part D’s initiation. Patients would then be followed from December 31, 2006 until 
death, renal transplantation or the last day of available data.  Cinacalcet exposure could be 
defined as a dichotomous, time-dependent variable indicating the presence or absence of a 
cinacalcet prescription during the study period.  Time-varying Cox proportional hazard 
regression models would assess the effect of cinacalcet prescription on fracture risk with 
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adjustment for baseline characteristics along with time-varying laboratory and IV vitamin D 
use.  
 Lastly, potentially inappropriate use of vitamin D therapy has been observed in an 
internationally representative sample of dialysis patients where investigators found that 
vitamin D was potentially overused in up to 46% of patients with low PTH (concentration 
<100 pg/mL) and potentially underused in up to 34% of patients with high PTH 
(concentration >400 pg/mL).
221
  To understand the appropriateness of vitamin D 
administration to dialysis patients and to elucidate the relationship between vitamin D use 
and fracture outcomes, the nephrology community must ensure that treatment decisions are 
based on current, reliable evidence.     
 
7.6   Conclusion 
 In conclusion, IV vitamin D use is highly prevalent among hemodialysis patients with 
both the percentage of users and dosage administered increasing over the past decade. 
Vitamin D dosing practices varied most poignantly by race and geographical location.  Black 
hemodialysis patients received over twice as much vitamin D as white patients and higher 
doses of the drug were administered in the southern region of the United States.  However, 
we found that the use of vitamin D in increasing doses was not significantly associated with 
fracture risk. After employing a statistical approach that mitigates the possible effects of 
confounding, we found that facilities with a high percentage of vitamin D users and facilities 
that provided high doses of vitamin D did not have an observed beneficial association with 
fracture risk, even after adjusting for variations in patient characteristics within dialysis 
facilities. 
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 The clinical benefit of IV vitamin D with respect to fracture risk has yet to be 
elucidated.  Results from this dissertation begin to address the dearth of large, population-
based studies investigating fracture risk among dialysis patients, generally, and serves as the 
first large-scale examination of the association between vitamin D and fracture risk among 
hemodialysis patients, to date.  The changing reimbursement environment in nephrology 
fosters an immediate need to understand the impact of varying facility-level vitamin D 
treatment decisions on patient outcomes given that financial incentives may reduce the 
administration of the drug.  Substantial evidence of vitamin D’s pleiotropic effects and its 
ability to successfully suppress PTH levels reaffirms the need to continue the administration 
drug given of the prevalence of SHPT in the dialysis patients.  However, researchers and 
clinicians must be simultaneously reminded that vitamin D’s benefit currently does not 
extend past effective manipulation of biochemical parameters. Future investigations are 
warranted to ensure that vitamin D is appropriately prescribed across dialysis facilities with a 
growing and diverse hemodialysis patient population. 
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APPENDICES 
 
Appendix 1. Guidelines for managing vitamin D based on intact parathyroid hormone 
(PTH) levels 
 
Source: http://www.kidney.org/professionals/kdoqi/guidelines_bone/Images/Algorithm5L.jpg 
 
  
167 
 
Appendix 2. Relationship between vitamin D variables, covariates, and fracture 
 
 
-Proportion of vitamin D users/facility 
    -Average vitamin D dose per patient/facility 
(Facility level measures of vitamin D exposure) 
Individual Patient Treatment 
with Vitamin D 
Prognostic Factors 
(Known and Unknown) 
Fracture 
 
Adapted from “Schmoor C, Caputo A, Schumacher M. Evidence from Nonrandomized Studies: A Case Study 
on the Estimation of Causal Effects. American Journal of Epidemiology. May 1, 2008 2008;167(9):1120-1129.” 
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Appendix 3. Description of covariates 
Variable  Type Definition Source 
Demographic characteristics 
Age Categorical 
transformed 
into dummies 
“Agegrp1”=1 if age is 
18≤x≤44 
“Agegrp2”=1 if age is 
45≤x≤64 
“Agegrp3”=1 if age is 
65≤x≤74 Reference 
“Agegrp4”=1 if age is ≥75 
USRDS Patient File 
Sex Dichotomous 1=male, 0=female USRDS Patient File 
Race Categorical 
transformed 
into dummies 
“White”=1 Reference 
“Black”=1 “Other_race”=1 
if race not white or black, or 
missing 
USRDS Patient File 
Medicaid eligibility Dichotomous 1=eligible, 0=not eligible USRDS Payer History 
File 
Comorbidities    
Acute MI Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
AIDS Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Anemia Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Autoimmune disorder Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
CABG/stent/PTCA 
placement 
Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Cancer Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
COPD/Asthma Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Diabetes mellitus Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Gastrointestinal bleed Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Hypertension Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Hyperthyroidism Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Ischemic heart disease Dichotomous 1=present, 0=absent USRDS Institutional 
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Claims File 
Liver disease Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Neurologic disorder Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Obese Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Other heart disorder Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Peptic ulcer disease Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Peripheral vascular 
disease 
Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Pneumonia Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Psychiatric disorder Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Pulmonary circulation 
disorder 
Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Stroke Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Substance use disorder Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Disease history characteristics 
Primary cause of ESRD Categorical 
transformed 
into dummies 
“Diabetes_cause”=1 if 
primary cause is diabetes 
Reference 
“Hypertension_cause”=1if 
primary cause is 
hypertension 
“GN_cause”=1 if primary 
cause is primary or 
secondary 
glomerulonephritis 
“Other_cause”=1 if primary 
cause is polycystic kidney 
disease, a urologic disease, 
or undefined 
USRDS Patient File 
Prior history of 
parathyroidectomy 
Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Facility characteristics    
Profit status Dichotomous 1=for-profit facility, 0=not 
for-profit facility 
USRDS Facility File 
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Practice setting Categorical 
transformed 
into dummies 
1=free-standing, 0=hospital USRDS Facility File 
Chain affiliation  Categorical 
transformed 
into dummies 
“Chain_1”=1 
 Reference 
“Chain_2”=1 
“Chain_3”=1 
“Chain_4”=1 
“Chain_5”=1 
“Chain_6”=1 
USRDS Facility File 
Size Categorical 
transformed 
into dummies 
“Small”=1 Reference 
“Medium”=1 
“Large”=1 
USRDS Facility File 
Region  Categorical 
transformed 
into dummies 
“NE_region”=1 if located in 
the northeastReference 
“MW_region”=1 if located 
in the midwest 
“S_region”=1 if located in 
the south 
“W_region”=1 if located in 
the west 
USRDS Facility File 
Functional status markers    
Use of personal assistance 
aids 
Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
Treatment characteristics    
Fistula  Dichotomous 1=present, 0=absent USRDS Institutional 
Claims File 
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Appendix 4. Facility intravenous vitamin D formulation preference
a
 by year 
 Year N Calctriol 
preferred (%) 
Paricalcitol 
preferred 
(%) 
Doxercalciferol 
preferred  
(%) 
Mixed 
preference
b
 
(%) 
No vitamin D 
administered 
 (%) 
1999 3572 97.6 0.0 0.0                   0.0 2.4 
2000 3783 36.4 17.7 0.0     44.5 1.4 
2001 3919 13.4 58.0 0.0 27.4 1.3 
2002 4109 6.0 68.5 4.6 20.0 1.1 
2003 4257 3.1 70.2 7.4 18.2 1.1 
2004 4410 1.7 60.4 20.6 16.3 1.1 
2005 4566 1.4 58.6 26.2 13.2 0.8 
2006 4683 1.2 58.6 26.2 13.2 0.8 
2007 4840 0.7 60.1 24.3 14.1 0.8 
2008 5056 0.6 68.4 18.0 12.0 1.0 
a
Preference defined as >75% of total vitamin D dose administered in a facility was for particular 
formulation 
b
Mixed preference defined as no formulation comprised >75% of total vitamin D dose administered in a 
facility 
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Appendix 5. Comparative histograms of non case-mix and case-mix adjusted 
proportion of vitamin D users per facility  
 
 
Correlation between non case-mix adjusted and case-mix adjusted proportion of vitamin D 
users per facility=0.930 
 
 
 
 
  
173 
 
Appendix 6. Number of patients in a facility with each respectivement measure of vitamin 
D exposure   
Case-mix adjusted proportion of vitamin D users 
 
Case-mix adjusted average vitamin D dose per patient 
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Appendix 7. Demographic and clinical characteristics of cohort by whether patient is in 
a facility in the lowest versus highest quartile of case-mix adjusted proportion of 
vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
N      34,000       33,950  
Age (years)    
   18-44 10.3 10.3              0.0 
   45-64 28.8 29.5              1.5 
   65-74 31.2 31.2              0.0 
   >= 75 29.7 29.0              1.5 
Race    
   White 63.5 59.7              7.8 
   Black 31.2 35.7              9.5 
   Other  5.3               4.6              3.2 
Female 47.1 47.6              1.0 
Medicaid eligible 40.4 46.4 12.1** 
Comorbidities    
   Acute MI   4.6  4.4              1.0 
   Anemia   1.1  1.1              0.0 
   Autoimmune disorder  80.0 86.8 18.4** 
   Cancer   3.4   3.2              1.1 
   COPD/Asthma   2.3   2.4               0.7 
   Diabetes mellitus 11.4 11.1 0.9 
   Gastrointestinal bleed 19.6 18.4 3.1 
   Heart-related procedure 58.5 59.1 1.2 
   HIV/AIDS   5.7   5.8 0.4 
   Hypertension 79.8 79.9 0.2 
   Hyperthyroidism   1.0   1.1 1.0 
   Ischemic heart disease 38.2 37.7 1.0 
   Liver disease  3.3   3.2 0.6 
   Neurologic disorder  7.6   7.5 0.4 
   Obese  4.0   4.2 1.0 
   Other heart disorder 52.3 51.7 1.2 
   Peptic ulcer disease 3.8   3.9 0.5 
   PVD 25.1 25.1 0.0 
   Pneumonia             10.0 10.0 0.0 
   Psychiatric disorder  4.5   4.3 1.0 
   PCD  3.2   3.0 1.2 
   Stroke 12.3 12.2 0.3 
   Substance use disorder  6.3   5.8 2.1 
Cause of ESRD    
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Appendix 7. Demographic and clinical characteristics of cohort by whether patient is in 
a facility in the lowest versus highest quartile of case-mix adjusted proportion of 
vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
   Diabetes mellitus 48.4 48.4 0.0 
   Hypertension 29.9 31.2 2.8 
   Glomerulonephritis   8.0   7.7 1.1 
   Other 13.7 12.6 3.3 
Parathyroidectomy   0.1   0.1 0.0 
For-profit 63.7 86.4 54.4** 
Free-standing 81.5 89.0 21.3** 
Chain    
   Chain #1 20.3 26.8 15.4** 
   Chain #2   7.1 16.4 29.2** 
   Chain #3   6.4 21.4 44.4** 
   Other chain 66.2 35.4 64.8** 
Facility size    
   Small 10.1   6.3 13.9** 
   Medium 44.8 43.9 1.8 
   Large 45.0 49.8 9.6 
Region    
   Midwest 28.3 17.8 25.1** 
   Northeast 13.7 21.5 20.6** 
   South 46.2 41.9 8.7 
   West 11.9 18.8 19.2** 
Use of personal 
assistance aids 
  6.0   6.4              1.7 
Fistula 24.7 24.8 0.2 
Iron user 85.4 92.7             23.5 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized 
difference; COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; 
HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;  PVD,  
peripheral vascular disease; PCD, pulmonary circulation disorder 
** An absolute standardized difference > 10 indicates significant imbalance of characteristic 
when comparing vitamin D users to non-vitamin D users 
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Appendix 8. Demographic and clinical characteristics of cohort by whether patient is in 
each quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Quartile 1 
[<25%] (%) 
Quartile 2  
[25-50%) 
(%) 
Quartile 3 [50-75%] 
(%) 
Quartile 4  
[>75%] 
(%) 
N 34,000    33,987          34,021 33,950 
Age (years)     
   18-44 10.3 10.4 10.0 10.3 
   45-64 28.8 29.0 29.1 29.5 
   65-74 31.2 31.3 31.2 31.2 
   >= 75 29.7 29.3 29.7 29.0 
Race     
   White 63.5 65.0 63.1 59.7 
   Black 31.2 29.7 32.2 35.7 
   Other   5.3   5.3   4.7  4.6 
Female 47.1 47.4 48.0 47.6 
Medicaid eligible 40.4 42.3 44.3 46.4 
Comorbidities     
   Acute MI 4.6 4.6   4.5 4.4 
   Anemia 1.1 1.2   1.1 1.1 
   Autoimmune 
disorder 
80.0 86.8 85.8 86.8 
   Cancer   3.4   3.4   3.6 3.2 
   COPD/Asthma   2.3   2.3   2.3 2.4 
   Diabetes mellitus 11.4 11.1 11.0 11.1 
   Gastrointestinal 
bleed 
19.6 19.3 19.1 18.4 
   Heart-related 
procedure 
58.5 59.9 58.8 59.1 
   HIV/AIDS   5.7   5.4   5.3   5.8 
   Hypertension 79.8 79.7 80.1 79.9 
   Hyperthyroidism   1.0 0.8   0.9   1.1 
   Ischemic heart 
disease 
38.2 38.9 38.6 37.7 
   Liver disease   3.3   3.2   3.7 3.2 
   Neurologic 
disorder 
  7.6   7.6   7.8 7.5 
   Obese   4.0   3.9   4.2   4.2 
   Other heart 
disorder 
52.3 52.6 52.2 51.7 
   Peptic ulcer 
disease 
  3.8   3.7   4.0 3.9 
   PVD 25.1 25.1 25.0 25.1 
   Pneumonia 10.0 10.2 10.0 10.0 
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Appendix 8. Demographic and clinical characteristics of cohort by whether patient is in 
each quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Quartile 1 
[<25%] (%) 
Quartile 2  
[25-50%) 
(%) 
Quartile 3 [50-75%] 
(%) 
Quartile 4  
[>75%] 
(%) 
   Psychiatric 
disorder 
 4.5  4.4   4.5   4.3 
   PCD   3.2  3.1   3.2   3.0 
   Stroke 12.3 12.8 12.8 12.2 
   Substance use 
disorder 
  6.3   6.3   6.0   5.8 
Cause of ESRD     
   Diabetes mellitus 48.4 49.3 49.1 48.4 
   Hypertension 29.9 29.2 29.9 31.2 
   
Glomerulonephritis 
  8.0  8.2   8.0         7.7 
   Other 13.7 13.3 13.0 12.6 
Parathyroidectomy   0.1   0.1   0.1   0.1 
For-profit 63.7 82.2 85.3 86.4 
Free-standing 81.5 88.0 90.1 89.0 
Chain     
   Chain #1 20.3 30.6 27.8 26.8 
   Chain #2   7.1 15.5 17.2 16.4 
   Chain #3   6.4   9.0 16.7 21.4 
   Other chain 66.2 44.9 38.2 35.4 
Facility size     
   Small 10.1 11.0 10.0   6.3 
   Medium 44.8 43.6 44.9 43.9 
   Large 45.0 45.5 45.1 49.8 
Region     
   Midwest 28.3 20.0 22.8 17.8 
   Northeast 13.7 19.3 15.1 21.5 
   South 46.2 46.2 45.3 41.9 
   West 11.9 14.5 16.8 18.8 
Use of personal 
assistance aids 
  6.0  6.2   6.3  6.4 
Fistula 24.7 25.2 24.9 24.8 
Iron user 85.4 92.0 92.4 92.7 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized difference; 
COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; HIV/AIDS, 
human immunodeficiency virus / acquired immunodeficiency syndrome;  PVD,  peripheral 
vascular disease; PCD, pulmonary circulation disorder 
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Appendix 9. Intercept generated from mixed-effects logistic regression model used to create 
the case-mix adjusted proportion of vitamin D users per facility 
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Appendix 10. Supremum tests
a
 of proportional hazards assumption for association 
between case-mix adjusted measures of vitamin D exposure and fracture outcomes 
 Case-mix Adjusted Proportion of 
VD Users
b
 
Case-mix Adjusted Average Vitamin 
D Dose per Patient
c
 
Outcome Max absolute 
Value 
P-Value Max absolute 
Value 
P-Value 
Any 
fracture 
52.00 0.368 83.61  0.087 
Pelvis/hip 41.35 0.227 46.94 0.285 
Vertebral 32.52 0.123 21.02 0.763 
Other
d
 38.74 0.113 54.74 0.022 
a
A non-significant p-value suggests that there was no sufficient evidence that the proportional hazards 
assumption was violated
 
b
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease 
c
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal disease 
d
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist fractures 
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Appendix 11. Kaplan-Meier time to fracture curves by race*vitamin D user status 
  
  
 
 
 
Log-Rank p<0.01 
Log-Rank p<0.01 Log-Rank p<0.01 
Log-Rank p<0.01 
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Appendix 12. Kaplan-Meier time to fracture curves by sex*vitamin D user status 
  
  
 
 
 
 
Log-Rank p<0.01 
Log-Rank p<0.01 Log-Rank p<0.01 
Log-Rank p<0.01 
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Appendix 13. Kaplan-Meier time to fracture curves by age*vitamin D user status 
  
  
 
 
 
Log-Rank p<0.01 
Log-Rank p<0.01 Log-Rank p<0.01 
Log-Rank p<0.01 
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Appendix 14. Multivariable
a
 Cox models of the association between facility-level case-mix 
adjusted average vitamin d dose per patient
b
 and fracture among subgroups (Years 2000-
2004) 
 Non-Black Male Age <65 years 
 HR (95% CI)
c
 HR (95% CI) HR (95% CI) 
Any 1.02 (0.92-1.12) 1.16 (1.06-1.28)** 1.06 (0.90-1.25) 
Pelvis/hip 1.08 (0.98-1.19) 1.25 (1.15-1.36)** 0.99 (0.64-1.54) 
Vertebral 0.84 (0.52-1.35) 1.04 (0.79-1.37) 1.12 (0.93-1.36) 
Other 0.98 (0.81-1.18) 1.05 (0.83-1.34) 1.07 (0.91-1.27) 
a
Cox models adjusted for age (except for the age subgroup analysis), sex (except for the sex subgroup analysis), 
race(except for the race subgroup analysis), Medicaid eligibility, the presence of comorbidities, primary cause of 
end-stage renal disease, prior history of parathyroidectomy, facility characteristics, use of personal assistance aids, 
and the presence of a fistula. 
b
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of ESRD 
c
Hazard Ratio (95% confidence interval) 
**p<0.01 
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Appendix 15. Cox models of the association between non-case-mix adjusted 
measures of vitamin D exposure and fracture risk (Years 2000-2004) 
Fracture Type Proportion of VD Users Average Vitamin D Dose 
per Patient 
 HR (95% CI)
a
 HR (95% CI) 
Any   
    Crude 0.66 (0.56-0.78)** 0.77 (0.49-1.20) 
    Adjusted
b
 1.10 (0.92-1.31) 1.00 (0.97-1.02) 
Pelvis/hip   
    Crude 0.57 (0.46-0.71)** 0.84 (0.38-1.88) 
    Adjusted 0.98 (0.77-1.25) 1.00 (0.98-1.03) 
Vertebral   
    Crude 0.62 (0.45-0.84)** 0.52 (0.38-0.70)** 
    Adjusted 1.08 (0.75-1.55) 0.95 (0.87-1.05) 
Other
c
   
    Crude 0.93 (0.69-1.25) 0.81 (0.65-1.02) 
    Adjusted 1.40 (1.00-1.94)** 0.99 (0.96-1.02) 
a
Hazard Ratio (95% confidence interval) 
b
Cox models adjusted for age, sex, race, Medicaid eligibility, comorbidities, primary cause of end-stage 
renal disease, prior history of parathyroidectomy, facility characteristics, use of personal assistance aids, and 
the presence of a fistula. 
c
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist fractures 
** p<0.05 
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Appendix 16. Cox models of the association between being 
in a facility in the highest quartile of case-mix adjusted 
average vitamin D dose per patient
a
 and fracture risk 
(Years 2000-2004) 
Fracture Type Facility in Highest Quartile 
 HR (95% CI)
b
 
Any  
    Crude 0.97 (0.91-1.04) 
    Adjusted
b
 1.03 (0.97-1.10) 
Pelvis/hip  
    Crude 0.99 (0.90-1.08) 
    Adjusted 1.05 (0.96-1.15) 
Vertebral  
    Crude 0.89 (0.78-1.01) 
    Adjusted 0.94 (0.83-1.08) 
Other
c
  
    Crude 0.99 (0.89-1.10) 
    Adjusted 1.03 (0.93-1.15) 
a
Cox models adjusted for age, sex, race, Medicaid eligibility, comorbidities, primary 
cause of end-stage renal disease, prior history of parathyroidectomy, facility 
characteristics, use of personal assistance aids, and the presence of a fistula. 
b
Hazard Ratio (95% confidence interval) 
c
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and 
forearm/wrist fractures 
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Appendix 17. Sensitivity analysis: Cox models of the association between measures of 
vitamin d exposure and fracture risk (Years 2000-2008) 
Fracture Type Proportion of Vitamin D 
Users
a
 
Average Vitamin D Dose 
per Patient
b
 
 HR (95% CI)
c
 HR (95% CI) 
Any   
    Crude 0.84 (0.70-1.00) 0.97 (0.89-1.07) 
    Adjusted
d
 0.88 (0.74-1.06) 1.02 (0.94-1.10) 
Pelvis/hip   
    Crude 0.81 (0.64-1.03) 0.98 (0.86-1.12) 
    Adjusted 0.85 (0.66-1.09) 1.03 (0.92-1.14) 
Vertebral   
    Crude 0.76 (0.55-1.06) 0.81 (0.60-1.10) 
    Adjusted 0.77 (0.54-1.11) 0.88 (0.66-1.17) 
Other
e
   
    Crude 0.99 (0.75-1.30) 1.01 (0.85-1.20) 
    Adjusted 1.02 (0.76-1.38) 1.03 (0.86-1.23) 
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease 
b
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal 
disease 
c
Hazard Ratio (95% confidence interval) 
d
Cox models adjusted for age, sex, race, Medicaid eligibility, comorbidities, primary cause of end-stage 
renal disease, prior history of parathyroidectomy, facility characteristics, use of personal assistance aids, and 
the presence of a fistula. 
e
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist fractures 
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Appendix 18. Description of length of intravenous vitamin D exposure measurement period in observational studies of 
hemodialysis patients 
First Author, 
Year 
Data 
Source 
Patient 
population 
Study design Main 
Predictor 
Outcome Length of 
vitamin D 
exposure 
measurement 
period 
Relevant notes? 
Dobrez,  
2004 
Records 
from major 
dialysis 
provider 
Incident 
HD 
patients 
Retrospective 
cohort 
IV 
vitamin D 
use 
Hospitalizations
/Hospital days 
A minimum 
of 60 days of 
HD and a 
minimum of 
10 IV vitamin 
D injections  
- 
Kilpatrick, 
2011 
Records 
from major 
dialysis 
provider 
Incident 
HD 
patients 
Case-
crossover 
IV 
vitamin D 
use 
Hypercalcemia/ 
hyperphosphate
-mia  
60 days - 
Shinaberger, 
2008 
Records 
from major 
for-profit 
dialysis 
provider 
All HD 
patients 
Retrospective 
cohort 
IV 
vitamin 
D use 
All-cause 
mortality 
90 days - 
Teng, 2003 Records 
from major 
for-profit 
dialysis 
provider 
All HD 
patients 
Retrospective 
cohort 
IV 
vitamin 
D use 
All-cause 
mortality 
Varied: Time 
between index 
date and 
censoring 
event whereby 
patient used 
one IV 
vitamin D 
drug 
exclusively 
Base-line 
laboratory values 
represent the mean 
value during the 3 
months before 
initiation of 
treatment with 
vitamin D 
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Appendix 18. Description of length of intravenous vitamin D exposure measurement period in observational studies of 
hemodialysis patients 
First Author, 
Year 
Data 
Source 
Patient 
population 
Study design Main 
Predictor 
Outcome Length of 
vitamin D 
exposure 
measurement 
period 
Relevant notes? 
Teng, 2005 Records 
from major 
for-profit 
dialysis 
provider 
Incident 
HD 
patients 
Retrospective 
cohort 
IV 
vitamin 
D use 
All-cause 
mortality 
Vitamin D 
measured as a 
time-varying 
variable.  
73% of those who 
were eventually 
treated with 
injectable vitamin 
D had started 
within 90 d of 
initiating chronic 
hemodialysis, 83% 
had started within 
180 d, and 93% 
had started within 
365 d 
Tentori, 2006 Records 
from major 
non-profit 
dialysis 
provider 
Incident 
HD 
patients 
Retrospective 
cohort 
IV 
vitamin 
D use 
All-cause 
mortality 
Varied: 30 
days & 90 
days 
- 
Tentori, 2009 Dialysis 
Outcomes 
and Practice 
Patterns 
Study 
(DOPPS)  
All HD 
patients 
Retrospective 
cohort 
IV/oral 
vitamin 
D use 
All-cause 
mortality 
Vitamin D 
prescription 
(yes/no) 
measured as a 
time-varying 
varying in the 
last week of 
the prior 4-
- 
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Appendix 18. Description of length of intravenous vitamin D exposure measurement period in observational studies of 
hemodialysis patients 
First Author, 
Year 
Data 
Source 
Patient 
population 
Study design Main 
Predictor 
Outcome Length of 
vitamin D 
exposure 
measurement 
period 
Relevant notes? 
month interval 
Wolf, 2008 Accelerated 
Mortality on 
Renal 
Replace-
ment 
(ArMORR)  
Incident 
HD 
patients 
Retrospective 
cohort 
Race & 
ethnicity
/IV 
vitamin 
D use  
All-cause 
mortality 
IV vitamin D 
analyzed as a 
time-
dependent 
covariate and 
calculated 
from the 
average 
dosage over 
each calendar 
quarter 
standardized 
to the total 
number of 
calendar 
quarters of 
follow-up. All 
other 
covariates 
collected at 
dialysis 
Among all 
patients, 77% were 
treated with 
vitamin D 
beginning at a 
median of day 16 
(interquartile range 
9 to 43 d) after 
initiating dialysis 
and continuing for 
a median duration 
of 270 d 
(interquartile range 
126 to 348 d), or 
77% of the total 
follow-up period.  
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Appendix 18. Description of length of intravenous vitamin D exposure measurement period in observational studies of 
hemodialysis patients 
First Author, 
Year 
Data 
Source 
Patient 
population 
Study design Main 
Predictor 
Outcome Length of 
vitamin D 
exposure 
measurement 
period 
Relevant notes? 
initiation 
Zhang, 2012 U.S. Renal 
Data System 
(USRDS)  
Incident 
HD 
patients 
Retrospective 
cohort 
IV 
epoetin, 
IV iron, 
and IV 
vitamin 
D use 
All-cause 
mortality 
90 days - 
Abbreviations: HD, hemodialysis; IV intravenous 
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Appendix 19.  Sensitivity analysis where baseline period changed to 30 days: 
Demographic and clinical characteristics of cohort by whether patient is in a facility in 
the lowest or highest quartile of case-mix adjusted proportion of vitamin D users  
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
N         42,474       42,476 - 
Age (years)    
   18-44       9.6   9.5              0.3 
   45-64     26.7 27.2              1.1 
   65-74     31.4 31.5              0.2 
   >= 75     32.2 31.8              0.9 
Race    
   White    67.2 62.5              9.9 
   Black    27.7 33.0            11.5 
   Other     5.1   4.6              2.3 
Female   47.2 47.7              1.0 
Medicaid eligible   35.6 40.7            10.5 
Comorbidities    
   Acute MI    1.3   1.3              0.0 
   Anemia    0.6   0.5              1.4 
   Autoimmune disorder  59.0 68.2 19.2** 
   Cancer   1.3   1.2              0.9 
   COPD/Asthma   0.4   0.4              0.0 
   Diabetes mellitus   5.0   4.8 0.9 
   Gastrointestinal bleed   8.4   7.5 3.3 
   Heart-related procedure  36.7 36.3 0.8 
   HIV/AIDS   1.6   1.7 0.8 
   Hypertension 41.4 38.9 5.1 
   Hyperthyroidism   0.3   0.4 1.7 
   Ischemic heart disease 15.7 15.1 1.7 
   Liver disease   1.5   1.1 3.5 
   Neurologic disorder   2.9   2.6 1.8 
   Obese   1.2   1.2 0.0 
   Other heart disorder  25.4 24.2 2.8 
   Peptic ulcer disease   1.0   1.1 1.0 
   PVD   9.1   8.8 1.1 
   Pneumonia   3.1   2.9 1.2 
   Psychiatric disorder   1.4   1.4 0.0 
   PCD   0.9   0.9 0.0 
   Stroke   5.0   4.9 0.5 
   Substance use disorder   1.5   1.5 0.0 
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Cause of ESRD    
   Diabetes mellitus  47.7 47.9              0.4 
   Hypertension  29.9 31.1              2.6 
   Glomerulonephritis   7.7               7.7              0.0 
   Other 14.7 13.3              4.0 
Parathyroidectomy   0.0   0.0 . 
For-profit 63.0  87.5 59.2** 
Free-standing 79.6  90.0 29.3** 
Chain    
   Chain #1 20.7 27.0 14.8** 
   Chain #2   6.2 19.4 40.3** 
   Chain #3   5.5 22.9 51.5** 
   Other chain 67.6 30.7 79.4** 
Facility size    
   Small   9.1   5.0 16.1** 
   Medium 43.5 47.5              8.0 
   Large 47.4 47.5              0.2 
Region    
   Midwest 27.7 20.1 17.9** 
   Northeast 15.8 17.9              5.6 
   South 44.7 42.3 4.8 
   West 11.9 19.7 21.5** 
Use of personal 
assistance aids 
  1.8   1.9              0.7 
Fistula   6.8   7.0 0.8 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized 
difference; COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; 
HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;  PVD,  
peripheral vascular disease; PCD, pulmonary circulation disorder 
** An absolute standardized difference > 10  indicates significant imbalance of characteristic 
when comparing vitamin D users to non-vitamin D users 
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Appendix 20.  Sensitivity analysis where baseline period changed to 90 days: 
Demographic and clinical characteristics of cohort by whether patient is in a facility in 
the lowest or highest quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
N       39,387       39,395  
Age (years)    
   18-44                9.9   9.9              0.0 
   45-64 27.8 28.5              1.6 
   65-74 31.3 31.4              0.2 
   >= 75 31.0 30.3              1.5 
Race    
   White 65.7 60.5 10.8** 
   Black 29.4 35.2 12.4* 
   Other  4.9   4.2              3.4 
Female 47.3 47.9              1.2 
Medicaid eligible 38.0 43.4 11.0** 
Comorbidities    
   Acute MI   2.9   2.8 0.6 
   Anemia   0.9   0.8 1.1 
   Autoimmune disorder 72.7 80.0 17.2** 
   Cancer   2.3   2.3              0.0 
   COPD/Asthma   1.2   1.2              0.0 
   Diabetes mellitus   8.7   8.3              1.4 
   Gastrointestinal bleed 14.6 13.3              3.8 
   Heart-related procedure 51.6 51.5 0.2 
   HIV/AIDS   3.4   3.5 0.5 
   Hypertension  66.2  65.3 1.9 
   Hyperthyroidism   0.5   0.7 2.6 
   Ischemic heart disease 28.7  28.1 1.3 
   Liver disease   2.3   2.2 0.7 
   Neurologic disorder   5.5   5.3 0.9 
   Obese   2.6   2.6 0.0 
   Other heart disorder 41.1 40.3 1.6 
   Peptic ulcer disease   2.5   2.3 1.3 
   PVD 18.0 17.3 1.8 
   Pneumonia   6.5   6.2 1.2 
   Psychiatric disorder   3.0   2.9 0.6 
   PCD   1.9   1.9 0.0 
   Stroke   9.1   8.9 0.7 
   Substance use disorder   3.9   3.6 1.6 
Cause of ESRD    
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Appendix 20.  Sensitivity analysis where baseline period changed to 90 days: 
Demographic and clinical characteristics of cohort by whether patient is in a facility in 
the lowest or highest quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
   Diabetes mellitus 48.3 48.2              0.2 
   Hypertension 30.0 31.2              2.6 
   Glomerulonephritis   7.7   7.6              0.4 
   Other 14.0 13.0              2.9 
Parathyroidectomy   0.0   0.0 . 
For-profit 63.6 87.2 57.0** 
Free-standing 80.3 89.7 26.6** 
Chain    
   Chain #1 20.1 25.8 13.6** 
   Chain #2   6.5 19.2 38.7** 
   Chain #3   5.8 21.1 46.0** 
   Other chain 67.6 33.9 71.6** 
Facility size    
   Small   9.6   5.5 15.6** 
   Medium 43.7 44.4              1.4 
   Large 46.7 50.1              6.8 
Region    
   Midwest 27.7 19.5 19.4** 
   Northeast 15.8 18.7              7.7 
   South 46.0 43.4              5.2 
   West 10.5 18.4 22.6** 
Use of personal 
assistance aids 
  3.9  3.8              0.5 
Fistula 16.4 16.8              1.1 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized 
difference; COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; 
HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;  PVD,  
peripheral vascular disease; PCD, pulmonary circulation disorder 
** An absolute standardized difference > 10 indicates significant imbalance of characteristic 
when comparing vitamin D users to non-vitamin D users 
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Appendix 21.  Sensitivity analysis where baseline period changed to 365 days: 
Demographic and clinical characteristics of cohort by whether patient is in a facility in 
the lowest or highest quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
N       24,846       24,823  
Age (years)    
   18-44 10.9 11.2              1.0 
   45-64 30.3 31.9              3.5 
   65-74 31.3 31.0              0.6 
   >= 75 27.5 26.0              3.4 
Race    
   White 62.9 58.6              8.8 
   Black 31.7 36.7 10.6** 
   Other   5.5   4.7              3.6 
Female 46.9 47.5              1.2 
Medicaid eligible 42.6 49.9 14.7** 
Comorbidities    
   Acute MI   7.1   7.1              0.0 
   Anemia   1.3   1.3              0.0 
   Autoimmune disorder 87.6 92.2 15.3** 
   Cancer   4.6   4.9              1.4 
   COPD/Asthma   4.2   4.3 0.5 
   Diabetes mellitus 14.5 14.2 0.9 
   Gastrointestinal bleed 25.7 24.5 2.8 
   Heart-related procedure 63.9 65.3 2.9 
   HIV/AIDS   8.8   9.3 1.7 
   Hypertension 89.7 90.3 2.0 
   Hyperthyroidism   1.7   1.6 0.8 
   Ischemic heart disease 48.1 48.1 0.0 
   Liver disease   4.4   4.9 2.4 
   Neurologic disorder 10.8 10.8 0.0 
   Obese   6.2   6.7 2.0 
   Other heart disorder 64.3 64.0 0.6 
   Peptic ulcer disease   6.1 6.6 2.1 
   PVD 34.4 34.8 0.8 
   Pneumonia 15.6 15.7 0.3 
   Psychiatric disorder   6.5   6.1 1.6 
   PCD   5.0   4.8 0.9 
   Stroke 16.9 17.4 1.3 
   Substance use disorder   9.6   9.0 2.1 
Cause of ESRD    
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Appendix 21.  Sensitivity analysis where baseline period changed to 365 days: 
Demographic and clinical characteristics of cohort by whether patient is in a facility in 
the lowest or highest quartile of case-mix adjusted proportion of vitamin D users 
Characteristics Lower Quartile (%) Upper Quartile (%) Absolute 
standardized 
difference 
   Diabetes mellitus 49.0  48.7              0.6 
   Hypertension 28.9  31.2              5.0 
   Glomerulonephritis   8.6   8.2              1.4 
   Other 13.5 11.9              4.8 
Parathyroidectomy   0.1   0.2              2.6 
For-profit 64.7 84.8 47.6** 
Free-standing 81.8 88.3 18.3** 
Chain    
   Chain #1 21.3 25.8 10.6** 
   Chain #2   8.5 15.3 21.1** 
   Chain #3   6.8 21.0 41.9** 
   Other chain 63.5 37.9 53.0** 
Facility size    
   Small 10.3   8.5              6.2 
   Medium 44.4 39.8              9.3 
   Large 45.3 51.7 12.8** 
Region    
   Midwest 26.2 18.0 19.9** 
   Northeast 15.1 20.5 14.2** 
   South 45.6 41.9              7.5 
   West 13.1 19.6 17.6** 
Use of personal 
assistance aids 
10.0 10.6              2.0 
Fistula 32.7 33.7 2.1 
Abbreviations: Acute MI, acute myocardial infarction; ASD, absolute standardized 
difference; COPD, chronic obstructive pulmonary disorder; ESRD, end-stage renal disease; 
HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;  PVD,  
peripheral vascular disease; PCD, pulmonary circulation disorder 
** An absolute standardized difference > 10 indicates significant imbalance of characteristic 
when comparing vitamin D users to non-vitamin D users 
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Appendix 22. Sensitivity analysis: Cox models of the association between measures of 
vitamin D exposure and fracture risk after adjusting for relevant covariates- 
Varying length of baseline to 30 days, 90 days, and 365 days 
Fracture Type Proportion of Vitamin D 
Users
a
 
Average Vitamin D Dose 
per Patient
b
 
 HR (95% CI)
c
 HR (95% CI) 
Length of baseline=30 days 
Any 0.88 (0.72-1.09) 1.10 (0.87-1.38) 
Pelvis/hip 0.88 (0.66-1.16) 1.36 (1.02-1.80)** 
Vertebral 0.82 (0.57-1.18) 0.02 (0.00-17.99) 
Other
e
 0.89 (0.61-1.31) 0.61 (0.26-1.44) 
Length of baseline=90 days 
Any 0.99 (0.80-1.23) 1.02 (0.97-1.07) 
Pelvis/hip 1.04 (0.78-1.39) 1.14 (1.08-1.19)** 
Vertebral 0.91 (0.62-1.36) 0.58 (0.17-1.95) 
Other 1.03 (0.70-1.52) 0.77 (0.51-1.16) 
Length of baseline=365 days 
Any 0.99 (0.72-1.34) 1.01 (0.94-1.09) 
Pelvis/hip 0.75 (0.49-1.15) 0.96 (0.84-1.09) 
Vertebral 0.70 (0.38-1.28) 1.01 (0.87-1.16) 
Other 1.92 (1.09-3.36)** 1.05 (0.97-1.14) 
** 
p<0.05 
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease 
b
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease 
c
Hazard Ratio (95% CI) 
d
Cox models adjusted for age, sex, race, Medicaid eligibility, comorbidities, primary cause of ESRD, prior 
history of parathyroidectomy, facility characteristics, use of personal assistance aids, and the presence of a 
fistula. 
e
Other fracture comprised of lower leg, shoulder/upper arm, ribs/sternum, femur, and forearm/wrist fractures 
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Appendix 23. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and vertebral fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
1.03 (0.65- 1.63) 0.911 1.06 (0.64- 1.74) 0.827 
Age (years)[Reference: 65-74]     
   18-44   0.35 (0.25- 0.50) <0.01 
   45-64   0.55 (0.46- 0.66) <0.01 
   >= 75   1.45 (1.28- 1.65) <0.01 
Female   1.89 (1.68- 2.13) <0.01 
Race [Reference: White]     
   Black   0.35 (0.29- 0.42) <0.01 
   Other   0.83 (0.63- 1.09) 0.177 
Comorbidities     
Medicaid eligible   0.86 (0.75- 0.98) 0.026 
   Acute MI   1.10 (0.86- 1.41) 0.431 
   Anemia   1.08 (0.92- 1.26) 0.376 
   Autoimmune disorder   1.67 (1.32- 2.12) <0.01 
   Cancer   1.44 (1.24- 1.67) <0.01 
   COPD/Asthma   1.15 (0.99- 1.32) 0.066 
   Diabetes mellitus   1.05 (0.91- 1.22) 0.492 
   Gastrointestinal bleed   1.33 (1.07- 1.65) 0.011 
   Heart-related procedure   1.03 (0.72- 1.45) 0.886 
   HIV/AIDS   1.57 (0.70- 3.53) 0.271 
   Hypertension   1.01 (0.87- 1.18) 0.851 
   Hyperthyroidism   0.82 (0.48- 1.40) 0.467 
   Ischemic heart disease   1.05 (0.93- 1.20) 0.437 
   Liver disease   1.83 (1.39- 2.41) <0.01 
   Neurologic disorder   0.97 (0.78- 1.21) 0.816 
   Obese   0.75 (0.54- 1.05) 0.094 
   Other heart disorder   1.43 (1.25- 1.64) <0.01 
   Peptic ulcer disease   1.12 (0.86- 1.45) 0.406 
   Peripheral vascular disease   0.88 (0.77- 1.00) 0.053 
   Pneumonia   1.16 (0.97- 1.39) 0.093 
   Psychiatric disorder   0.94 (0.70- 1.25) 0.655 
   Pulmonary circulation disorder   1.18 (0.89- 1.56) 0.241 
   Stroke   0.93 (0.79- 1.10) 0.414 
   Substance use disorder   1.10 (0.84- 1.44) 0.497 
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Appendix 23. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and vertebral fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   1.09 (0.92- 1.28) 0.311 
   Glomerulonephritis   0.99 (0.77- 1.28) 0.959 
   Other   1.27 (1.05- 1.53) 0.012 
Parathyroidectomy   1.02 (0.15- 6.98) 0.987 
For-profit   1.08 (0.87- 1.34) 0.490 
Free-standing   0.97 (0.76- 1.23) 0.802 
Chain [Reference: Chain #1]     
   Chain #2   0.77 (0.63- 0.93) <0.01 
   Chain #3   0.81 (0.66- 0.99) 0.038 
   Other chain   0.88 (0.75- 1.02) 0.096 
Facility size [Reference: Small]     
   Medium   1.05 (0.85- 1.29) 0.655 
   Large   0.96 (0.78- 1.19) 0.720 
Region [Reference: Northeast]     
   Midwest   1.04 (0.88- 1.24) 0.622 
   South   1.06 (0.89- 1.26) 0.503 
   West   1.21 (1.00- 1.46) 0.055 
Use of personal assistance aids   1.29 (1.05- 1.57) 0.013 
Fistula   1.17 (1.03- 1.33) 0.015 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 24. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a 
and vertebral fractures 
 Model 1 Model 2 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted average vitamin D 
dose/patient 
0.70 (0.37- 1.34) 0.285 0.76 (0.41- 1.40) 0.378 
Age (years)[Reference: 65-74]     
   18-44   0.35 (0.25- 0.50) <0.01 
   45-64   0.55 (0.46- 0.66) <0.01 
   >= 75   1.45 (1.29- 1.65) <0.01 
Female   1.89 (1.68- 2.13) <0.01 
Race [Reference: White]     
   Black   0.35 (0.29- 0.42) <0.01 
   Other   0.83 (0.63- 1.08) 0.169 
Comorbidities     
Medicaid eligible   0.86 (0.75- 0.98) 0.026 
   Acute MI   1.10 (0.86- 1.40) 0.435 
   Anemia   1.08 (0.92- 1.27) 0.362 
   Autoimmune disorder   1.67 (1.32- 2.12) <0.01 
   Cancer   1.44 (1.24- 1.67) <0.01 
   COPD/Asthma   1.14 (0.99- 1.32) 0.067 
   Diabetes mellitus   1.05 (0.91- 1.22) 0.490 
   Gastrointestinal bleed   1.33 (1.07- 1.65) 0.011 
   Heart-related procedure   1.03 (0.72- 1.46) 0.882 
   HIV/AIDS   1.57 (0.70- 3.53) 0.271 
   Hypertension   1.02 (0.87- 1.18) 0.845 
   Hyperthyroidism   0.82 (0.48- 1.41) 0.471 
   Ischemic heart disease   1.05 (0.92- 1.20) 0.443 
   Liver disease   1.83 (1.39- 2.41) <0.01 
   Neurologic disorder   0.97 (0.78- 1.21) 0.814 
   Obese   0.75 (0.54- 1.05) 0.095 
   Other heart disorder   1.43 (1.25- 1.64) <0.01 
   Peptic ulcer disease   1.12 (0.86- 1.45) 0.406 
   Peripheral vascular disease   0.88 (0.77- 1.00) 0.054 
   Pneumonia   1.16 (0.97- 1.39) 0.093 
   Psychiatric disorder   0.94 (0.70- 1.25) 0.650 
   Pulmonary circulation disorder   1.18 (0.89- 1.56) 0.241 
   Stroke   0.93 (0.79- 1.10) 0.415 
   Substance use disorder   1.10 (0.84- 1.44) 0.500 
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Appendix 24. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a 
and vertebral fractures 
 Model 1 Model 2 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   1.09 (0.93- 1.28) 0.306 
   Glomerulonephritis   0.99 (0.77- 1.28) 0.965 
   Other   1.27 (1.06- 1.53) 0.011 
Parathyroidectomy   1.02 (0.15- 7.04) 0.981 
For-profit   1.09 (0.88- 1.35) 0.420 
Free-standing   0.97 (0.76- 1.23) 0.780 
Chain [Reference: Chain #1]     
   Chain #2   0.77 (0.63- 0.94) 0.010 
   Chain #3   0.82 (0.67- 1.00) 0.048 
   Other chain   0.87 (0.75- 1.02) 0.082 
Facility size [Reference: Small]     
   Medium   1.05 (0.85- 1.29) 0.656 
   Large   0.96 (0.78- 1.19) 0.724 
Region [Reference: Northeast]     
   Midwest   1.04 (0.87- 1.23) 0.664 
   South   1.05 (0.89- 1.25) 0.546 
   West   1.21 (1.00- 1.46) 0.056 
Use of personal assistance aids   1.29 (1.05- 1.57) 0.013 
Fistula   1.17 (1.03- 1.33) 0.015 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 25. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and pelvis/hip fractures 
 Crude Multivariable 
Covariates HR (95% CI) p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
0.96 (0.70- 1.33) 0.809 1.05 (0.74- 1.48) 0.789 
Age (years)[Reference: 65-74]     
   18-44   0.23 (0.16- 0.31) <0.01 
   45-64   0.51 (0.44- 0.57) <0.01 
   >= 75   1.85 (1.69- 2.02) <0.01 
Female   1.80 (1.66- 1.95) <0.01 
Race [Reference: White]     
   Black   0.38 (0.34- 0.43) <0.01 
   Other   0.70 (0.56- 0.87) <0.01 
Comorbidities     
Medicaid eligible   0.92 (0.83- 1.01) 0.073 
   Acute MI   1.02 (0.85- 1.22) 0.872 
   Anemia   1.01 (0.91- 1.13) 0.813 
   Autoimmune disorder   1.11 (0.90- 1.36) 0.332 
   Cancer   1.10 (0.99- 1.22) 0.091 
   COPD/Asthma   1.05 (0.96- 1.16) 0.303 
   Diabetes mellitus   1.13 (1.02- 1.25) 0.023 
   Gastrointestinal bleed   1.08 (0.92- 1.27) 0.323 
   Heart-related procedure   0.85 (0.65- 1.11) 0.241 
   HIV/AIDS   1.56 (0.84- 2.91) 0.163 
   Hypertension   0.95 (0.85- 1.06) 0.371 
   Hyperthyroidism   1.19 (0.85- 1.66) 0.304 
   Ischemic heart disease   1.11 (1.01- 1.21) 0.022 
   Liver disease   1.36 (1.09- 1.71) <0.01 
   Neurologic disorder   1.10 (0.95- 1.27) 0.199 
   Obese   0.50 (0.38- 0.67) <0.01 
   Other heart disorder   1.17 (1.07- 1.27) <0.01 
   Peptic ulcer disease   1.19 (0.99- 1.43) 0.057 
   Peripheral vascular disease   1.04 (0.95- 1.14) 0.424 
   Pneumonia   1.00 (0.88- 1.14) 0.979 
   Psychiatric disorder   1.26 (1.06- 1.49) <0.01 
   Pulmonary circulation disorder   1.03 (0.84- 1.28) 0.751 
   Stroke   1.18 (1.06- 1.32) <0.01 
   Substance use disorder   1.40 (1.17- 1.68) <0.01 
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Appendix 25. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and pelvis/hip fractures 
 Crude Multivariable 
Covariates HR (95% CI) p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   1.05 (0.94- 1.16) 0.411 
   Glomerulonephritis   0.91 (0.76- 1.08) 0.284 
   Other   1.15 (1.01- 1.32) 0.036 
Parathyroidectomy   2.26 (0.84- 6.08) 0.107 
For-profit   1.00 (0.88- 1.14) 0.984 
Free-standing   1.11 (0.94- 1.30) 0.209 
Chain [Reference: Chain #1]     
   Chain #2   0.88 (0.77- 1.01) 0.067 
   Chain #3   0.94 (0.82- 1.08) 0.378 
   Other chain   0.97 (0.87- 1.08) 0.563 
Facility size [Reference: Small]     
   Medium   0.95 (0.83- 1.09) 0.461 
   Large   0.90 (0.79- 1.03) 0.130 
Region [Reference: Northeast]     
   Midwest   1.03 (0.91- 1.16) 0.685 
   South   1.08 (0.96- 1.21) 0.208 
   West   1.08 (0.94- 1.24) 0.292 
Use of personal assistance aids   1.25 (1.09- 1.44) <0.01 
Fistula   1.12 (1.02- 1.23) 0.014 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 26. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a 
and pelvis/hip fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted average vitamin D 
dose/patient 
1.04 (0.91- 1.19) 0.598 1.05 (0.94- 1.16) 0.386 
Age (years)[Reference: 65-74]     
   18-44   0.23 (0.16- 0.31) <0.01 
   45-64   0.51 (0.44- 0.57) <0.01 
   >= 75   1.85 (1.69- 2.02) <0.01 
Female   1.80 (1.66- 1.95) <0.01 
Race [Reference: White]     
   Black   0.38 (0.34- 0.43) <0.01 
   Other   0.70 (0.56- 0.87) <0.01 
Comorbidities     
Medicaid eligible   0.92 (0.83- 1.01) 0.073 
   Acute MI   1.02 (0.85- 1.22) 0.871 
   Anemia   1.01 (0.91- 1.13) 0.807 
   Autoimmune disorder   1.11 (0.90- 1.36) 0.333 
   Cancer   1.10 (0.99- 1.22) 0.091 
   COPD/Asthma   1.05 (0.96- 1.16) 0.303 
   Diabetes mellitus   1.13 (1.02- 1.25) 0.023 
   Gastrointestinal bleed   1.08 (0.92- 1.27) 0.321 
   Heart-related procedure   0.85 (0.65- 1.11) 0.241 
   HIV/AIDS   1.56 (0.84- 2.91) 0.163 
   Hypertension   0.95 (0.85- 1.06) 0.369 
   Hyperthyroidism   1.19 (0.85- 1.66) 0.302 
   Ischemic heart disease   1.11 (1.01- 1.21) 0.022 
   Liver disease   1.36 (1.09- 1.71) <0.01 
   Neurologic disorder   1.10 (0.95- 1.28) 0.199 
   Obese   0.50 (0.38- 0.67) <0.01 
   Other heart disorder   1.16 (1.07- 1.27) <0.01 
   Peptic ulcer disease   1.19 (0.99- 1.43) 0.058 
   Peripheral vascular disease   1.04 (0.95- 1.14) 0.425 
   Pneumonia   1.00 (0.88- 1.14) 0.977 
   Psychiatric disorder   1.26 (1.06- 1.49) <0.01 
   Pulmonary circulation disorder   1.03 (0.84- 1.28) 0.750 
   Stroke   1.18 (1.06- 1.32) <0.01 
   Substance use disorder   1.40 (1.17- 1.68) <0.01 
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Appendix 26. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a 
and pelvis/hip fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   1.04 (0.94- 1.16) 0.413 
   Glomerulonephritis   0.91 (0.76- 1.08) 0.282 
   Other   1.15 (1.01- 1.32) 0.036 
Parathyroidectomy   2.26 (0.84- 6.09) 0.107 
For-profit   1.00 (0.88- 1.14) 0.987 
Free-standing   1.11 (0.94- 1.30) 0.219 
Chain [Reference: Chain #1]     
   Chain #2   0.88 (0.77- 1.01) 0.066 
   Chain #3   0.94 (0.82- 1.08) 0.375 
   Other chain   0.97 (0.87- 1.08) 0.538 
Facility size [Reference: Small]     
   Medium   0.95 (0.83- 1.09) 0.460 
   Large   0.90 (0.79- 1.03) 0.131 
Region [Reference: Northeast]     
   Midwest   1.03 (0.91- 1.16) 0.691 
   South   1.08 (0.96- 1.21) 0.213 
   West   1.08 (0.94- 1.24) 0.291 
Use of personal assistance aids   1.25 (1.09- 1.44) <0.01 
Fistula   1.12 (1.02- 1.23) 0.014 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 27. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and other  fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
1.39 (0.89- 2.16) 0.143 1.33 (0.83- 2.13) 0.235 
Age (years)[Reference: 65-74]     
   18-44   0.71 (0.56- 0.90) <0.01 
   45-64   0.91 (0.80- 1.04) 0.174 
   >= 75   1.27 (1.13- 1.43) <0.01 
Female   2.12 (1.91- 2.36) <0.01 
Race [Reference: White]     
   Black   0.44 (0.39- 0.50) <0.01 
   Other   0.61 (0.47- 0.80) <0.01 
Comorbidities     
Medicaid eligible   1.07 (0.95- 1.19) 0.255 
   Acute MI   0.81 (0.64- 1.04) 0.103 
   Anemia   1.07 (0.93- 1.23) 0.368 
   Autoimmune disorder   1.31 (1.04- 1.65) 0.024 
   Cancer   1.11 (0.96- 1.29) 0.162 
   COPD/Asthma   1.05 (0.93- 1.19) 0.442 
   Diabetes mellitus   1.09 (0.95- 1.25) 0.201 
   Gastrointestinal bleed   1.25 (1.03- 1.52) 0.027 
   Heart-related procedure   0.96 (0.69- 1.33) 0.811 
   HIV/AIDS   0.99 (0.49- 1.99) 0.967 
   Hypertension   1.12 (0.97- 1.30) 0.126 
   Hyperthyroidism   1.04 (0.67- 1.61) 0.867 
   Ischemic heart disease   1.02 (0.91- 1.13) 0.787 
   Liver disease   1.49 (1.17- 1.89) <0.01 
   Neurologic disorder   1.24 (1.04- 1.47) 0.014 
   Obese   1.18 (0.95- 1.47) 0.124 
   Other heart disorder   1.31 (1.17- 1.46) <0.01 
   Peptic ulcer disease   0.95 (0.74- 1.22) 0.703 
   Peripheral vascular disease   0.94 (0.84- 1.06) 0.302 
   Pneumonia   1.03 (0.88- 1.21) 0.732 
   Psychiatric disorder   1.11 (0.89- 1.38) 0.352 
   Pulmonary circulation disorder   1.06 (0.82- 1.37) 0.651 
   Stroke   1.07 (0.92- 1.24) 0.392 
   Substance use disorder   1.23 (1.00- 1.53) 0.054 
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Appendix 27. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and other  fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   0.74 (0.65- 0.85) <0.01 
   Glomerulonephritis   0.58 (0.46- 0.74) <0.01 
   Other   0.86 (0.72- 1.02) 0.080 
Parathyroidectomy   0.00 (0.00- 0.00) <0.01 
For-profit   1.08 (0.91- 1.29) 0.394 
Free-standing   1.08 (0.87- 1.33) 0.482 
Chain [Reference: Chain #1]     
   Chain #2   0.87 (0.74- 1.03) 0.096 
   Chain #3   1.00 (0.85- 1.17) 0.987 
   Other chain   0.97 (0.85- 1.10) 0.610 
Facility size [Reference: Small]     
   Medium   1.02 (0.86- 1.21) 0.840 
   Large   0.89 (0.75- 1.06) 0.206 
Region [Reference: Northeast]     
   Midwest   1.06 (0.91- 1.24) 0.433 
   South   0.87 (0.75- 1.01) 0.070 
   West   0.96 (0.80- 1.14) 0.605 
Use of personal assistance aids   1.32 (1.11- 1.56) <0.01 
Fistula   0.97 (0.87- 1.09) 0.623 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 28. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a
 and other fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
0.97 (0.82- 1.15) 0.736 0.95 (0.79- 1.13) 0.563 
Age (years)[Reference: 65-74]     
   18-44   0.71 (0.56- 0.89) <0.01 
   45-64   0.91 (0.80- 1.04) 0.171 
   >= 75   1.27 (1.13- 1.43) <0.01 
Female   2.12 (1.91- 2.36) <0.01 
Race [Reference: White]     
   Black   0.44 (0.39- 0.51) <0.01 
   Other   0.61 (0.47- 0.79) <0.01 
Comorbidities     
Medicaid eligible   1.07 (0.96- 1.19) 0.244 
   Acute MI   0.81 (0.64- 1.04) 0.101 
   Anemia   1.07 (0.93- 1.23) 0.339 
   Autoimmune disorder   1.31 (1.04- 1.65) 0.023 
   Cancer   1.11 (0.96- 1.29) 0.162 
   COPD/Asthma   1.05 (0.93- 1.19) 0.445 
   Diabetes mellitus   1.09 (0.95- 1.25) 0.201 
   Gastrointestinal bleed   1.25 (1.03- 1.52) 0.027 
   Heart-related procedure   0.96 (0.70- 1.33) 0.816 
   HIV/AIDS   0.99 (0.49- 1.99) 0.969 
   Hypertension   1.12 (0.97- 1.30) 0.124 
   Hyperthyroidism   1.04 (0.67- 1.61) 0.853 
   Ischemic heart disease   1.01 (0.91- 1.13) 0.792 
   Liver disease   1.49 (1.17- 1.90) <0.01 
   Neurologic disorder   1.24 (1.04- 1.47) 0.014 
   Obese   1.19 (0.95- 1.47) 0.123 
   Other heart disorder   1.31 (1.17- 1.46) <0.01 
   Peptic ulcer disease   0.95 (0.74- 1.22) 0.707 
   Peripheral vascular disease   0.94 (0.84- 1.06) 0.302 
   Pneumonia   1.03 (0.88- 1.21) 0.728 
   Psychiatric disorder   1.11 (0.89- 1.38) 0.358 
   Pulmonary circulation disorder   1.06 (0.82- 1.37) 0.654 
   Stroke   1.07 (0.92- 1.24) 0.391 
   Substance use disorder   1.23 (0.99- 1.53) 0.056 
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Appendix 28. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a
 and other fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   0.74 (0.65- 0.85) <0.01 
   Glomerulonephritis   0.58 (0.46- 0.74) <0.01 
   Other   0.86 (0.72- 1.02) 0.081 
Parathyroidectomy   0.00 (0.00- 0.00) <0.01 
For-profit   1.11 (0.93- 1.32) 0.251 
Free-standing   1.06 (0.86- 1.31) 0.564 
Chain [Reference: Chain #1]     
   Chain #2   0.87 (0.74- 1.03) 0.109 
   Chain #3   1.01 (0.86- 1.19) 0.883 
   Other chain   0.96 (0.84- 1.09) 0.486 
Facility size [Reference: Small]     
   Medium   1.02 (0.86- 1.21) 0.824 
   Large   0.90 (0.76- 1.07) 0.223 
Region [Reference: Northeast]     
   Midwest   1.06 (0.90- 1.23) 0.492 
   South   0.86 (0.75- 1.00) 0.051 
   West   0.96 (0.81- 1.14) 0.621 
Use of personal assistance aids   1.32 (1.11- 1.56) <0.01 
Fistula   0.97 (0.87- 1.09) 0.626 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal disease
  
b
Hazard Ratio (95% confidence interval) 
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Appendix 29. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and any  fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
1.05 (0.82- 1.34) 0.722 1.10 (0.86- 1.42) 0.447 
Age (years)[Reference: 65-74]     
   18-44   0.40 (0.34- 0.48) <0.01 
   45-64   0.65 (0.59- 0.71) <0.01 
   >= 75   1.56 (1.47- 1.67) <0.01 
Female   1.88 (1.77- 1.99) <0.01 
Race [Reference: White]     
   Black   0.40 (0.37- 0.44) <0.01 
   Other   0.70 (0.61- 0.82) <0.01 
Comorbidities     
Medicaid eligible   0.95 (0.89- 1.01) 0.126 
   Acute MI   0.95 (0.83- 1.09) 0.474 
   Anemia   1.05 (0.96- 1.13) 0.288 
   Autoimmune disorder   1.29 (1.12- 1.47) <0.01 
   Cancer   1.21 (1.12- 1.31) <0.01 
   COPD/Asthma   1.08 (1.01- 1.16) 0.027 
   Diabetes mellitus   1.10 (1.02- 1.19) 0.011 
   Gastrointestinal bleed   1.20 (1.07- 1.35) <0.01 
   Heart-related procedure   0.91 (0.75- 1.09) 0.301 
   HIV/AIDS   1.25 (0.81- 1.94) 0.313 
   Hypertension   1.00 (0.93- 1.08) 0.984 
   Hyperthyroidism   1.03 (0.79- 1.33) 0.837 
   Ischemic heart disease   1.08 (1.01- 1.15) 0.021 
   Liver disease   1.53 (1.32- 1.78) <0.01 
   Neurologic disorder   1.12 (1.01- 1.24) 0.029 
   Obese   0.83 (0.71- 0.97) 0.018 
   Other heart disorder   1.26 (1.18- 1.34) <0.01 
   Peptic ulcer disease   1.10 (0.96- 1.25) 0.175 
   Peripheral vascular disease   0.98 (0.92- 1.05) 0.552 
   Pneumonia   1.05 (0.95- 1.15) 0.326 
   Psychiatric disorder   1.16 (1.02- 1.31) 0.022 
   Pulmonary circulation disorder   1.07 (0.92- 1.23) 0.380 
   Stroke   1.09 (1.00- 1.18) 0.050 
   Substance use disorder   1.26 (1.11- 1.42) <0.01 
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Appendix 29. Cox models of the association between the case-mix adjusted proportion of 
vitamin D users
a 
and any  fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   0.97 (0.90- 1.05) 0.441 
   Glomerulonephritis   0.81 (0.71- 0.93) <0.01 
   Other   1.08 (0.98- 1.19) 0.118 
Parathyroidectomy   1.03 (0.38- 2.74) 0.958 
For-profit   1.02 (0.92- 1.12) 0.751 
Free-standing   1.09 (0.97- 1.23) 0.155 
Chain [Reference: Chain #1]     
   Chain #2   0.87 (0.79- 0.95) <0.01 
   Chain #3   0.94 (0.86- 1.04) 0.214 
   Other chain   0.96 (0.89- 1.04) 0.286 
Facility size [Reference: Small]     
   Medium   1.00 (0.91- 1.10) 0.958 
   Large   0.92 (0.83- 1.01) 0.094 
Region [Reference: Northeast]     
   Midwest   1.05 (0.96- 1.15) 0.267 
   South   1.01 (0.93- 1.10) 0.752 
   West   1.07 (0.96- 1.18) 0.215 
Use of personal assistance aids   1.26 (1.14- 1.40) <0.01 
Fistula   1.09 (1.02- 1.16) 0.012 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects logistic regression adjusting for age, sex, race and cause of renal 
disease
  
b
Hazard Ratio (95% confidence interval) 
 
 
 
 
 212 
 
Appendix 30. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a
 and any fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Case-mix adjusted proportion of vitamin D 
users 
0.98 (0.87- 1.11) 0.767 0.99 (0.90- 1.09) 0.831 
Age (years)[Reference: 65-74]     
   18-44   0.40 (0.34- 0.48) <0.01 
   45-64   0.65 (0.59- 0.71) <0.01 
   >= 75   1.57 (1.47- 1.67) <0.01 
Female   1.88 (1.77- 1.99) <0.01 
Race [Reference: White]     
   Black   0.40 (0.37- 0.44) <0.01 
   Other   0.70 (0.61- 0.82) <0.01 
Comorbidities     
Medicaid eligible   0.95 (0.89- 1.02) 0.131 
   Acute MI   0.95 (0.83- 1.09) 0.472 
   Anemia   1.05 (0.96- 1.13) 0.273 
   Autoimmune disorder   1.29 (1.12- 1.47) <0.01 
   Cancer   1.21 (1.12- 1.31) <0.01 
   COPD/Asthma   1.08 (1.01- 1.16) 0.027 
   Diabetes mellitus   1.10 (1.02- 1.19) 0.011 
   Gastrointestinal bleed   1.20 (1.07- 1.35) <0.01 
   Heart-related procedure   0.91 (0.75- 1.09) 0.302 
   HIV/AIDS   1.25 (0.81- 1.94) 0.312 
   Hypertension   1.00 (0.93- 1.08) 0.980 
   Hyperthyroidism   1.03 (0.79- 1.33) 0.827 
   Ischemic heart disease   1.08 (1.01- 1.15) 0.022 
   Liver disease   1.53 (1.32- 1.78) <0.01 
   Neurologic disorder   1.12 (1.01- 1.24) 0.029 
   Obese   0.83 (0.71- 0.97) 0.018 
   Other heart disorder   1.26 (1.18- 1.34) <0.01 
   Peptic ulcer disease   1.10 (0.96- 1.25) 0.174 
   Peripheral vascular disease   0.98 (0.92- 1.05) 0.552 
   Pneumonia   1.05 (0.95- 1.15) 0.325 
   Psychiatric disorder   1.16 (1.02- 1.31) 0.023 
   Pulmonary circulation disorder   1.07 (0.92- 1.23) 0.382 
   Stroke   1.09 (1.00- 1.18) 0.049 
   Substance use disorder   1.25 (1.11- 1.42) <0.01 
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Appendix 30. Cox models of the association between the case-mix adjusted average vitamin D 
dose per patient
a
 and any fractures 
 Crude Multivariable 
Covariates HR (95% CI)
b
 p HR (95% CI) p 
Cause of ESRD [Reference: Diabetes Mellitus]     
   Hypertension   0.97 (0.90- 1.05) 0.443 
   Glomerulonephritis   0.81 (0.71- 0.93) <0.01 
   Other   1.08 (0.98- 1.19) 0.118 
Parathyroidectomy   1.03 (0.39- 2.75) 0.950 
For-profit   1.02 (0.93- 1.13) 0.626 
Free-standing   1.08 (0.96- 1.22) 0.177 
Chain [Reference: Chain #1]     
   Chain #2   0.87 (0.79- 0.96) <0.01 
   Chain #3   0.94 (0.86- 1.04) 0.240 
   Other chain   0.95 (0.88- 1.03) 0.238 
Facility size [Reference: Small]     
   Medium   1.00 (0.91- 1.10) 0.950 
   Large   0.92 (0.84- 1.02) 0.099 
Region [Reference: Northeast]     
   Midwest   1.05 (0.96- 1.14) 0.292 
   South   1.01 (0.93- 1.10) 0.815 
   West   1.07 (0.96- 1.18) 0.211 
Use of personal assistance aids   1.26 (1.14- 1.40) <0.01 
Fistula   1.09 (1.02- 1.16) 0.012 
Abbreviations: Acute MI, acute myocardial infarction; COPD, chronic obstructive pulmonary disorder; ESRD, 
end-stage renal disease; HIV/AIDS, human immunodeficiency virus / acquired immunodeficiency syndrome;   
a
Case-mix adjusted using mixed-effects linear regression adjusting for age, sex, race and cause of renal disease
  
b
Hazard Ratio (95% confidence interval) 
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